[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 119
1. Hotta T, Takifuji K, Arii K, Yokoyama S, Matsuda K, Higashiguchi T, Tominaga T, Oku Y, Yamaue H: Potential predictors of long-term survival after surgery for patients with stage IV colorectal cancer. Anticancer Res; 2006 Mar-Apr;26(2B):1377-83
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential predictors of long-term survival after surgery for patients with stage IV colorectal cancer.
  • BACKGROUND: The prognosis of patients with colorectal cancer is considered to be affected by several factors.
  • Recently, chemotherapy for this disease has been demonstrated to be effective for long-term survival.
  • In this study, the potential predictors, including chemotherapy regimens for survival after surgery, in patients with stage IV colorectal cancer are presented.
  • PATIENTS AND METHODS: Univariate and multivariate analyses of potential predictors of survival after surgery were carried out for 56 patients with stage IV colorectal cancer who had undergone surgery, including 22 with rectal and 34 with colon cancer.
  • There was a significant difference among chemotherapy regimens (p=0.021).
  • In multivariate analyses, there were 5 favorable factors that influenced overall survival after surgery: lymph node metastasis (p=0.029), no bone metastasis (p=0.012), no peritoneal invasion (p=0.018), no primary liver resection (p=0.004) and the chemotherapy regimen (p=0.008).
  • CONCLUSION: Five factors, namely lymph node metastasis, bone metastasis, peritoneal invasion, primary liver resection and chemotherapy, are potential predictors of survival after surgery for patients with stage IV colorectal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Hepatectomy. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Rate. Tegafur / administration & dosage. Tegafur / adverse effects. Uracil / administration & dosage. Uracil / adverse effects

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619547.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


2. Pasetto LM, Falci C, Rizzo E, De Salvo GL, Gasparini G, D'Andrea M, Bajetta E, Platania M, Alabiso O, Miraglia S, Oniga F, Biason R, Chetrì MC, Fedele P, Massara G, Romaniello I, Giordano M, Luchena G, Buzzi F, Ricotta R, Siena S, Monfardini S: Palliative treatment for elderly patients with colon cancer in ten Italian medical oncology units. Anticancer Res; 2008 May-Jun;28(3B):1813-20
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative treatment for elderly patients with colon cancer in ten Italian medical oncology units.
  • BACKGROUND: Palliative chemotherapy significantly reduces mortality in patients with stage IV colon cancer, but is less prescribed with rising age.
  • In this paper, we highlight the pattern of palliative treatment and possible effects on survival among elderly patients.
  • PATIENTS AND METHODS: From January to December 2004, 78 files on the management of stage IV colorectal cancer (CRC) patients over 70 years, collected from 10 Italian Centres, were retrospectively examined.
  • Determinants of receipt of palliative chemotherapy and their relation to toxicity and survival were considered.
  • RESULTS: The proportion of elderly patients receiving first-line palliative chemotherapy was 98.7% and it was evaluated according to age, gender, educational level and comorbidities; patients receiving second-line therapy comprised 47.4%, those receiving third-line therapy 14.1% and those treated with a fourth-line therapy totalled 2.6%.
  • Among progressive patients after second-line therapy, 45.8% usually undergo third line therapy; the remaining 54.2% undergo BSC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Palliative Care / utilization
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Disease Progression. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / analogs & derivatives. Fluorouracil / therapeutic use. Humans. Italy. Leucovorin / administration & dosage. Male. Medical Oncology / methods. Mitomycin / administration & dosage. Neoplasm Staging. Oncology Service, Hospital. Organoplatinum Compounds / administration & dosage. Retrospective Studies. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18630465.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 1548R74NSZ / Tegafur; 50SG953SK6 / Mitomycin; 56HH86ZVCT / Uracil; 6804DJ8Z9U / Capecitabine; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; 1-UFT protocol
  •  go-up   go-down


3. Check JH, Dix E, Sansoucie L, Check D: Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon - case report. Anticancer Res; 2009 May;29(5):1611-3
Hazardous Substances Data Bank. MIFEPRISTONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon - case report.
  • BACKGROUND: Mifepristone, a progesterone receptor antagonist has been found to improve the length and quality of life in various spontaneous murine cancer models including tumors without progesterone receptors theoretically by inhibiting an immunomodulatory protein that suppresses natural killer cell function in the tumor microenvironment.
  • MATERIALS AND METHODS: Mifepristone 200 mg per day by mouth was given to two patients with stage 4 colon cancer with extensive metastases.
  • Though the metastatic lesions did not disappear, no new ones appeared for a long time and the ones present did not grow.
  • The drug was extremely well tolerated.
  • CONCLUSION: The use of progesterone receptor antagonists may present a novel immunotherapy to help fight cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Colonic Neoplasms / drug therapy. Mifepristone / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443374.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 320T6RNW1F / Mifepristone
  •  go-up   go-down


Advertisement
4. Burz C, Berindan-Neagoe IB, Balacescu O, Tanaselia C, Ursu M, Gog A, Vlase L, Chintoanu M, Balacescu L, Leucuta SE, Irimie A, Cristea V: Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients. J Gastrointestin Liver Dis; 2009 Mar;18(1):39-43
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients.
  • AIM: to evaluate the therapeutic efficacy of oxaliplatin and to analyze the pharmacokinetics of both ultrafiltrable (free) and protein-bound platinum in patients with metastatic colon cancer.
  • METHOD: 60 patients with stage IV colon carcinoma received 4-6 (mean 4.5) cycles of oxaliplatin based combination chemotherapy.
  • The pharmacokinetics of oxaliplatin was evaluated in 8 patients who were given 85 mg/sqm or 130 mg/sqm using an infusion time of 2-4 h.
  • The median time of progression was 9.3 months.
  • CONCLUSION: Oxaliplatin is active and well tolerated in patients with advanced colon cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Colonic Neoplasms / drug therapy. Organoplatinum Compounds / pharmacokinetics
  • [MeSH-minor] Adult. Aged. Area Under Curve. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / blood. Fluorouracil / pharmacokinetics. Humans. Infusions, Intravenous. Leucovorin / administration & dosage. Leucovorin / adverse effects. Leucovorin / blood. Leucovorin / pharmacokinetics. Male. Mass Spectrometry. Metabolic Clearance Rate. Middle Aged. Neoplasm Staging. Protein Binding. Time Factors. Treatment Outcome

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19337632.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


5. Shibaki T, Morimoto N: [Advanced rectal cancer in an older patient, in whom metastatic liver lesions were effectively controlled with oral UFT+LV and venous CPT-11 administration--case report]. Gan To Kagaku Ryoho; 2006 Jun;33(6):825-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advanced rectal cancer in an older patient, in whom metastatic liver lesions were effectively controlled with oral UFT+LV and venous CPT-11 administration--case report].
  • He was diagnosed with sigmoid colon cancer with multiple metastatic lesions in the right lobe of the liver.
  • The final diagnosis was stage IV sigmoid colon cancer with metastasis to the omentum.
  • One month after the operation, adjuvant chemotherapy with oral administration of tegafur/uracil compound (UFT) and Leucovorin (LV), and drip venous infusion of irinotecan hydrochloride (CPT-11) was initiated (UFT 300 mg/day for 14 days, LV 75 mg/day for 14 days, CPT-11 90 mg/m(2) on the 1 st day, with 1 course consisting of 21 days).
  • The levels of tumor markers, CA19-9 and CEA, and the size of metastases on CT were reduced remarkably after one and 4 courses of this therapy, respectively.
  • Although the administration was temporarily discontinued due to low-grade nausea, we continued the treatment.
  • Adjuvant chemotherapy with an oral administering agent is favorable for older patients with advanced colorectal cancer to reduce side effects and preserve the quality of life.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / secondary. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Aged, 80 and over. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Colon, Sigmoid / surgery. Colostomy. Drug Administration Schedule. Drug Combinations. Humans. Infusions, Intra-Arterial. Leucovorin / administration & dosage. Male. Omentum / pathology. Peritoneal Neoplasms / secondary. Remission Induction. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770106.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / UFT(R) drug; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


6. Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, Yeatman T, Coppola D, Chen J: SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem; 2009 Jul 3;284(27):18210-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SirT1 is an inhibitor of proliferation and tumor formation in colon cancer.
  • The NAD-dependent deacetylase SirT1 regulates factors involved in stress response and cell survival and is a potential drug target of activators and inhibitors.
  • Determination of SirT1 function in tumor cells is important for its targeting in cancer therapy.
  • We found that SirT1 knockdown by short hairpin RNA accelerates tumor xenograft formation by HCT116 cells, whereas SirT1 overexpression inhibits tumor formation.
  • Furthermore, pharmacological inhibition of SirT1 stimulates cell proliferation under conditions of growth factor deprivation.
  • Paradoxically, SirT1 inhibition also sensitizes cells to apoptosis by chemotherapy drugs.
  • Immunohistochemical staining revealed high level SirT1 in normal colon mucosa and benign adenomas.
  • SirT1 overexpression was observed in approximately 25% of stage I/II/III colorectal adenocarcinomas but rarely found in advanced stage IV tumors.
  • This pattern is consistent with SirT1 having pleiotropic effects during cancer development (anti-proliferation and anti-apoptotic).
  • These results suggest a rationale for the use of SirT1 activators and inhibitors in the prevention and treatment of colon cancer.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 17;403(6771):795-800 [10693811.001]
  • [Cites] Science. 2000 Sep 22;289(5487):2126-8 [11000115.001]
  • [Cites] Nature. 2001 Mar 8;410(6825):227-30 [11242085.001]
  • [Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]
  • [Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]
  • [Cites] Nature. 2003 Sep 11;425(6954):191-6 [12939617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10794-9 [12960381.001]
  • [Cites] Cell. 2004 Feb 20;116(4):551-63 [14980222.001]
  • [Cites] EMBO J. 2004 Jun 16;23(12):2369-80 [15152190.001]
  • [Cites] Science. 2004 Jul 16;305(5682):390-2 [15205477.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5947-52 [7954427.001]
  • [Cites] Nature. 2005 Mar 3;434(7029):113-8 [15744310.001]
  • [Cites] Cell Metab. 2005 Jul;2(1):67-76 [16054100.001]
  • [Cites] Cell Metab. 2005 Aug;2(2):105-17 [16098828.001]
  • [Cites] Cell. 2005 Nov 4;123(3):437-48 [16269335.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10457-63 [16288037.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):28-38 [16354677.001]
  • [Cites] Oncogene. 2006 Jan 12;25(2):176-85 [16170353.001]
  • [Cites] PLoS Biol. 2006 Feb;4(2):e31 [16366736.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4368-77 [16618762.001]
  • [Cites] Nat Cell Biol. 2006 Sep;8(9):1025-31 [16892051.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8122-35 [16923962.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):337-42 [17086191.001]
  • [Cites] Cell. 2006 Dec 15;127(6):1109-22 [17112576.001]
  • [Cites] Mol Cell. 2007 Feb 23;25(4):543-57 [17317627.001]
  • [Cites] Arch Dermatol Res. 2007 May;299(2):103-6 [17180656.001]
  • [Cites] Mol Cell. 2007 Jul 6;27(1):149-62 [17612497.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6612-8 [17638871.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5489-504 [17694089.001]
  • [Cites] Biochem J. 2007 Nov 1;407(3):451-60 [17620057.001]
  • [Cites] Biotechnol J. 2007 Nov;2(11):1360-8 [17806102.001]
  • [Cites] Nature. 2007 Nov 29;450(7170):712-6 [18046409.001]
  • [Cites] Mol Biol Cell. 2008 Mar;19(3):1210-9 [18184747.001]
  • [Cites] PLoS One. 2008;3(4):e2020 [18414679.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):312-23 [18835033.001]
  • (PMID = 19433578.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112215; United States / NCI NIH HHS / CA / R01 CA112215-03; United States / NCI NIH HHS / CA / CA121291; United States / NCI NIH HHS / CA / R01 CA121291; United States / NCI NIH HHS / CA / CA112215-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Small Interfering; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2709385
  •  go-up   go-down


7. Ebisui C, Souma I, Fukuchi N, Izawa H, Yoshida T, Sakita I, Kanai T, Fujimoto T, Kouro T: [A case of stage IV diffusely infiltrating colon cancer treated by surgical resection and chemoradiation therapy]. Gan To Kagaku Ryoho; 2002 Nov;29(12):2410-2
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of stage IV diffusely infiltrating colon cancer treated by surgical resection and chemoradiation therapy].
  • A 62-year-old male patient presented at the hospital because of left lower abdominal tumor.
  • Based on preoperative examination and biopsy results, he was diagnosed with stage IV diffusely infiltrating colon cancer (scirrhous type) with paraaortic lymph node metastases.
  • This chemotherapy produced no change in response in the paraaortic lymph node metastases for a long time.
  • In addition, left inguinal lymph node was treated with irradiation therapy (total 50 Gy).
  • It is known that the prognosis in cases of diffusely infiltrating colorectal cancer is extremely poor.
  • However, this case might suggest that intensive therapies with surgery and chemoradiation are useful in maintaining quality of life and improving survival.
  • [MeSH-major] Adenocarcinoma / therapy. Camptothecin / analogs & derivatives. Sigmoid Neoplasms / therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Colectomy. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Lymphatic Metastasis. Male

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12484087.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


8. Mado K, Ishii Y, Mazaki T, Ushio M, Masuda H, Takayama T: A case of bone metastasis of colon cancer that markedly responded to S-1/CPT-11 combination chemotherapy and became curable by resection. World J Surg Oncol; 2006;4:3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of bone metastasis of colon cancer that markedly responded to S-1/CPT-11 combination chemotherapy and became curable by resection.
  • BACKGROUND: An oral combined fluoropyrimidine anticancer drug, tegafur/gimeracil/oteracil potassium (S-1), has recently been used alone or in combination for colon cancer.
  • CASE PRESENTATION: The patient was a 42-year-old man with sigmoid colon cancer with direct invasion of the urinary bladder and multiple costal metastases.
  • A diagnosis of T4, M1, stage IV sigmoid colon cancer was made, and curative resection was considered impossible.
  • This treatment was followed by 2 weeks absent period, and repeated every 4 weeks.
  • Following this treatment, the multiple costal metastases resolved.
  • Down-staging to T3, M0, stage IIA was achieved, and curative resection was judged to be possible.
  • CONCLUSION: Occasional cases in which S-1/CPT-11 therapy was effective have been recently reported.
  • The patient's tumor became resectable despite the discovery of colon cancer associated with bone metastasis at the initial examination, offering hope for cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cancer Res Clin Oncol. 1999;125(3-4):134-40 [10235466.001]
  • [Cites] Oncology. 1999 Oct;57(3):202-10 [10545788.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):141-5 [10901361.001]
  • [Cites] Dis Colon Rectum. 1999 Dec;42(12):1592-7 [10613479.001]
  • [Cites] N Engl J Med. 2000 Sep 28;343(13):905-14 [11006366.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):939-43 [11592762.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3605-16 [12202661.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3721-8 [12963704.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):229-37 [14657227.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1209-14 [15051767.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2355-61 [15160338.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2170-6 [15470715.001]
  • [Cites] Jpn J Clin Oncol. 2005 Feb;35(2):88-9 [15709093.001]
  • [Cites] J Gastroenterol. 1995 Oct;30(5):615-8 [8574333.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):808-15 [9053508.001]
  • (PMID = 16417646.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1395313
  •  go-up   go-down


9. Karoui M, Koubaa W, Delbaldo C, Charachon A, Laurent A, Piedbois P, Cherqui D, Tran Van Nhieu J: Chemotherapy has also an effect on primary tumor in colon carcinoma. Ann Surg Oncol; 2008 Dec;15(12):3440-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy has also an effect on primary tumor in colon carcinoma.
  • BACKGROUND: This study characterizes the histological effect of chemotherapy (CT) on primary colonic tumors.
  • METHODS: Between 2000 and 2006, 38 patients with stage IV colon cancer underwent resection of the primary, after chemotherapy (CT group, n = 16) or without preoperative CT (control group, n = 22).
  • For all primary tumors, histological analysis included: fibrosis, acellular necrosis, acellular mucin pools, lymphoplasmacytic infiltration, and changes at tumor surface.
  • Tumor regression grade (TRG) was determined by the amount of residual tumor cells and was graded from 1 to 5.
  • Major histological tumor regression (TRG2) was observed in 70% of patients treated by CT and none of the not treated patients (P < 0.0001).
  • TRG in the primary was comparable to the TRG in the corresponding liver metastases for 7/9 patients who underwent both colonic and hepatic resection after CT.
  • CONCLUSION: CT induces major histological response in 70% of colon cancers.
  • These results support a policy of initial CT management for stage IV colon cancer and may warrant future studies of neoadjuvant CT in locally advanced colon carcinomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Liver Neoplasms / drug therapy. Neoplasm, Residual / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Remission Induction. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18850249.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Mukai M, Oida Y, Mukoyama S, Okamoto Y, Ito I, Nakasaki H, Kawai K, Sato S, Makuuchi H: Efficacy of combination chemotherapy for stage IV colon cancer with extensive peritoneal dissemination and multiple liver metastases: a case report. Oncol Rep; 2002 Nov-Dec;9(6):1339-43
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of combination chemotherapy for stage IV colon cancer with extensive peritoneal dissemination and multiple liver metastases: a case report.
  • A patient was diagnosed as having subacute ileus due to advanced cancer of the descending colon with multiple liver metastases and was treated by palliative left hemicolectomy.
  • He was considered to have Stage IV cancer based on the finding of extensive peritoneal dissemination.
  • Histopathological examination showed that the tumor was moderately differentiated adenocarcinoma.
  • Postoperative palliative chemotherapy was given with 5-FU and LV twice a month as 1 course, and he received a total of 3 courses.
  • When bilateral pleural effusions developed about 1 year postoperatively, CPT-11 was changed to CDGP.
  • Jaundice and massive ascites eventually developed, and he died about 1 year and 5 months postoperatively.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Camptothecin / administration & dosage. Colectomy. Fatal Outcome. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Staging. Pleural Effusion

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12375045.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


11. Patwardhan M, Fisher DA, Mantyh CR, McCrory DC, Morse MA, Prosnitz RG, Cline K, Samsa GP: Assessing the quality of colorectal cancer care: do we have appropriate quality measures? (A systematic review of literature). J Eval Clin Pract; 2007 Dec;13(6):831-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the quality of colorectal cancer care: do we have appropriate quality measures? (A systematic review of literature).
  • RATIONALE, AIMS AND OBJECTIVES: The burden of illness from colorectal cancer (CRC) can be reduced by improving the quality of care.
  • Most measures are important, but need to be developed and field-tested.
  • The best available measures relate to pathology and chemotherapy.
  • No measures are available for assessing quality of management of stage IV rectal cancer and hepatic metastasis; chemotherapy for stage II colon cancer; and procedure notes.
  • [MeSH-major] Colonic Neoplasms / therapy. Quality Assurance, Health Care / standards. Rectal Neoplasms / therapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070253.001).
  • [ISSN] 1356-1294
  • [Journal-full-title] Journal of evaluation in clinical practice
  • [ISO-abbreviation] J Eval Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] England
  • [Number-of-references] 117
  •  go-up   go-down


12. van Loon J, Janssen MH, Ollers M, Aerts HJ, Dubois L, Hochstenbag M, Dingemans AM, Lalisang R, Brans B, Windhorst B, van Dongen GA, Kolb H, Zhang J, De Ruysscher D, Lambin P: PET imaging of hypoxia using [18F]HX4: a phase I trial. Eur J Nucl Med Mol Imaging; 2010 Aug;37(9):1663-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Noninvasive PET imaging of tumour hypoxia could help in the selection of those patients who could benefit from chemotherapy or radiation with specific antihypoxic treatments such as bioreductive drugs or hypoxic radiosensitizers.
  • METHODS: Patients with a histologically proven solid cancer without curative treatment options were eligible for this study.
  • RESULTS: Six patients with stage IV carcinoma were included, four with non-small-cell lung carcinoma, one with thymus carcinoma, and one with colon carcinoma.
  • No toxicity was observed in any of the patients at either dose level.
  • CONCLUSION: The findings of this study showed that [(18)F]HX4 PET imaging for the detection of hypoxia is not associated with any toxicity.
  • [MeSH-major] Nitroimidazoles / adverse effects. Positron-Emission Tomography. Triazoles / adverse effects
  • [MeSH-minor] Aged. Cell Hypoxia. Dose-Response Relationship, Drug. Female. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. Neoplasms / diagnostic imaging. Neoplasms / pathology. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2007 Jun;43(9):1392-8 [17512190.001]
  • [Cites] J Nucl Med. 2005 Jan;46(1):106-13 [15632040.001]
  • [Cites] Radiat Res. 1987 Aug;111(2):292-304 [3628717.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Aug;35(8):1544-9 [18509637.001]
  • [Cites] Radiother Oncol. 2008 Apr;87(1):142-6 [18207269.001]
  • [Cites] Eur J Cancer. 2002 Jan;38(2):240-57 [11803141.001]
  • [Cites] Eur J Nucl Med. 1995 Mar;22(3):265-80 [7789400.001]
  • [Cites] J Nucl Med. 2008 Jun;49 Suppl 2:129S-48S [18523070.001]
  • [Cites] J Cell Biochem. 2009 Aug 15;107(6):1053-62 [19479945.001]
  • [Cites] Phys Med Biol. 2005 May 21;50(10 ):2209-24 [15876662.001]
  • (PMID = 20369236.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol; 0 / Nitroimidazoles; 0 / Triazoles
  •  go-up   go-down


13. de Gramont Lesparre AH, Chibaudel B, Bourges O, Perez-Staub N, Tournigand C, Maindrault-Goebel F, André T, Larsen AK, Afchain P, Louvet C: Definition of oxaliplatin sensitivity in patients with advanced colorectal cancer previously treated with oxaliplatin-based therapy. J Clin Oncol; 2009 May 20;27(15_suppl):4024

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Definition of oxaliplatin sensitivity in patients with advanced colorectal cancer previously treated with oxaliplatin-based therapy.
  • : 4024 Background: Oxaliplatin combined with fluoropyrimidines is standard adjuvant therapy in stage III colon cancer and first-line therapy in stage IV colorectal cancer.
  • Oxaliplatin can be reintroduced either at relapse, or after maintenance or after chemotherapy holidays.
  • METHODS: Stage IV pts entered in the OPTIMOX1 and 2 studies (FOLFOX4, FOLFOX7 followed by maintenance without oxaliplatin or chemotherapy holidays) and pts having relapsed after metastases surgery and neoadjuvant or adjuvant FOLFOX for resectable stage IV were eligible if they were rechallenged with FOLFOX.
  • RESULTS: 330 pts were included: male 60%, colon/rectum/both 62%/35%/2%, resectable/unresectable: 14%/86%, PS 0-1 / >1: 90%/10%, sites 1/>1: 57%/43%.
  • 23 pts had adjuvant and 22 pts had neoadjuvant chemotherapy.
  • CONCLUSIONS: A prolonged interval between two FOLFOX therapies or a prolonged PFS at first-line FOLFOX predict the efficacy of oxaliplatin reintroduction.
  • The interval between two FOLFOX therapies does not identify a completely refractory population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961524.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Hoffman KR: Potential prevention and treatment of oxaliplatin associated peripheral neuropathy. J Clin Oncol; 2004 Jul 15;22(14_suppl):8093

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential prevention and treatment of oxaliplatin associated peripheral neuropathy.
  • : 8093 Background: The major toxicities of oxaliplatin are two different types of peripheral neuropathies, a reversible one related to the drug's infusion and an irreversible one based on the cumulative dose received.The incidence of onset and the severity of the neuropathy increase as the number of cycles increase as does the prevalence of the toxicity.
  • Gabapentin (Neurontin) and carbamazepine (Tegretol) are two drugs used in the treatment of autonomic dysfunction and peripheral neuropathic pain.
  • METHODS: 34 consecutive patients receiving oxaliplatin-5-FU-leukovorin rescue chemotherapy for stage IV colon cancer were available for study.
  • Treatment was determined by random drawing of treatment options.
  • RESULTS: In the intial study of 24 patients, grade 1 toxicity had to be reported before treatment was intiated with either drug, usually after the 2nd cycle.
  • Treatment was begun a week before the 3rd cycle.
  • To judge whether these agents could totally prevent the sensory neuropathy, the next 10 patients have been randomized at the start of their treatment to either gabapentin, carbamazepine or nothing.
  • After 3 cycles the 6 treated patients have grade 1 sensory neuropathy while 2 of the 4 non-prophylaxed patients had grade 2 sensory neuropathy and were started on therapy before cycle 3.
  • No drug toxicity associated with either carbamazepine or gabapentin was observed.
  • CONCLUSIONS: While a prospective, double-blinded randomized trial needs to confirm these findings, gabapentin or carbamazepine can be considered as adjuvant therapy to minimize the sensory neuropathic toxicity of oxaliplatin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015992.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Eton O, Billings L, Kim K, Prieto V, Davis D, Frazier ML, Diwan AH, McGary E, Papadopoulos N, Bedikian AY: Phase II trial of imatinib mesylate (STI-571) in metastatic melanoma (MM). J Clin Oncol; 2004 Jul 15;22(14_suppl):7528

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7528 Background: Imatinib mesylate (Gleevec™), an oral inhibitor of phosphorylation of certain tyrosine kinases (TK), is active in gastrointestinal stromal tumors which are chemotherapy resistant.
  • Perhaps MM may respond to Gleevec, especially if the tumor cells or microenvironment express one of the known TK targets: KIT, PDGF receptors α or β, c-abl, or ARG.
  • METHODS: Tumor biopsies from MM patients (pts) were screened by immunohistochemistry (IHC) for TK expression in more than 25% of the cells, as a condition for enrollment in a Phase II trial testing Gleevec @ 400 mg bid.
  • RESULTS: All 31 pts screened met this criterion and 21 of them were treated with Gleevec (median age 58, male [13]; stage IV [19]; PS 0-1 [20]; prior Rx: none [8], Intron-A [8], one chemotherapy [5]).
  • The one patient with strongest expression of KIT in over 75% of tumor cells tolerated treatment for one year and achieved near complete response in in-transit, inguinal/iliac, and lung metastases with marked PET scan improvement as early as 6 weeks.
  • Quantitative dual immunofluorescence in baseline and 2<sup>nd</sup> week tumor specimens revealed a decrease in phosphoKIT relative to total KIT expression in the responder and also in 4 of 5 non-responders tested to-date.
  • CD31/TUNEL assay showed an increase in both tumor and endothelial cell apoptosis in the responding tumor.
  • Sequencing from this tumor's RNA revealed serine deletion at codon 715 of kit (Exon 15, Kinase II Domain), probably a result of alternate RNA splicing, with a short:long isoform ratio of 5:1.
  • This alternate splicing has been seen in colon cancer but not in normal colon from the same patient and may be a tumor specific event.
  • Sixteen pts (77%) had progressive disease within 6 weeks and 4 pts within 12 weeks, obviating accrual into the 2<sup>nd</sup> stage.
  • CONCLUSIONS: Strong TK expression in a majority of tumor cells by IHC may predict Gleevec response in MM.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014941.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Lang I, Hitre E, Horvath Z, Hungarian CRC Irinotecan Treatment Group: Two-year follow up results of a population-based prospective case control study of 143 stage IV colorectal cancer (CRC) patients treated with 2&lt;sup&gt;nd&lt;/sup&gt; line irinotecan (iri) outside of clinical trial. J Clin Oncol; 2004 Jul 15;22(14_suppl):3687

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two-year follow up results of a population-based prospective case control study of 143 stage IV colorectal cancer (CRC) patients treated with 2<sup>nd</sup> line irinotecan (iri) outside of clinical trial.
  • : 3687 Background: 2<sup>nd</sup> line iri treatment for stage for CRC has been financed by the Hungarian Natiional Insurance Company since 2001.
  • This therapy was found to be active in clinical trials as compared to BSC and in 5-FU treated patients.
  • METHODS: All data of the patients (>70 yr, ECOG 0-2, no brain metastasis) were reported to an independent committee prior to iri treatment, after every 2<sup>nd</sup> cycle up 6 cycles and then every six months until death.
  • First-line chemotherapy was bolus or infusional 5-FU-Leucovorin.
  • 62 patients had rectal cancer, 79 had colon cancer.
  • Primary tumor was resected in 124 cases.
  • At a two years follow-up time 35 out of 143 pts were alive (24,5 %).
  • Median OS was significantly longer if primary tumor was removed (16,77 vs 8,43 months; p=0,0002).
  • Grade III/IV diarrhoea, vomiting and granulocytopenia were around 20 %.
  • CONCLUSIONS: In a population-based compassionate setting the efficacy and safety of 2<sup>nd</sup> line iri therapy was comparable to those found in randomised phase III trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014700.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Wolmark N, Wieand S, Lembersky B, Colangelo L, Smith R, Pazdur R: A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: Results of NSABP Protocol C-06. J Clin Oncol; 2004 Jul 15;22(14_suppl):3508

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: Results of NSABP Protocol C-06.
  • METHODS: Between February 1997 and March 1999, 1,608 patients (805 and 803 in each arm) with stage II and III carcinoma of the colon were randomized to receive either oral UFT+LV (tegafur, 300 mg/m<sup>2</sup>/day and uracil in a 1:4 molar ratio p.o. x 28 days; leucovorin 90 mg/day p.o. x 28 days, each 35 day cycle x 5) or FULV (5-FU, 500 mg/m<sup>2</sup> iv bolus weekly x 6; LV, 500 mg/m<sup>2</sup> iv weekly x 6, each 8 week cycle x 3 Results: With a mean time on study of 64 months for patients with follow-up there were no significant differences in disease-free survival or overall survival between the two treatment arms.
  • The Fact C quality of life metric disclosed no significant difference; other secondary quality of life measurements during chemotherapy administration appeared to favor UFT.
  • CONCLUSION: Oral UFT + LV achieved equivalent DFS and S when compared to iv FULV in patients with stage II and III carcinoma of the colon.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016482.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields AL, Carver G, Mayer RJ: Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). J Clin Oncol; 2004 Jul 15;22(14_suppl):3500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803).
  • : 3500 Background: Irinotecan prolongs survival in second line 5FU-refractory metastatic colorectal cancer (MCRC).
  • We conducted a phase III randomized study to evaluate whether IFL was also superior to weekly bolus FL after curative resection for stage III colon cancer.
  • METHODS: Eligible patients had T<sub>x</sub>N<sub>1-2</sub>M<sub>0</sub> disease, Zubrod 0-2, and no prior chemotherapy.
  • Patients (pts) received either IFL (irinotecan 125mg/m2 over 90 minutes followed by leucovorin 20 mg/m2 IV bolus and then 5FU 500mg/m2 IV bolus, given 4 weeks on, 2 weeks off, x 5 cycles (30 weeks total)) or the Roswell Park schedule of FL (leucovorin 500mg/m2 IV over 2 hours plus 5FU 500 mg/m2 at 1 hour after start of leucovorin, given 6 weeks on, two weeks off, x 4 cycles (32 weeks total)).
  • 18 deaths occurred on the IFL arm during treatment vs. 6 deaths on the FL arm (p=0.008).
  • CONCLUSIONS: In stage III colon cancer, IFL, as compared to FL, is associated with a greater degree of neutropenia, neutropenic fever, and death on treatment, with no associated clinical benefit.
  • Weekly bolus IFL should not be used in the management of stage III colon cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016485.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Bhargava A, Seetharamu N, Shrestha S, Mehrotra B: Chemotherapy dose delivery in elderly patients with lung and colon cancer; a single institution study. J Clin Oncol; 2004 Jul 15;22(14_suppl):8261

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy dose delivery in elderly patients with lung and colon cancer; a single institution study.
  • : 8261 Background: Chemotherapy dose delivery in the elderly is a challenge.
  • Often, elderly patients undergo surgery but not all receive adjuvant or palliative chemotherapy despite proven benefit of these regimens to improve survival.
  • The purpose of our study was to analyze the practice patterns of chemotherapy dose ordering and delivery in patients with ages 70 years and above who were diagnosed with lung or colorectal cancer (CRC) at our institution.
  • METHODS: A retrospective review of chemotherapy charts was performed for patients identified over the age of 70 years with a diagnosis of CRC and lung cancer at our institution from 1998-2002.
  • We studied the chemotherapy regimens, dose modifications and concurrent use of radiation therapy in lung cancer and CRC.
  • RESULTS: 36 patients were identified who received chemotherapy (n=21 lung ca; n=15 CRC).
  • Stage distribution: lung ca (IIIA n=5; IIIB n=9, IV n=5, small cell lung ca n=2).
  • CRC (high risk II n=8, III n=5, IV n=2).
  • 12 of 21 pts.treated for lung ca received concurrent chemotherapy and radiation therapy.
  • 4/12 (33%) were treated with a single drug, carboplatin or paclitaxel with radiation.
  • 8/14 (57%) pts completed 5 weeks or more of planned radiation treatment.
  • CONCLUSIONS: Elderly patients require significant dose reductions and modifications to tolerate chemotherapy +/- XRT safely and are frequently unable to complete proposed treatments.
  • The impact of established treatment regimens on survival in elderly patients needs to be further investigated No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016706.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Fuchs C, Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Bertagnolli MM: KRAS mutation, cancer recurrence, and patient survival in stage III colon cancer: Findings from CALGB 89803. J Clin Oncol; 2009 May 20;27(15_suppl):4037

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KRAS mutation, cancer recurrence, and patient survival in stage III colon cancer: Findings from CALGB 89803.
  • : 4037 Purpose: KRAS mutation in stage IV colorectal cancer predicts resistance to anti-EGFR targeted treatment (cetuximab or panitumumab).
  • However, whether the presence of KRAS mutation independently predicts the survival of colon cancer patients remains uncertain.
  • METHODS: We conducted a prospective observational study of 508 cases identified among 1264 patients with stage III colon cancer who enrolled in a randomized adjuvant chemotherapy trial (5-fluorouracil, leucovorin with or without irinotecan) between April 1999 and May 2001 (CALGB 89803; Saltz et al.
  • Kaplan-Meier and Cox proportional hazard models were used to assess the significance of KRAS mutational status and adjusted for potential confounders including age, sex, tumor location, T stage, N stage, performance status, adjuvant chemotherapy arm and microsatellite instability (MSI) status.
  • RESULTS: When compared to patients with wild-type KRAS, those with a mutation in KRAS did not experience any difference in disease-free (DFS), recurrence-free (RFS), or overall survival (OS) (log-rank P>0.56 for DFS, RFS, and OS).
  • Five-year DFS was 62% for KRAS-mutated and 63% for KRAS-wild-type patients.
  • Five-year RFS was 64% for KRAS-mutated and 66% for KRAS- wild-type patients.
  • Five-year OS was 74% for KRAS-mutated and 73% for KRAS-wild-type patients.
  • The effect of KRAS mutation on patient survival did not differ according to clinical features, chemotherapy arm or MSI status, and the effect of adjuvant chemotherapy assignment on outcome did not differ according to KRAS status.
  • CONCLUSIONS: In this large clinical trial of chemotherapy in patients with stage III colon cancer, KRAS mutational status was not associated with any significant influence on disease-free or overall survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961543.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Arora ML, Saha S, Sirop S, Chakravarty B, Korant A, Soni M, Wiese D, Desai D, Ganatra B, Kaushal S, Iddings D: The impact of the number of lymph node metastases on the overall recurrence of colon cancer in the era of sentinel lymph node mapping. J Clin Oncol; 2009 May 20;27(15_suppl):4049

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of the number of lymph node metastases on the overall recurrence of colon cancer in the era of sentinel lymph node mapping.
  • : 4049 Background: Sentinel Lymph Node Mapping (SLNM) in colon Cancerc (Cca) has been shown to be successful, sensitive and accurate.
  • For recurrence analysis, exclusion criteria included: stage IV disease, benign pathology, lost to follow-up, refusal of indicated chemotherapy, non cancer related death or second cancer.
  • A retrospective matched control (diagnosed with Cca undergoing standard colon resection without SLNM, gp B) from our own institution were analyzed and compared to the SLNM group for the same period.
  • SLNM was successful in 99.8% of pts, with a sensitivity, negative (-ve) predictive value, and overall accuracy of 85.3%, 91.7% and 94.4% respectively.
  • Of these, 49 had stage I, 46 had stage II and 58 had stage III disease.
  • The recurrence rates were 4.1%, 8.6% and 15.5% in stage I, II, and III disease respectively.
  • CONCLUSIONS: SLNM in Cca is associated with decreased rates of recurrence as compared to conventional therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961561.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Biagi JJ, Wong R, Brierley J, Rahal R, Ross J: Assessing compliance with practice treatment guidelines by treatment centers and the reasons for noncompliance. J Clin Oncol; 2009 May 20;27(15_suppl):e17506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing compliance with practice treatment guidelines by treatment centers and the reasons for noncompliance.
  • : e17506 Background: Cancer Care Ontario (CCO) is the chief advisor on cancer care to the government of Ontario, a province with a population of more than 12 million.
  • One of the many roles of CCO is to develop evidence based consensus-derived treatment practice guidelines for all major cancer types, through its Program in Evidence-based Care (PEBC).
  • To determine province-wide compliance with these guidelines, a pilot project assessed the proportion of patients with stage III colon cancer (CC) treated in concordance with the corresponding treatment guideline.
  • Initial results are made available to the regional cancer centers (RCC) in the province and to the public through web based Cancer Systems Quality Index (CSQI, http://www.cancercare.on.ca/qualityindex2007/ ).
  • METHODS: The guideline (http://www.cancercare.on.ca/pdf/pebc2-29s.pdf) states that patients with resected stage 3 CC will have adjuvant fluoropyrimidine-based chemotherapy within eight weeks of resection.
  • Patients at each of 11 RCC who presented in 2007/2008 with stage III CC and the proportion treated according to the guidelines were identified.
  • RESULTS: Across eight RCC with complete chart results to date 376 patients with stage 3 CC were identified, 244 (65%, range 47% to 72%) treated in concordance with the guideline, including 13% treated with capecitabine and 6% on clinical trials.
  • The reasons for non-concordance of the 132 remaining cases were: age and co morbid conditions 48 (13%), patient choice 36 (10%), referred for treatment outside the RCC system 16 (4%), stage incorrect and other 32 (9%).
  • CONCLUSIONS: Adjuvant chemotherapy treatment of stage III CC at the RCC across the Province of Ontario was concordant with the guideline in the majority of patients, and appropriate clinical reasons for non-compliance were identified.
  • Data from all 11 RCC will be presented along with concordance within the eight-week time frame stated in the guideline .

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963242.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Zanon C, Bortolini M, Chiappino I, Simone P, Bruno F, Gaglia P, Airoldi M, Deriu L, Mashiah A: Cytoreductive surgery combined with intraperitoneal chemohyperthermia for the treatment of advanced colon cancer. World J Surg; 2006 Nov;30(11):2025-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery combined with intraperitoneal chemohyperthermia for the treatment of advanced colon cancer.
  • BACKGROUND: Chemohyperthermic peritoneal perfusion (CHPP) after extensive cytoreductive surgery is a possible choice as a regional treatment for peritoneal carcinomatosis (PC).
  • The multicentric France EVOCAPE 1 study demonstrated that the median overall survival of patients with colon peritoneal carcinomatosis subjected to conventional surgical and/or chemotherapeutic treatment was 5.2 months.
  • Historically, mitomycin C is the drug of choice in the treatment of intraperitoneal carcinomatosis from colon cancer.
  • METHODS: Twenty-five patients affected by stage IV colon cancer with only peritoneal involvement and a prior completion of at least a partial first cycle of systemic chemotherapeutic and/or surgical treatment (24 patients) were enrolled.
  • CONCLUSIONS: In referral centers CHPP after optimal surgical debulking is a safe procedure for peritoneal carcinomatosis from colonic cancer.
  • A closed abdomen CHPP procedure lasting 1 hour and standard mitomycin C at a dosage of 15 mg/m(2) is probably as efficacious as other hyperthermic procedures, using higher mitomycin C dosages, with a comparable or lower number of cases of side effects.
  • These results, as in other published phase II studies, justify future randomized trials to assess definitively the role of CHPP in the treatment of locally advanced colon neoplasms in western countries.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colonic Neoplasms / therapy. Hyperthermia, Induced. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Humans. Infusions, Parenteral. Middle Aged. Neoplasm Staging. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):727-31 [10622499.001]
  • [Cites] Arch Surg. 2003 Jan;138(1):26-33 [12511145.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):694-8 [11821450.001]
  • [Cites] J Surg Oncol. 2000 May;74(1):41-4 [10861608.001]
  • [Cites] Ann Surg Oncol. 1996 Jan;3(1):44-50 [8770301.001]
  • [Cites] Biomed Pharmacother. 1995;49(9):429-30 [8746079.001]
  • [Cites] J Cancer Res Clin Oncol. 1997;123(1):6-12 [8996534.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3284-92 [15310771.001]
  • [Cites] Int J Surg Investig. 2000;1(5):431-9 [11341599.001]
  • [Cites] Am Surg. 2000 Jun;66(6):561-8 [10888132.001]
  • [Cites] Eur J Surg Oncol. 2005 Mar;31(2):147-52 [15698730.001]
  • [Cites] Eur J Surg Oncol. 2000 Nov;26(7):663-8 [11078613.001]
  • [Cites] Cancer Treat Res. 1996;81:51-61 [8834575.001]
  • [Cites] Ann Chir. 2000 Sep;125(7):631-42 [11051692.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):358-63 [10640968.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43 Suppl:S15-25 [10357554.001]
  • [Cites] Drugs. 1995 Jan;49(1):11-9 [7705211.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):71-6 [11443611.001]
  • [Cites] Eur J Cancer. 2001 May;37(8):979-84 [11334722.001]
  • [Cites] Life Sci. 1996;58(7):535-43 [8632706.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2512-9 [10861427.001]
  • [Cites] Int J Hyperthermia. 2001 Sep-Oct;17(5):456-64 [11587082.001]
  • [Cites] Ann Oncol. 2002 Feb;13(2):267-72 [11886004.001]
  • [Cites] Oncologist. 2005 Feb;10(2):112-22 [15709213.001]
  • [Cites] Br J Surg. 2000 Aug;87(8):1006-15 [10931042.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):286-90 [11373107.001]
  • (PMID = 17058031.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Katsumoto Y, Maruyama KT, Furukawa J, Nagai K, Maruyama N, Tanaka J, Yokoyama S, Yokouchi H, Kinuta M: [A case of lymph node metastasis after 7 years from Hartmann's operation for stage IV sigmoid colon carcinoma]. Gan To Kagaku Ryoho; 2004 Oct;31(11):1930-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of lymph node metastasis after 7 years from Hartmann's operation for stage IV sigmoid colon carcinoma].
  • In 1995, she underwent Hartmann's operation for sigmoid colon carcinoma.
  • Histological stage was IV [se, n4(+), P0, H0, M(-)].
  • Adjuvant chemotherapy was performed by MMC and 5'-DFUR.
  • CT examination revealed a retroperitoneal tumor-like shadow and Para-aortic lymph nodes were swelling.
  • There were massive lymph nodes metastasis, and tumor resection was impossible.
  • Following several systemic chemotherapies such as UFT/CPT-11 and TS-1, the tumor progressed and liver metastasis appeared.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Laparotomy. Middle Aged. Retroperitoneal Neoplasms / secondary. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15553763.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


25. Jacob S, Ng W, Asghari R, Delaney GP, Barton MB: Estimation of an optimal chemotherapy utilisation rate for colon cancer: an evidence-based benchmark for cancer care. Eur J Cancer; 2009 Sep;45(14):2503-9
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimation of an optimal chemotherapy utilisation rate for colon cancer: an evidence-based benchmark for cancer care.
  • BACKGROUND: Optimal chemotherapy (CT) utilisation rates can serve as benchmarks to assess the quality of cancer care.
  • This study aims to determine the optimal proportion of patients with colon cancer that should receive chemotherapy at least once.
  • METHODS: An optimal chemotherapy utilisation tree was constructed using indications for chemotherapy identified from evidence-based treatment guidelines.
  • Data on the proportion of patient and tumour-related attributes for which chemotherapy was indicated were obtained and merged with the treatment indications to calculate an optimal chemotherapy utilisation rate (CTU rate).
  • This optimal rate was compared with reported actual rates of chemotherapy utilisation.
  • RESULTS: Chemotherapy is indicated at least once in 55% of patients with colon cancer.
  • While 89% of colon cancer patients presenting with Stage IV disease should optimally receive chemotherapy, 38-52% actually received chemotherapy as part of their initial treatment.
  • CONCLUSION: The optimal chemotherapy utilisation rate can serve as an evidence-based benchmark in the planning and evaluation of chemotherapy services.
  • Chemotherapy may be under-utilised in the initial management of patients presenting with metastatic colon cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benchmarking. Colonic Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19527926.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


26. Hobday TJ, Erlichman C: Adjuvant therapy of colon cancer: a review. Clin Colorectal Cancer; 2002 Feb;1(4):230-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant therapy of colon cancer: a review.
  • Colon cancer is a common cause of cancer-related mortality.
  • Complete surgical resection of the primary tumor and/or select metastatic lesions can be curative in many patients.
  • The risk of recurrence after resection can be predicted by pathologic staging.
  • Large prospective randomized trials over the past 2 decades have clearly shown an increased overall survival for patients with resected stage III colon cancer who are treated with adjuvant 5-fluorouracil-based chemotherapy.
  • The benefit of adjuvant chemotherapy for patients with stage II disease remains controversial.
  • There is indirect evidence to support adjuvant chemotherapy after resection of metastatic disease.
  • Locoregional approaches such as radiation, hepatic arterial infusion, or portal vein chemotherapy remain investigational.
  • Adjuvant immunotherapy with monoclonal antibodies is emerging as a therapeutic option that might complement chemotherapy.
  • Future challenges include improving adjuvant chemotherapy with the addition and/or substitution of new agents, resolving which subset of patients with stage II and resected stage IV colon cancer might benefit from therapy, validating the benefit of immunotherapy, and investigating locoregional therapies compared with systemic therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Colorectal Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Chemotherapy, Adjuvant. Fluorouracil / administration & dosage. Humans. Immunotherapy. Leucovorin / administration & dosage. Levamisole / administration & dosage. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12450421.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 2880D3468G / Levamisole; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 52
  •  go-up   go-down


27. Moosmann N, Heinemann V: Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer. Expert Rev Anticancer Ther; 2008 Mar;8(3):319-29
Hazardous Substances Data Bank. CETUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer.
  • Modern chemotherapy combinations for metastatic colorectal cancer (mCRC) comprise 5-fluorouracil (5-FU), folinic acid and irinotecan or oxaliplatin.
  • Infusional 5-FU, folinic acid plus oxaliplatin (FOLFOX) is a standard of care not only for patients with stage IV disease, but also in the adjuvant setting of stage III colon cancer patients.
  • The EGF receptor antibody, cetuximab, induces synergistic antitumor activity when combined with chemotherapy.
  • A number of Phase I and II trials investigated the combination of cetuximab plus oxaliplatin-based chemotherapy for the first-line treatment of mCRC.
  • This combined cytotoxic and targeted treatment approach prooved to be safe and provided encouraging efficacy data, which are among the highest so far observed in the systemic treatment of mCRC.
  • This review presents recent data on oxaliplatin, cetuximab and the combination of both for mCRC as well as possible future indications in the palliative, adjuvant and neoadjuvant setting of modern CRC treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18366281.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; PQX0D8J21J / Cetuximab
  • [Number-of-references] 58
  •  go-up   go-down


28. Shoji H, Kuroki M, Hiramoto K, Matsumura Y, Miura A, Kikuchi Y, Hirakawa H: [A case of metastatic colorectal cancer suffering from hyperammonemic encephalopathy induced by 5-FU, continuously treated with FOLFOX therapy]. Gan To Kagaku Ryoho; 2010 Aug;37(8):1583-6
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of metastatic colorectal cancer suffering from hyperammonemic encephalopathy induced by 5-FU, continuously treated with FOLFOX therapy].
  • We report a rare case of metastatic colorectal cancer who suffered from hyperammonemic encephalopathy induced by 5- FU and was continuously treated with FOLFOX therapy.
  • A 50-year-old man with ileus was diagnosed with ascending colon cancer Stage IV, and a right hemicolectomy was performed.
  • Postoperative chemotherapy with modified FOLFOX6 was performed.
  • Laboratory examination revealed hyperammonemia, so branched-chain amino acid solutions and high-volume drip infusion were started for its treatment.
  • We changed to chemotherapy for FOLFOX4 using branched-chain amino acid solutions and drip infusion.
  • The tumor marker level normalized following two courses, and CT following ten courses showed that the size of the lung metastasis and abdominal lymph node had reduced significantly.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Fluorouracil / adverse effects. Hyperammonemia / chemically induced. Lung Neoplasms / drug therapy
  • [MeSH-minor] Amino Acids, Branched-Chain / therapeutic use. Combined Modality Therapy. Humans. Leucovorin / adverse effects. Leucovorin / therapeutic use. Lymphatic Metastasis / radiography. Male. Middle Aged. Organoplatinum Compounds / adverse effects. Organoplatinum Compounds / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20716892.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Amino Acids, Branched-Chain; 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


29. Janney LM, Waterbury NV: Capecitabine-warfarin interaction. Ann Pharmacother; 2005 Sep;39(9):1546-51
Hazardous Substances Data Bank. WARFARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To report a case of concomitant warfarin therapy with consecutive cycles of capecitabine therapy, providing time of onset, magnitude, and assessment of the interaction.
  • CASE SUMMARY: A 59-year-old man receiving chronic warfarin therapy for a mechanical mitral valve replacement was diagnosed with stage IV metastatic colon cancer.
  • He was started on capecitabine/irinotecan after his cancer progressed with fluorouracil/leucovorin and the FOLFOX 6 regimen (oxaliplatin, leucovorin, and continuous fluorouracil infusion).
  • In this case, the Naranjo probability scale indicates a highly probable drug interaction between warfarin and capecitabine.
  • CONCLUSIONS: As more patients require anticoagulation, and as chemotherapy agents such as capecitabine become available, the likelihood for these drug interactions increases.
  • In our patient, close monitoring of therapy allowed successful use of warfarin and capecitabine.
  • [MeSH-minor] Capecitabine. Colonic Neoplasms / complications. Colonic Neoplasms / drug therapy. Drug Interactions. Fluorouracil / analogs & derivatives. Heart Valve Prosthesis Implantation. Humans. International Normalized Ratio. Male. Middle Aged. Mitral Valve / surgery

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16014372.001).
  • [ISSN] 1060-0280
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 5Q7ZVV76EI / Warfarin; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


30. Ladino M, Guardiola VD, Paniagua M: Mirtazapine-induced hyponatremia in an elderly hospice patient. J Palliat Med; 2006 Apr;9(2):258-60
Hazardous Substances Data Bank. MIANSERIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Mirtazapine, which enhances central noradrenergic and serotonergic activity, is a commonly prescribed drug for mood disorders in elderly patients due to the low incidence of adverse effects.
  • Nevertheless, geriatric patients in general are more prone to experience adverse drug effects.
  • CASE SUMMARY: A 72-year-old Latino male with stage IV colon cancer entered into hospice care and was treated for major depressive disorder with mirtazapine.
  • On day 6 of treatment, he was somnolent and confused.
  • Upon discontinuation of mirtazapine, the patient's mental status improved, and his sodium level returned to normal.
  • Hyponatremia, although an uncommon adverse effect of mirtazapine therapy, should be considered in the elderly patient with altered mental status or delirium who has recently initiated mirtazapine therapy.
  • [MeSH-minor] Aged. Colonic Neoplasms. Humans. Male

  • MedlinePlus Health Information. consumer health - Hospice Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16629552.001).
  • [ISSN] 1096-6218
  • [Journal-full-title] Journal of palliative medicine
  • [ISO-abbreviation] J Palliat Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents, Tricyclic; 250PJI13LM / Mianserin; A051Q2099Q / mirtazapine
  •  go-up   go-down


31. Stelzner S, Hellmich G, Koch R, Ludwig K: Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol; 2005 Mar 15;89(4):211-7
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis.
  • BACKGROUND: The prognostic impact of primary tumor resection in patients presenting with unresectable synchronous metastases from colorectal carcinoma (CRC) is not well established.
  • In the present study, we analyzed fifteen factors to define the value of primary tumor resection with regard to prognosis.
  • PATIENTS AND METHODS: We identified 186 consecutive patients with proven stage IV CRC from the year 1995 to 2001.
  • The tests were repeated for 107 patients who had no symptoms from their primary tumor.
  • RESULTS: Overall there were six independent variables with a relationship to survival: performance status, ASA-class, CEA level, metastatic load, extent of primary tumor, and chemotherapy.
  • In the asymptomatic patients we investigated 13 factors, 3 of which proved to be independent predictors of survival: performance status, CEA level, and chemotherapy.
  • Resection of primary tumor was only predictive of survival if in-hospital mortality was excluded.
  • CONCLUSION: Resection of the tumor, if possible, is doubtless the best option for stage IV CRC patients with severe symptoms caused by their primary tumor.
  • In asymptomatic patients, chemotherapy is preferable to surgery.
  • [MeSH-major] Colonic Neoplasms / mortality. Palliative Care. Rectal Neoplasms / mortality
  • [MeSH-minor] Aged. Female. Humans. Male. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15726622.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Kleespies A, Füessl KE, Seeliger H, Eichhorn ME, Müller MH, Rentsch M, Thasler WE, Angele MK, Kreis ME, Jauch KW: Determinants of morbidity and survival after elective non-curative resection of stage IV colon and rectal cancer. Int J Colorectal Dis; 2009 Sep;24(9):1097-109
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determinants of morbidity and survival after elective non-curative resection of stage IV colon and rectal cancer.
  • PURPOSE: The benefit of elective primary tumor resection for non-curable stage IV colorectal cancer (CRC) remains largely undefined.
  • METHODS: Using a prospective database, we analyzed potential risk factors in 233 patients, who were electively operated for non-curable stage IV CRC between 1996 and 2002.
  • RESULTS: Patients with colon cancer (CC = 156) and rectal cancer (RC = 77) were comparable with regard to age, sex, comorbidity, American Society of Anesthesiologists score, carcinoembryonic antigen levels, hepatic spread, tumor grade, resection margins, 30-day mortality (CC 5.1%, RC 3.9%) and postoperative chemotherapy. pT4 tumors, carcinomatosis, and non-anatomical resections were more common in colon cancer patients, whereas enterostomies (CC 1.3%, RC 67.5%, p < 0.0001), anastomotic leaks (CC 7.7%, RC 24.2%, p = 0.002), and total surgical complications (CC 19.9%, RC 40.3%, p = 0.001) were more frequent after rectal surgery.
  • Independent determinants of an increased postoperative morbidity were primary rectal cancer, hepatic tumor load >50%, and comorbidity >1 organ.
  • Prognostic factors for limited postoperative survival were hepatic tumor load >50%, pT4 tumors, lymphatic spread, R1-2 resection, and lack of chemotherapy.
  • CONCLUSIONS: Palliative resection is associated with a particularly unfavorable outcome in rectal cancer patients presenting with a locally advanced tumor (pT4, expected R2 resection) or an extensive comorbidity, and in all CRC patients who show a hepatic tumor load >50%.
  • For such patients, surgery might be contraindicated unless the tumor is immediately life-threatening.
  • [MeSH-major] Colonic Neoplasms / surgery. Elective Surgical Procedures / adverse effects. Palliative Care. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Comorbidity. Female. Humans. Liver Neoplasms. Male. Middle Aged. Morbidity. Prognosis. Risk Assessment. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2002 Sep;89(9):1096-102 [12190673.001]
  • [Cites] Colorectal Dis. 2007 Jun;9(5):430-7 [17504340.001]
  • [Cites] Arch Surg. 2000 May;135(5):530-4; discussion 534-5 [10807276.001]
  • [Cites] Dis Colon Rectum. 2003 Dec;46(12):1646-52 [14668590.001]
  • [Cites] Dis Colon Rectum. 1982 Nov-Dec;25(8):749-54 [7172942.001]
  • [Cites] J Surg Oncol. 2002 Sep;81(1):3-7 [12210018.001]
  • [Cites] Br J Surg. 1997 Dec;84(12):1731-6 [9448628.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):233-41; discussion 241-2 [12892803.001]
  • [Cites] Ann Surg Oncol. 2008 Apr;15(4):1099-106 [18181002.001]
  • [Cites] Br J Surg. 2001 Oct;88(10 ):1352-6 [11578291.001]
  • [Cites] BMJ. 2000 Sep 2;321(7260):531-5 [10968812.001]
  • [Cites] Ann Surg. 2003 Aug;238(2):203-13 [12894013.001]
  • [Cites] J Gastrointest Surg. 2004 Mar-Apr;8(3):262-5 [15019919.001]
  • [Cites] Ann Surg Oncol. 2002 Dec;9(10):954-60 [12464586.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):107-16 [11163503.001]
  • [Cites] Int J Colorectal Dis. 2009 Jun;24(6):699-709 [19221767.001]
  • [Cites] Dis Colon Rectum. 1990 Oct;33(10):846-50 [1698594.001]
  • [Cites] Br J Surg. 2000 Sep;87(9):1142-55 [10971419.001]
  • [Cites] Am J Surg. 2000 Dec;180(6):407-11; discussion 412 [11182388.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1155-60 [16035135.001]
  • [Cites] Dis Colon Rectum. 1997 Feb;40(2):156-60 [9075749.001]
  • [Cites] Z Gastroenterol. 2002 Aug;40(8):551-6 [12297977.001]
  • [Cites] Int J Colorectal Dis. 2004 May;19(3):197-202 [14618348.001]
  • [Cites] J Surg Oncol. 2006 Jun 1;93(7):523-8 [16705728.001]
  • [Cites] Gut. 2003 Apr;52(4):568-73 [12631671.001]
  • [Cites] Dis Colon Rectum. 1988 Nov;31(11):842-7 [2460299.001]
  • [Cites] Br J Surg. 1996 Aug;83(8):1116-20 [8869321.001]
  • [Cites] J Am Coll Surg. 2003 May;196(5):722-8 [12742204.001]
  • [Cites] Arch Surg. 1987 Jun;122(6):640-3 [2437881.001]
  • [Cites] Br J Surg. 2001 Feb;88(2):163-4 [11167862.001]
  • [Cites] Ann Surg Oncol. 2005 Aug;12(8):637-45 [15965730.001]
  • [Cites] Semin Oncol. 2006 Oct;33(5 Suppl 10):S26-34 [17145522.001]
  • [Cites] Gastrointest Endosc. 2000 May;51(5):580-5 [10805846.001]
  • [Cites] Dis Colon Rectum. 1997 Dec;40(12):1425-9 [9407979.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] Surg Endosc. 2008 Aug;22(8):1818-25 [18095024.001]
  • [Cites] Dis Colon Rectum. 1981 Jul-Aug;24(5):355-60 [6167412.001]
  • [Cites] ANZ J Surg. 2004 Apr;74(4):229-32 [15043733.001]
  • [Cites] Dis Colon Rectum. 1981 Nov-Dec;24(8):606-9 [6172244.001]
  • [Cites] Dis Colon Rectum. 2004 Sep;47(9):1455-61 [15486741.001]
  • [Cites] Br J Surg. 1995 Oct;82(10):1397-400 [7489177.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):11-4 [9102251.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Endoscopy. 2008 Mar;40(3):184-91 [18322873.001]
  • [Cites] Surgery. 2005 Jan;137(1):42-7 [15614280.001]
  • [Cites] Surg Gynecol Obstet. 1981 Dec;153(6):864-8 [6171042.001]
  • [Cites] J Surg Oncol. 2005 Mar 15;89(4):211-7 [15726622.001]
  • [Cites] Z Gastroenterol. 2004 Oct;42(10 ):1129-77 [15508058.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8 [15383792.001]
  • (PMID = 19495779.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


33. Seshimo K, Yamashita Y, Oishi M, Yokomichi N, Ikeda H, Katoh H, Yamamura M, Kodera M, Maejima R, Kobayashi K, Takita K: [A case of stage IV AFP producing cecal cancer responding to mFOLFOX6 leading to a partial response]. Gan To Kagaku Ryoho; 2009 Aug;36(8):1375-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of stage IV AFP producing cecal cancer responding to mFOLFOX6 leading to a partial response].
  • We report a case of stage IV AFP producing cecal cancer responding to mFOLFOX6 leading to a partial response.
  • The patient was a 72-year-old female with multiple liver metastases of cecal cancer.
  • Final findings revealed cecal cancer, type 3, 60 x 55 mm, pSI (right ovary), pN3, sH3, sP0, cM0, fStage IV, respectively.
  • After surgery, chemotherapy with mFOLFOX6 was performed.
  • After 4 courses, a significant tumor reduction (PR) was obtained.
  • This case suggests that chemotherapy with mFOLFOX6 is a potential regimen for AFP producing colon cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cecal Neoplasms / drug therapy. alpha-Fetoproteins / biosynthesis

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19692783.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 0 / alpha-Fetoproteins; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


34. Wilson CT, Fletcher PC: Dealing with colon cancer: one woman's emotional journey. Clin Nurse Spec; 2002 Nov;16(6):298-305

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dealing with colon cancer: one woman's emotional journey.
  • Using information from more than 200 clinical interviews, Kubler-Ross revealed a trend in emotions over time in most, but not all, of her patients, which enabled her to formulate a model of coping with death that included 5 interdependent emotional stages: denial, anger, bargaining, depression, and acceptance.
  • The purpose of this case study was to examine one individual's emotional journey after being diagnosed with terminal colon cancer.
  • (1) to provide the participant with a voice and to allow her story to be told by examining the major external events (ie,surgery, chemotherapy) occurring since the diagnosis that affected her emotional and physical well-being and (2) to determine whether the participant's emotional journey paralleled Kubler-Ross's model, to what extent, and whether new emotions or stages occurred.
  • The participant, a 50-year-old female, was diagnosed with stage 4 Duke Stage D colon cancer.
  • Four other highly salient emotions were also prevalent throughout the participant's experience with colon cancer, namely joy, fear, hope, and numbness.
  • This case study clearly depicts the unique thoughts and emotions during one woman's struggle with colon cancer, sentiments that are often overlooked in quantitative analysis.
  • [MeSH-major] Colonic Neoplasms / psychology. Emotions

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12464845.001).
  • [ISSN] 0887-6274
  • [Journal-full-title] Clinical nurse specialist CNS
  • [ISO-abbreviation] Clin Nurse Spec
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Fahy BN, D'Angelica M, DeMatteo RP, Blumgart LH, Weiser MR, Ostrovnaya I, Gonen M, Jarnagin WR: Synchronous hepatic metastases from colon cancer: changing treatment strategies and results of surgical intervention. Ann Surg Oncol; 2009 Feb;16(2):361-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous hepatic metastases from colon cancer: changing treatment strategies and results of surgical intervention.
  • More effective chemotherapeutic agents have broadened the role of hepatic resection in the management of patients with synchronous hepatic metastases from colon cancer.
  • This study examines the management patterns and the role of hepatobiliary surgical evaluation in patients with synchronous stage IV colon cancer.
  • Patients with synchronous hepatic metastases from colon cancer evaluated and treated from 1/99 to 11/04 were analyzed retrospectively.
  • Demographic, disease-related, and treatment-related variables were reviewed and correlated with disease-specific survival (DSS).
  • Patients who underwent operative exploration +/- debulking had less hepatic disease but also received more chemotherapy than patients not explored and those who never underwent hepatobiliary surgical evaluation.
  • Variables associated with improved DSS included: carcinoembryonic antigen level < or =200 ng/ml, node-negative primary tumor, < or =4 liver metastases, unilobar metastases, largest metastasis < or =5 cm, and hepatic resection.
  • A multidisciplinary treatment approach which combines both medical and surgical modalities may be associated with improved survival.
  • [MeSH-major] Colonic Neoplasms / surgery. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Carcinoembryonic Antigen / analysis. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19050976.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


36. Wein A, Riedel C, Brückl W, Kastl S, Reingruber B, Hohenberger W, Hahn EG: Weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) with folinic acid (FA) in adjuvant therapy of colon cancer. Z Gastroenterol; 2001 Feb;39(2):153-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) with folinic acid (FA) in adjuvant therapy of colon cancer.
  • After curative resection (R-0) of primary colon cancer or curative metastases resection, the efficacy, toxicity and compliance of a weekly 24-h infusion of high-dose 5-FU with folinic acid was examined in a prospective feasibility trial.
  • From June 1995 to June 1997, 19 patients were included, 11 patients with UICC stage III and 8 patients with UICC stage IV colon cancer.
  • The adjuvant therapy was administered for 6 months.
  • 90% of the patients received the planned 18 chemotherapy applications.
  • After a median follow-up of 51 months (range: 37-59 months), 82% of the patients (9 out of 11) with stage III remained free of recurrence.
  • In stage IV only 12% of the patients (1 out of 8) remained free of recurrence.
  • Now it is tested within randomized phase III trials of the "Arbeitsgemeinschaft Gastroenterologische Onkologie (AGO)" of the "Deutsche Gesellschaft für Verdauungs- und Stoffwechselerkrankungen" for UICC stage III colon cancer.
  • Concerning stage IV, adjuvant therapy was not effective, a fact that seems to justify new drugs and new therapeutic strategies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Fluorouracil / administration & dosage. Leucovorin / administration & dosage
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Drug Administration Schedule. Feasibility Studies. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Survival Rate

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11253506.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


37. Derwinger K, Wettergren Y, Odin E, Carlsson G, Gustavsson B: A study of the MTHFR gene polymorphism C677T in colorectal cancer. Clin Colorectal Cancer; 2009 Jan;8(1):43-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A study of the MTHFR gene polymorphism C677T in colorectal cancer.
  • PURPOSE: The aim of this study was to examine the clinical significance of the methylenetetrahydrofolate reductase (MTHFR) gene polymorphism C677T in colorectal cancer (CRC).
  • The hypothesis was that the genotype could affect the risk of cancer development and the results of cancer treatment.
  • Tolerability of chemotherapy and possible side effects were analyzed by genotype.
  • RESULTS: No genotype was associated with an increased risk of CRC or higher cancer stage.
  • The patients with CT/TT genotype had significantly greater risk of suffering side effects from fluoropyrimidine (5-fluorouracil) treatment (P < .05).
  • In stage III colon cancer, the patients with CT/TT genotype had a poorer prognosis than those with the CC genotype.
  • Though the genotype-associated side effect risks remained in stage IV, the effect on survival was not significant (P < .1).
  • CONCLUSION: The MTHFR polymorphism C677T does, in our material, not affect the risk of CRC; however, it can affect the sensitivity to chemotherapy and the risk of side-effects and therefore survival in stage III and possibly stage IV colon cancer.
  • It could be a future predictive factor in the choice of a treatment regimen.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Female. Genotype. Humans. Male. Middle Aged. Neoplasm Staging. Polymorphism, Genetic. Prognosis. Proportional Hazards Models. Retrospective Studies. Statistics, Nonparametric. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19203896.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


38. Hiraki M, Yakushiji H, Hashiguchi K, Harada S: [Combination chemotherapy with oral TS-1 and low-dose CPT-11 by hepatic arterial infusion for multiple hepatic metastases from colon cancer--a case report]. Gan To Kagaku Ryoho; 2005 Jul;32(7):1055-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combination chemotherapy with oral TS-1 and low-dose CPT-11 by hepatic arterial infusion for multiple hepatic metastases from colon cancer--a case report].
  • Combined chemotherapy consisting of oral TS-1 and low-dose CPT-11 by hepatic arterial infusion is suggested to be a new effective treatment for multiple liver metastases from colorectal cancer.
  • A 53-year-old man was diagnosed with multiple hepatic metastases from advanced colon cancer (Stage IV).
  • The patient underwent partial resection of the colon and catheter insertion into hepatic artery for arterial infusion in November 2003.
  • He was treated with postoperative combination chemotherapy consisting of UFT and low-dose CPT-11.
  • In spite of the reduction of metastatic liver tumors after 2 cycles of the chemotherapy, a metastatic pleural tumor appeared.
  • Therefore, we judged the effect of the chemotherapy to be a progressive disease and changed UFT in the regimen to TS-1.
  • TS-1 was administered orally at 80 mg/body/day under a 2-weeks-on and 1-week-off regimen for 3 times.
  • Tumors showed a reduction rate of 37.4% after the combination therapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Colonic Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Administration, Oral. Ambulatory Care. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Hepatic Artery. Humans. Infusion Pumps, Implantable. Infusions, Intra-Arterial. Male. Middle Aged. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044973.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


39. Baumhoer D, Armbrust T, Ramadori G: Nonsurgical treatment of the primary tumor in four consecutive cases of metastasized colorectal carcinoma. Endoscopy; 2005 Dec;37(12):1232-6
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonsurgical treatment of the primary tumor in four consecutive cases of metastasized colorectal carcinoma.
  • BACKGROUND AND STUDY AIMS: Surgical resection of the primary tumor is standard treatment in stage IV colorectal cancer, but palliative surgery is associated with high morbidity and mortality and with uncertain benefit.
  • By studying a small series of such patients, we aimed to assess whether endoscopic techniques can offer an effective alternative form of nonsurgical palliative treatment for the prevention of local complications caused by a primary colorectal tumor.
  • PATIENTS AND METHODS: We treated four consecutive patients who had stage IV colorectal cancer by endoscopic tumor debulking, either using a standard polypectomy snare technique alone or by argon plasma coagulation ablation followed by snare debulking of the primary tumor.
  • RESULTS: Palliation was achieved in all patients, demonstrated by regression of the primary tumor and absence of symptoms related to the colonic tumor during the observation period of up to 24 months.
  • No procedure-associated complications were observed and it was possible to commence systemic chemotherapy immediately after the endoscopic treatment in all four patients.
  • CONCLUSIONS: We believe that surgical resection of the primary tumor is not appropriate in all patients with stage IV colorectal cancer, and that this form of treatment should be reserved for patients with signs of complete obstruction in whom local ablative procedures are not possible.
  • Simple endoscopic techniques for treatment of the primary tumor, in conjunction with systemic chemotherapy, may be the most suitable form of management for patients with stage IV colorectal tumors.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Colonoscopy / methods. Colorectal Neoplasms / therapy. Intestinal Obstruction / therapy. Liver Neoplasms / secondary. Palliative Care / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Humans. Immunohistochemistry. Male. Neoplasm Staging. Prognosis. Risk Assessment. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome


40. Handa R, Kato T, Miyake Y, Oshima K, Oshima S, Iijima S, Yamamoto H, Kurokawa E, Kikkawa N: [A long term survival case of advanced colon cancer with adjacent organ involvement and multiple liver metastases]. Gan To Kagaku Ryoho; 2006 Nov;33(12):1795-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A long term survival case of advanced colon cancer with adjacent organ involvement and multiple liver metastases].
  • We report a long-term survival case of advanced colon cancer with adjacent organ involvement and multiple liver metastases.
  • An advanced colon cancer of the cecum was found with a colonoscopy.
  • Abdominal CT showed advanced colon cancer with adjacent organ involvement and multiple liver metastases.
  • He received right hemi-colon resection and right hepatic lobectomy.
  • The patient was followed by 8 courses of adjuvant chemotherapy with 5-FU.
  • Usually the prognoses of Stage IV colorectal cancer patients are very unpleasant.
  • Even thougn a few patients with Stage IV colorectal cancer can be a long-term survivor after multiple operations, we need to consider carefully the indication of the operation and QOL for a Stage IV colorectal cancer patient.
  • [MeSH-minor] Chemotherapy, Adjuvant. Colectomy. Fluorouracil / therapeutic use. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Survivors

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212110.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


41. Shiba Y, Umekita N, Noda K, Kitamura M: [A case report of recurrence of liver metastases from colorectal cancer, which seemed to have vanished for a time by intra-aortic chemotherapy]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1829-31
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of recurrence of liver metastases from colorectal cancer, which seemed to have vanished for a time by intra-aortic chemotherapy].
  • A 66-year-old man underwent lower anterior resection for rectum cancer with multiple liver metastases.
  • The diagnosis was Stage IV well-differentiated tubular adeno carcinoma. n1H3M(-).
  • As adjuvant chemotherapy, we chose intra-arterial infusion of 5-FU 1,500 mg/body/week from July 2002 to February 2003.
  • As the strategy for liver metastasis of colon cancer, it is better to perform a surgical resection as soon as the focus becomes resectable.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antimetabolites, Antineoplastic / administration & dosage. Colorectal Neoplasms / pathology. Fluorouracil / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Combined Modality Therapy. Hepatectomy. Humans. Infusions, Intra-Arterial. Male. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315954.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


42. Reinacher-Schick A, Pohl M, Schmiegel W: [Chemotherapy of colorectal cancer]. Internist (Berl); 2009 Nov;50(11):1239-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy of colorectal cancer].
  • [Transliterated title] Die medikamentöse Therapie des kolorektalen Karzinoms.
  • Colorectal cancer (CRC) is the second leading cause of cancer death in the western world.
  • The introduction of new and effective chemotherapeutic substances and biologics in the past decade has significantly improved the systemic treatment of patients with CRC.
  • In stage III colon cancer combination chemotherapy with oxaliplatin is the standard of care.
  • In stage IV cancer the choice of therapy is dependent on the clinical status of the patient.
  • For some patients primary resection of metastases or resection after combination therapy and downsizing of lesions offers a chance for cure.
  • In the palliative setting intensive combination treatment is indicated if the patient suffers from tumor related symptoms or a rapid progress of the disease.
  • The aim of palliative therapy is the prolongation of survival and the improvement of quality of life.
  • Furthermore, the introduction of the mutational status of the KRAS oncogene as the first predictive marker into clinical care is an important step towards the individualization of treatment in CRC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colorectal Neoplasms / drug therapy. Palliative Care / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2007 Jul 14;370(9582):143-52 [17630037.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3117-25 [19451425.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):2013-9 [18421054.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4983-90 [17075116.001]
  • [Cites] Z Gastroenterol. 2008 Aug;46(8):799-840 [18759205.001]
  • [Cites] Z Gastroenterol. 2008 May;46(5):435-40 [18461519.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10 ):1626-34 [18316791.001]
  • [Cites] Ann Oncol. 2005 Aug;16(8):1311-9 [15870084.001]
  • [Cites] Internist (Berl). 2007 Jan;48(1):51-8 [17160665.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]
  • [Cites] J Clin Oncol. 2008 Dec 20;26(36):5910-7 [19018087.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):663-71 [19114683.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3109-16 [19451431.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1670-6 [17470860.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4217-23 [17548840.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1797-806 [15067028.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):2006-12 [18421053.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1007-16 [18358928.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2696-704 [15987918.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):102-9 [17194911.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):229-37 [14657227.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):394-400 [16421419.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):1922-3 [18421044.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1539-44 [17442997.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4976-82 [17075115.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12 ):1766-72 [15550581.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] N Engl J Med. 2000 Sep 28;343 (13):905-14 [11006366.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4906-11 [18794541.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3385-90 [19414665.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3706-12 [15867200.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1209-14 [15051767.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4085-91 [16943526.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1658-64 [17470858.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 [15467030.001]
  • [Cites] Z Gastroenterol. 2004 Oct;42(10 ):1129-77 [15508058.001]
  • [Cites] Lancet. 2007 Jul 14;370(9582):135-42 [17630036.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):753-61; discussion 761-3 [17481478.001]
  • (PMID = 19838655.001).
  • [ISSN] 1432-1289
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


43. Carsin AE, Sharp L, Cronin-Fenton DP, Céilleachair AO, Comber H: Inequity in colorectal cancer treatment and outcomes: a population-based study. Br J Cancer; 2008 Jul 22;99(2):266-74
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inequity in colorectal cancer treatment and outcomes: a population-based study.
  • Several uncertainties surround optimal management of colorectal cancer.
  • We investigated treatment patterns and factors influencing treatment receipt and mortality in routine clinical practice.
  • We included 15 249 individuals, recorded by the National Cancer Registry (Ireland), with primary invasive colon or rectal tumours, diagnosed during 1994-2002.
  • Logistic regression and Cox proportional hazards were used to determine factors associated with treatment receipt within 1 year of diagnosis and with mortality, respectively.
  • A total of 78% had colorectal resection, 31% chemotherapy, and 13% radiotherapy (4% colon; 28% rectum).
  • Half of stage IV patients underwent resection.
  • Chemotherapy and radiotherapy use increased by at least 10% per annum.
  • Patient-related factors were significantly associated with treatment receipt.
  • Chemotherapy was significantly associated with lower mortality for stage III, but not stage II, colon cancer.
  • For rectal cancer, pre-operative radiotherapy was associated with reduced mortality.
  • Surgery and chemotherapy were associated with longer survival for stage IV patients.
  • The observed inequities in treatment and outcomes suggest that there is potential for further dissemination of therapies in routine practice.
  • Improving treatment availability overall, and equity, has the potential to reduce mortality.
  • [MeSH-major] Colorectal Neoplasms / mortality. Colorectal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Medical Oncology / methods. Medical Oncology / trends. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2000 Jan;36(2):151-69 [10741273.001]
  • [Cites] Colorectal Dis. 2007 Jun;9(5):430-7 [17504340.001]
  • [Cites] BMJ. 2000 Sep 2;321(7260):531-5 [10968812.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2719-26 [17563393.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):784-96 [17714993.001]
  • [Cites] Eur J Surg Oncol. 2007 Oct;33(8):993-7 [17400420.001]
  • [Cites] Gut. 2000 Oct;47(4):533-8 [10986214.001]
  • [Cites] Lancet. 2000 Sep 16;356(9234):968-74 [11041397.001]
  • [Cites] Radiother Oncol. 2000 Nov;57(2):137-42 [11054517.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):850-7 [11390534.001]
  • [Cites] J Clin Oncol. 2001 Sep 1;19(17):3712-8 [11533092.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]
  • [Cites] Br J Surg. 2001 Oct;88(10):1352-6 [11578291.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1291-304 [11684209.001]
  • [Cites] Br J Cancer. 2001 Nov 2;85(9):1251-7 [11720457.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1192-202 [11870160.001]
  • [Cites] Gut. 2002 Jul;51(1):60-4 [12077093.001]
  • [Cites] Br J Cancer. 2002 Nov 18;87(11):1221-6 [12439709.001]
  • [Cites] J Epidemiol Community Health. 2003 Apr;57(4):301-9 [12646548.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1293-300 [12663717.001]
  • [Cites] J Am Coll Surg. 2003 May;196(5):722-8 [12742204.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14):2073-9 [12957462.001]
  • [Cites] Cancer Invest. 2003;21(5):701-7 [14628428.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1797-806 [15067028.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] Clin Colorectal Cancer. 2004 Jun;4 Suppl 1:S22-8 [15212702.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3475-84 [15337795.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] IARC Sci Publ. 1993;(121):1-806 [8258476.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2123-34 [9610691.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] N Z Med J. 1999 Jul 9;112(1091):248-50 [10448981.001]
  • [Cites] Gut. 2005 Feb;54(2):268-73 [15647193.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2696-704 [15987918.001]
  • [Cites] Ann Surg Oncol. 2005 Aug;12(8):637-45 [15965730.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 5;97(19):1407-27 [16204691.001]
  • [Cites] JAMA. 2005 Dec 7;294(21):2703-11 [16333005.001]
  • [Cites] Ann Surg Oncol. 2006 Jun;13(6):887-98 [16614880.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2006 Aug;18(6):436-40 [16909965.001]
  • [Cites] Am J Gastroenterol. 2006 Oct;101(10):2308-18 [17032196.001]
  • [Cites] Toxicol Lett. 2006 Dec 1;167(2):131-41 [17027201.001]
  • [Cites] Chest. 2007 May;131(5):1557-66 [17494805.001]
  • [Cites] Arch Surg. 2000 May;135(5):530-4; discussion 534-5 [10807276.001]
  • (PMID = 18594530.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2480963
  •  go-up   go-down


44. van Steenbergen LN, Elferink MA, Krijnen P, Lemmens VE, Siesling S, Rutten HJ, Richel DJ, Karim-Kos HE, Coebergh JW, Working Group Output of The Netherlands Cancer Registry: Improved survival of colon cancer due to improved treatment and detection: a nationwide population-based study in The Netherlands 1989-2006. Ann Oncol; 2010 Nov;21(11):2206-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival of colon cancer due to improved treatment and detection: a nationwide population-based study in The Netherlands 1989-2006.
  • BACKGROUND: We described changes in treatment of colon cancer over time and the impact on survival in The Netherlands in the period 1989-2006.
  • PATIENTS AND METHODS: All 103,744 patients with invasive colon cancer during 1989-2006 in The Netherlands were included.
  • Data were extracted from The Netherlands Cancer Registry.
  • Trends in treatment over time were analysed and multivariable relative survival analysis was carried out.
  • RESULTS: The administration of adjuvant chemotherapy in stage III patients <75 years increased from 19% in 1989-1993 to 79% in 2004-2006 and from 1% to 19% in stage III patients ≥75 years.
  • Among stage IV patients, resection rates of the primary tumour decreased from 72% to 63%, while chemotherapy administration increased from 23% to 64% in those <75 years.
  • Stage III patients with adjuvant chemotherapy exhibited a relative excess risk of 0.4 (95% confidence interval 0.4-0.4) compared with those without.
  • Among stage IV patients, resection of primary tumour, palliative chemotherapy, and metastasectomy were important prognostic factors.
  • CONCLUSIONS: There were substantial improvements in management and survival of colon cancer from 1989 to 2006.
  • Stage III disease patients with colon cancer experienced the largest improvement in survival, most likely related to the increased administration of adjuvant chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20439339.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


45. Nagata Y, Omuro Y, Shimoyama T, Sasaki E, Okamoto R, Maeda Y, Kishida S, Sasaki T: [A case of colon cancer with reversible posterior leukoencephalopathy syndrome following 5-FU and oxaliplatin (FOLFOX regime)]. Gan To Kagaku Ryoho; 2009 Jul;36(7):1163-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of colon cancer with reversible posterior leukoencephalopathy syndrome following 5-FU and oxaliplatin (FOLFOX regime)].
  • A 35-year-old woman with ileus was diagnosed with sigmoid cancer Stage IV (T4N4M0P2H0), and excision of the sigmoid colon, and left ureteroureteral anastomosis was performed.
  • Postoperative chemotherapy with FOLFOX4 was performed.
  • Complications of hypertension were seen on day 6, and convulsions on day 11 after chemotherapy.
  • The patient was treated with antihypertensive therapy and anticonvulsive therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Posterior Leukoencephalopathy Syndrome / chemically induced. Sigmoid Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620809.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


46. Fernández-Lobato B, Díaz-Carrasco MS, Pareja A, Marín M, Vila N, de la Rubia A: [Therapeutic use and profile of toxicity of the FOLFOX4 regimen]. Farm Hosp; 2009 Mar-Apr;33(2):89-95
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic use and profile of toxicity of the FOLFOX4 regimen].
  • [Transliterated title] Uso terapéutico y perfil de toxicidad del esquema FOLFOX4.
  • INTRODUCTION: Since the publication of the MOSAIC test results in 2004, the FOLFOX4 regimen has been established as an adjuvant treatment which is recommended in stage III colorectal cancer.
  • METHODS: Descriptive study of treatments with FOLFOX4 prescribed between April 2005 and March 2007.
  • The following data was collected: age, gender, diagnosis, stage of the illness (TNM classification) and adverse reactions, expressing severity according to Common Toxicity Criteria 2.0.
  • The diagnoses were: 28 colon cancer (4 stage II, 17 stage III, and 7 stage IV), 10 rectal cancer (1 stage II, 4 stage III, and 5 stage IV) and 1 stage IV gastric cancer.
  • ) When the study was completed, 9 patients continued active treatment with the regimen (average 6.8 cycles.
  • 14 patients stopped their treatment (an average of 8.1 cycles) due to toxicity in 10 cases, clinical progression in 3 cases and one patient died.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Humans. Leucovorin / adverse effects. Leucovorin / therapeutic use. Male. Middle Aged. Organoplatinum Compounds / adverse effects. Organoplatinum Compounds / therapeutic use

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19480796.001).
  • [ISSN] 1130-6343
  • [Journal-full-title] Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria
  • [ISO-abbreviation] Farm Hosp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


47. Lang A, Graeven U: [Systemic therapy of colorectal carcinoma]. MMW Fortschr Med; 2007 Jun 7;149(23):36-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Systemic therapy of colorectal carcinoma].
  • [Transliterated title] Onkologen setzen auf neue Kombinationen. Systemische Therapie des kolorektalen Karzinoms.
  • The therapeutic strategy for colorectal carcinoma is based upon the UICC stage.
  • For stage II colon cancer, the indication for adjuvant chemotherapy has not been verified.
  • On the other hand, beginning with stage III, the benefit of this therapy for lymph node metastases is undisputed.
  • Although neoaduvant therapy is not indicated for colon cancer, it is standard procedure for rectal carcinoma in this stage.
  • The objective of palliative chemotherapy in UICC stage IV is to extend the quality of life.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Colonoscopy. Combined Modality Therapy. Disease-Free Survival. Humans. Neoadjuvant Therapy. Neoplasm Staging. Palliative Care. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18062576.001).
  • [ISSN] 1438-3276
  • [Journal-full-title] MMW Fortschritte der Medizin
  • [ISO-abbreviation] MMW Fortschr Med
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


48. Itabashi M, Tada Y, Bamba Y, Takemoto K, Yoshimura Y, Kimura M, Hirosawa T, Ogawa S, Kameoka S: Case of peritoneal dissemination of colon cancer in which PET/CT was useful in determining the indicated surgical procedure. Int Surg; 2009 Jan-Feb;94(1):80-3
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of peritoneal dissemination of colon cancer in which PET/CT was useful in determining the indicated surgical procedure.
  • The right half of the colon was resected in a 70-year-old woman in August 2002 for ascending colon cancer.
  • The peritoneum was also resected because of metastasis (Stage IV).
  • Since tumor markers gradually increased, positron emission tomography (PET)/ computed tomography (CT) revealed peritoneal dissemination.
  • CT did not reveal well-defined tumor shadows.
  • Postoperative progress was favorable; the patient was discharged and enjoys a favorable quality of life through outpatient adjuvant chemotherapy.
  • PET/CT is suggested to be useful in observing the progress of peritoneal dissemination and may be of assistance in determining the course of treatment.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Tomography, Emission-Computed. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20099433.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


49. Hofmann LJ, Lee S, Waddell B, Davis KG: Effect of race on colon cancer treatment and outcomes in the Department of Defense healthcare system. Dis Colon Rectum; 2010 Jan;53(1):9-15
MedlinePlus Health Information. consumer health - African American Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of race on colon cancer treatment and outcomes in the Department of Defense healthcare system.
  • PURPOSE: The increase in mortality noted in African Americans with colon cancer is attributed to advanced stage at presentation and disparities in treatment received.
  • The aim of this study was to assess the influence of race on the treatments and survival of colon cancer patients in an equal-access healthcare system.
  • METHODS: This retrospective cohort study included African American and white patients with colon cancer treated at Department of Defense facilities.
  • Disease stage, surgery performed, chemotherapy used, and overall survival were evaluated.
  • RESULTS: Of the 6958 colon cancer patients identified, 1115 were African American.
  • African Americans presented more frequently with stage IV disease, 23% vs 17% for whites (P < .001).
  • There was no difference in the use of systemic chemotherapy for stage III colon cancer (73.5% for African Americans vs 72.2% for whites; chi2, P > .05) or stage IV colon cancer (56.3% for African Americans vs 54.4% for whites; chi2, P > .05).
  • After adjusting for gender, age, tumor grade, and stage, African American race was not a risk factor for survival in Cox proportional hazard analysis (hazard ratio, 0.981; 95% confidence interval, 0.888-1.084).
  • African American patients undergo surgery and chemotherapy is administered at rates equal to whites for all stages of colon cancer.
  • [MeSH-major] African Americans. Colonic Neoplasms / epidemiology. European Continental Ancestry Group
  • [MeSH-minor] Aged. Continental Population Groups. Humans. Middle Aged. Retrospective Studies. Treatment Outcome. United States

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20010344.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Renouf D, Kennecke H, Gill S: Trends in chemotherapy utilization for colorectal cancer. Clin Colorectal Cancer; 2008 Nov;7(6):386-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in chemotherapy utilization for colorectal cancer.
  • BACKGROUND: Since 1990, significant advances have occurred in the adjuvant and metastatic treatment of colorectal cancer (CRC).
  • Not all patients may be eligible for chemotherapy (CT), and the proportions and characteristics of patients who receive treatment are not well defined.
  • In this study, treatment patterns of patients referred to the British Columbia Cancer Agency (BCCA) with early-stage colon cancer and metastatic CRC between 1990 and 2004 are described.
  • PATIENTS AND METHODS: This study included patients with stage II or III colon cancer or stage IV CRC at presentation referred to the BCCA during a 1-year period for 3 time cohorts: 1990, 2000, and 2004.
  • RESULTS: A total of 1421 patients were included: stage II/III, n = 915; stage IV, n = 506.
  • Chemotherapy utilization increased significantly from 1990 to 2004 for adjuvant CT (1990: 29%; 2000: 45%; 2004: 52%; P < .001) and for palliative CT (1990: 35%; 2000: 51%; 2004: 63%; P < .001).
  • The proportion of patients with stage II disease treated with adjuvant CT dramatically increased (1990: 4%; 2000: 26%; 2004: 30%; P < .001).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Colorectal Neoplasms / drug therapy
  • [MeSH-minor] Aged. British Columbia / epidemiology. Chemotherapy, Adjuvant. Chi-Square Distribution. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Palliative Care. Retrospective Studies. Risk Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19036691.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


51. Takahashi S, Iiai T, Shimada Y, Kobayashi Y, Suda K, Iwaya A, Maruyama S, Tani T, Hatakeyama K: [A long-term survival case of far-advanced colon cancer with Virchow's lymph node and lung metastasis that responded to multidisciplinary therapy]. Gan To Kagaku Ryoho; 2009 Jan;36(1):127-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A long-term survival case of far-advanced colon cancer with Virchow's lymph node and lung metastasis that responded to multidisciplinary therapy].
  • Under a diagnosis of advanced cecal colon cancer with metastasis to Virchow's and paraaortic lymph nodes and lungs, a laparoscopic-assisted ileocecal resection with D2 lymph node dissection was performed.
  • The lesion was judged to be SI(ileum), N2, H0, P0, M1(Virchow's lymph node, No. 216, lungs), Stage IV.
  • After the operation, he received chemotherapy with 5-FU/l-LV(RPMI method), LV/UFT, FOLFOX, FOLFIRI in succession, and cancer aggravation was generally controlled.
  • He has survived for 3 years since operation, and shows good QOL under the treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cecal Neoplasms / drug therapy. Cecal Neoplasms / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary
  • [MeSH-minor] Aged. Biopsy. Carcinoembryonic Antigen / blood. Combined Modality Therapy. Humans. Lymphatic Metastasis / pathology. Male. Neoplasm Staging. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19151578.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


52. Nakamura Y, Fujiwara H, Sonoyama T, Ochiai T, Shimizu T, Ichikawa D, Okamoto K, Sakakura C, Ueda Y, Itoi H, Otsuji E, Hagiwara A, Yamagishi H, Mitsuishi Y, Kishida T: [A case of unresectable multiple liver metastases from colon cancer successfully treated by hepatic arterial infusion chemotherapy and systemic immunotherapy (IFNANK) followed by hepatic resection]. Gan To Kagaku Ryoho; 2004 Oct;31(11):1812-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of unresectable multiple liver metastases from colon cancer successfully treated by hepatic arterial infusion chemotherapy and systemic immunotherapy (IFNANK) followed by hepatic resection].
  • The patient was a 76-year-old man, diagnosed with sigmoid colon cancer with unresectable multible liver metastases.
  • After sigmoidectomy with D2 regional lymphnode dissection on June 21, 2002 (moderately differentiated adenocarcinoma, ss, n(-), H3, P0, M(-), Stage IV), intermittent hepatic arterial infusion chemotherapy using 5-FU (1,250 mg/body/3 hr) and CDDP (10 mg/body/30 min) was performed weekly for 23 times, and then biweekly for 15 times.
  • During the regional chemotherapy, IFNANK therapy was performed biweekly as systemic immunotherapy.
  • As a result, serum levels of tumor markers were remarkably decreased, and the metastatic liver tumors had disappeared in the CT finding in July 2003.
  • Thereafter, IFNANK therapy was continued without the chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colonic Neoplasms / pathology. Immunotherapy / methods. Liver Neoplasms / secondary. Liver Neoplasms / therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Interferon-alpha / pharmacology. Leukapheresis. Lymph Node Excision. Male

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15553724.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interferon-alpha; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


53. O'Connell JB, Maggard MA, Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst; 2004 Oct 6;96(19):1420-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging.
  • BACKGROUND: The recently revised American Joint Committee on Cancer (AJCC) sixth edition cancer staging system increased the stratification within colon cancer stages II and III defined by the AJCC fifth edition system.
  • Using nationally representative Surveillance, Epidemiology, and End Results (SEER) data, we compared survival rates associated with colon cancer stages defined according to both AJCC systems.
  • METHODS: Using SEER data (from January 1, 1991, through December 31, 2000), we identified 119,363 patients with colon adenocarcinoma and included all patients in two analyses by stages defined by AJCC fifth and sixth edition systems.
  • Kaplan-Meier analyses were used to compare overall and stage-specific 5-year survival.
  • According to stages defined by the AJCC fifth edition system, 5-year stage-specific survivals were 93.2% for stage I, 82.5% for stage II, 59.5% for stage III, and 8.1% for stage IV.
  • According to stages defined by the AJCC sixth edition system, 5-year stage-specific survivals were 93.2% for stage I, 84.7% for stage IIa, 72.2% for stage IIb, 83.4% for stage IIIa, 64.1% for stage IIIb, 44.3% for stage IIIc, and 8.1% for stage IV.
  • Under the sixth edition system, 5-year survival was statistically significantly better for patients with stage IIIa colon cancer (83.4%) than for patients with stage IIb disease (72.2%) (P<.001).
  • CONCLUSIONS: The AJCC sixth edition system for colon cancer stratifies survival more distinctly than the fifth edition system by providing more substages.
  • The association of stage IIIa colon cancer with statistically significantly better survival than stage IIb in the new system may reflect current clinical practice, in which stage III patients receive chemotherapy but stage II patients generally do not.
  • [MeSH-major] Colonic Neoplasms / classification. Colonic Neoplasms / mortality. Neoplasm Staging

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2005 Nov 16;97(22):1705-6; author reply 1706-7 [16288127.001]
  • [CommentIn] J Natl Cancer Inst. 2005 Mar 16;97(6):463-4; author reply 464-5 [15770013.001]
  • [CommentIn] J Natl Cancer Inst. 2004 Oct 6;96(19):1408-9 [15467022.001]
  • (PMID = 15467030.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


54. Nakahara O, Beppu T, Ishiko T, Mizumoto T, Masuda T, Hosaka S, Okabe H, Takamori H, Kanemitsu K, Hirota M, Baba H: [A long-term survival case of liver and mediastinal LN metastases from colon cancer treated with intensive multimodal therapy]. Gan To Kagaku Ryoho; 2006 Nov;33(12):1792-4
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A long-term survival case of liver and mediastinal LN metastases from colon cancer treated with intensive multimodal therapy].
  • A 50-year-old man with multiple liver and mediastinal LN metastases from sigmoid colon cancer was admitted to our hospital in May 2005.
  • In October 2002, a radical resection of the original tumor and liver metastases were performed at a previous hospital.
  • Histologically, the tumor was diagnosed as Stage IV.
  • He was treated with an oral anticancer agent as an adjuvant therapy.
  • In January 2005, the CEA level was increased to 3.2 ng/ml and CT scan revealed a solitary liver metastasis.
  • On admission to our hospital, a systemic chemotherapy by FOLFOX4 was begun.
  • In January 2006, radio frequency ablation (RFA) and partial hepatectomy were enforced and then, the tumor marker returned to normal.
  • He has been alive without any sign of recurrence for 42 months from the initial treatment.
  • In conclusion, intensive combination therapies for remote metastases of colon cancer might be promising to obtain a long-term survival without ruining QOL.
  • [MeSH-major] Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoembryonic Antigen / blood. Chemotherapy, Adjuvant. Combined Modality Therapy. Fluorouracil / therapeutic use. Hepatectomy. Humans. Leucovorin / therapeutic use. Lymphatic Metastasis. Male. Middle Aged. Organoplatinum Compounds / therapeutic use

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212109.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


55. Yamamoto A, Ishibashi K, Tajima Y, Hatano S, Ishiguro T, Osawa T, Okada N, Kumamoto K, Yokoyama M, Haga N, Ishida H: [Successfully resected an isolated extraperitoneal metastasis of sigmoid colon cancer--a case report]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2644-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successfully resected an isolated extraperitoneal metastasis of sigmoid colon cancer--a case report].
  • We herein report an extremely rare operative case of an isolated extraperitoneal metastasis of colon cancer.
  • A female patient had undergone a sigmoidectomy for ileus due to sigmoid colon cancer when she was 40 years old.
  • Peritoneal metastasis, 5 mm in diameter, was on the sigmoid colon mesentery and she was histologically diagnosed as Stage IV.
  • She received fluorouracil-based adjuvant chemotherapy for 24 months.
  • Serum CEA increased in spite of giving UFT/LV, so we changed to mFOLFOX6 therapy.
  • Serum CEA decreased until it reached to a normal range after 9 courses, and stopped mFOLFOX6 therapy.
  • A histological examination of the tumor revealed a moderately differentiated adenocarcinoma similar to colon cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224666.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


56. Uña E: Atypical presentation of acute neurotoxicity secondary to oxaliplatin. J Oncol Pharm Pract; 2010 Dec;16(4):280-2
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 62-year-old female diagnosed with stage IV colon cancer, underwent palliative treatment with combination of oxaliplatin (130 mg/m( 2) on day 1), capecitabine (1.250 mg/m(2) bid on days 1 to 14 every 3 weeks), and bevacizumab.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Angiogenesis Inhibitors / administration & dosage. Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bevacizumab. Capecitabine. Colonic Neoplasms / drug therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Fluorouracil / therapeutic use. Humans. Leg. Middle Aged. Muscle Cramp / chemically induced. Muscle Cramp / drug therapy. Palliative Care. Paresthesia / chemically induced. Paresthesia / drug therapy. Treatment Outcome

  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20015928.001).
  • [ISSN] 1477-092X
  • [Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • [ISO-abbreviation] J Oncol Pharm Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


57. Kamiński B, Kobiorska-Nowak J, Bień S: [Distant metastases to nasal cavities and paranasal sinuses, from the organs outside the head and neck]. Otolaryngol Pol; 2008;62(4):422-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At that time, the correct diagnosis requires only to compare the pathology report from the primary biopsy, with the biopsy from the lump in the head and neck.
  • MATERIAL: 4 cases, out of 46 all distant metastases to the head and neck region, localized in the nasal cavity and paranasal sinuses, diagnosed and treated in Dept. of ORL H&N surgery, Holy Cross Cancer Centre, from 2001 to 2007.
  • Case I. F. 71 years; the metastasis of colonic carcinoma to the sphenoid sinus as a first symptom of the disease).
  • The palliative Rtg-therapy was applied, and patient died in 2 months after diagnosis was established.
  • Case II. M. 69 y with metastasis of kidney cancer (Ca clarocellulare) to the nasal cavity, during a palliative stage of the disease due to multiple lung metastases.
  • Patient was treated with multiple courses of chemotherapy due to generalization of the disease.
  • Cases III. F. 50 years in palliative stage of the breast cancer, with metastases to the bones and hepar and with metastasis to the maxillary sinus.
  • Received palliative Rtg. therapy on the region of metastasis.
  • Case IV. F. 54 years in palliative stage of the colonic cancer, with multiple metastases to the lungs and hepar; with metastasis to the maxillary sinus.
  • During hemotherapy a symptoms of tumor of the maxillary sinus appeared, confirmed as a metastasis.
  • The palliative Rtg-therapy on the region of metastasis.
  • In the majority of distant metastases to the nose and paranasal sinuses, the palliative therapy is the only possible option of treatment.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Renal Cell / pathology. Colonic Neoplasms / pathology. Paranasal Sinus Neoplasms / secondary. Skull Base Neoplasms / secondary
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Poland. Prognosis. Survival Analysis. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837216.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


58. Holt PR, Kozuch P, Mewar S: Colon cancer and the elderly: from screening to treatment in management of GI disease in the elderly. Best Pract Res Clin Gastroenterol; 2009;23(6):889-907
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon cancer and the elderly: from screening to treatment in management of GI disease in the elderly.
  • Colorectal cancer is one of the commonest tumours in the Westernized world affecting mainly the elderly.
  • This neoplasm in older individuals occurs more often in the right colon and grows more rapidly than in the young, often shows a mucinous histology and mismatch repair gene changes.
  • Effective screening permits discovery of colorectal cancer at an early highly treatable stage and allows for detection and removal of premalignant colorectal adenomas.
  • Screening methods that focus on cancer detection use fecal assays for the presence of blood or altered DNA, those for detection of adenomas (and early cancer) use endoscopic or computerised radiologic techniques.
  • Broad use of screening methods has lowered colorectal cancer development by about 50%.
  • In addition, prevention of the earliest stage of colon carcinogenesis has been shown to be effective in small prospective studies and epidemiologic surveys but have not been employed in the general population.
  • Since 1996 the chemotherapeutic armamentarium for metastatic colorectal cancer has grown beyond 5-fluorouracil to include an oral 5-fluorouracil prodrug, capecitabine as well as irinotecan and oxaliplatin.
  • Most stage IV patients are treated with all of these drugs over 2 or 3 sequential lines of palliative chemotherapy and attain median survivals approaching 24 months.
  • Lastly, adjuvant oxaliplatin plus 5-fluorouracil for high risk resected stage II and stage III colon cancer patient has led to substantial improvement in cure rates.
  • With appropriate care of age associated comorbidities these treatment modalities are feasible and effective in the geriatric population.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1765-71 [14652238.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 16;313(3):784-8 [14697260.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):229-37 [14657227.001]
  • [Cites] Gut. 2004 Feb;53(2):284-90 [14724165.001]
  • [Cites] N Engl J Med. 2004 Mar 4;350(10):991-1004 [14999111.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):11-27 [15000146.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1201-8 [14993230.001]
  • [Cites] Dis Colon Rectum. 2004 May;47(5):665-73 [15054679.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7 [15166961.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] Trends Mol Med. 2004 Jul;10(7):324-30 [15242680.001]
  • [Cites] Ann Surg. 2005 May;241(5):715-22, discussion 722-4 [15849507.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3545-51 [15908665.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Jul;314(1):1-8 [15805430.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2696-704 [15987918.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):34-41 [16012932.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4866-75 [15939922.001]
  • [Cites] Mech Ageing Dev. 2005 Sep;126(9):987-1002 [15893363.001]
  • [Cites] Science. 2005 Aug 5;309(5736):886-7 [16081723.001]
  • [Cites] Gastroenterology. 2005 Sep;129(3):837-45 [16143123.001]
  • [Cites] Eur J Cancer. 2005 Oct;41(15):2297-303 [16140008.001]
  • [Cites] Gastroenterology. 2005 Oct;129(4):1163-70 [16230070.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3523-9 [18640933.001]
  • [Cites] Br J Cancer. 2008 Aug 5;99(3):532-5 [18628760.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8671-8 [16314627.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):255-62 [16454827.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):189-93 [16492904.001]
  • [Cites] Br J Cancer. 2006 Apr 10;94(7):969-75 [16552438.001]
  • [Cites] JAMA. 2006 May 24;295(20):2357-65 [16720821.001]
  • [Cites] Dis Colon Rectum. 2006 Jun;49(6):816-24 [16741639.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4085-91 [16943526.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):885-95 [16943401.001]
  • [Cites] Int J Colorectal Dis. 2007 Jan;22(1):77-83 [16538491.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2418-21 [17164364.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):15-22 [17086168.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1683-9 [17188959.001]
  • [Cites] J Natl Cancer Inst. 2007 Jan 17;99(2):129-36 [17227996.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Jan;5(1):111-7 [17161655.001]
  • [Cites] Ann Intern Med. 2007 Mar 6;146(5):361-4 [17339621.001]
  • [Cites] Cancer Detect Prev. 2007;31(1):3-11 [17289293.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):585-92 [17239930.001]
  • [Cites] Oncologist. 2007 Mar;12(3):312-9 [17405895.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1658-64 [17470858.001]
  • [Cites] Dis Colon Rectum. 2007 May;50(5):604-10 [17160571.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2351-9 [17551129.001]
  • [Cites] JAMA. 2007 Aug 15;298(7):754-64 [17699009.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3644-8 [17704414.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1745-52 [17855692.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4224-30 [17548839.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4217-23 [17548840.001]
  • [Cites] J Natl Cancer Inst. 2007 Oct 3;99(19):1462-70 [17895475.001]
  • [Cites] Gut. 2007 Nov;56(11):1585-9 [17591622.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4779-86 [17947725.001]
  • [Cites] N Engl J Med. 2007 Nov 15;357(20):2040-8 [18003960.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5390-6 [18048820.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11594-600 [18089788.001]
  • [Cites] Gastroenterology. 2008 Jan;134(1):29-38 [18022173.001]
  • [Cites] JAMA. 2008 Mar 5;299(9):1027-35 [18319413.001]
  • [Cites] J Clin Oncol. 2001 Nov 1;19(21):4097-106 [11689577.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):1931-8 [11932894.001]
  • [Cites] Am J Clin Oncol. 2002 Apr;25(2):126-30 [11943888.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):759-66 [12035031.001]
  • [Cites] World J Gastroenterol. 2008 Jul 28;14(28):4429-33 [18680219.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Sep;67(3):255-62 [18400508.001]
  • [Cites] N Engl J Med. 2008 Sep 18;359(12):1207-17 [18799557.001]
  • [Cites] Br J Cancer. 2008 Oct 7;99(7):1046-9 [18797465.001]
  • [Cites] Cancer Res. 2008 Oct 15;68(20):8541-6 [18922929.001]
  • [Cites] Ann Intern Med. 2008 Nov 4;149(9):627-37 [18838716.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5326-34 [18854571.001]
  • [Cites] Br J Cancer. 2008 Dec 16;99(12):1991-2000 [19034277.001]
  • [Cites] Ann Intern Med. 2009 Jan 6;150(1):1-8 [19075198.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):196-203 [19124498.001]
  • [Cites] Gut. 2009 Feb;58(2):241-8 [18852257.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2651-7 [12039926.001]
  • [Cites] J Nutr. 2002 Aug;132(8 Suppl):2413S-2418S [12163703.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3478-83 [12177109.001]
  • [Cites] Ann Intern Med. 2002 Oct 1;137(7):603-12 [12353948.001]
  • [Cites] Mech Ageing Dev. 2002 Nov;123(12):1543-52 [12470892.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):600-7 [12612897.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):879-80 [12621130.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Prog Exp Tumor Res. 2003;37:1-24 [12795046.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):755-62 [12917207.001]
  • [Cites] J Clin Invest. 2003 Nov;112(9):1351-60 [14597761.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Jun;1(1):32-8 [18841250.001]
  • [Cites] Ann Oncol. 2009 Jan;20(1):5-16 [18922882.001]
  • [Cites] Br J Cancer. 2009 Feb 24;100(4):611-6 [19209175.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 18;101(4):267-76 [19211442.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 18;101(4):256-66 [19211452.001]
  • [Cites] Gastroenterology. 2009 Mar;136(3):741-54 [19166855.001]
  • [Cites] Am J Gastroenterol. 2009 Mar;104(3):739-50 [19240699.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 May;63(6):1017-22 [18781300.001]
  • [Cites] N Engl J Med. 2009 Apr 2;360(14):1408-17 [19339720.001]
  • [Cites] Crit Rev Oncol Hematol. 2009 May;70(2):134-44 [19111473.001]
  • [Cites] Cancer. 2009 May 1;115(9):1967-76 [19235249.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3109-16 [19451431.001]
  • [Cites] J Surg Oncol. 2009 Oct 1;100(5):364-71 [19235181.001]
  • [Cites] Gut. 2010 Jan;59(1):62-8 [19671542.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):136-47 [10623704.001]
  • [Cites] Lancet. 2000 Apr 8;355(9211):1211-4 [10770302.001]
  • [Cites] Eur J Cancer Prev. 1999 Dec;8 Suppl 1:S73-86 [10772421.001]
  • [Cites] Curr Top Microbiol Immunol. 2000;249:101-18 [10802941.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8403-8 [10900004.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] World J Surg. 2000 Sep;24(9):1081-90 [11036286.001]
  • [Cites] Lancet. 2000 Sep 16;356(9234):968-74 [11041397.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):433-8 [11283620.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2282-92 [11304782.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1264-6 [11504772.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):438-47; discussion 447-50 [15319715.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6919-23 [15466182.001]
  • [Cites] Lancet. 2004 Oct 2-8;364(9441):1219-28 [15464182.001]
  • [Cites] Cancer. 1967 Sep;20(9):1520-61 [6038396.001]
  • [Cites] Int J Cancer. 1985 Aug 15;36(2):179-86 [4018911.001]
  • [Cites] J Clin Oncol. 1987 Oct;5(10):1559-65 [2443619.001]
  • [Cites] Cancer. 1988 Dec 1;62(11):2373-7 [3179952.001]
  • [Cites] Gastroenterology. 1988 Dec;95(6):1556-63 [3181679.001]
  • [Cites] J Clin Oncol. 1989 Oct;7(10):1407-18 [2476530.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] N Engl J Med. 1992 Mar 5;326(10):653-7 [1736103.001]
  • [Cites] J Natl Cancer Inst. 1992 Oct 21;84(20):1572-5 [1404450.001]
  • [Cites] N Engl J Med. 1993 May 13;328(19):1365-71 [8474513.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] Arch Intern Med. 1995 Sep 11;155(16):1741-8 [7654107.001]
  • [Cites] Int J Colorectal Dis. 1996;11(1):45-8 [8919342.001]
  • [Cites] Lancet. 1996 Nov 30;348(9040):1472-7 [8942775.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):858-64 [9307184.001]
  • [Cites] Br J Surg. 1998 Jul;85(7):897-901 [9692559.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1413-8 [9807987.001]
  • [Cites] N Engl J Med. 1999 Jan 14;340(2):101-7 [9887161.001]
  • [Cites] Ann Pharmacother. 2005 Jan;39(1):128-35 [15590869.001]
  • [Cites] Am J Gastroenterol. 2005 Feb;100(2):390-4 [15667497.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Feb;3(2):150-8 [15704049.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1071-80 [15713944.001]
  • [Cites] Dig Dis Sci. 2005 Nov;50(11):2147-52 [16240230.001]
  • [Cites] Eur J Surg Oncol. 2008 Apr;34(4):428-32 [17466484.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1443-51 [18349394.001]
  • [Cites] Aliment Pharmacol Ther. 2008 Apr;27(8):697-712 [18248653.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1007-16 [18358928.001]
  • [Cites] Anticancer Drugs. 2008 Jun;19(5):447-64 [18418212.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):2006-12 [18421053.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2311-9 [18390971.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4465-78 [18519710.001]
  • [Cites] Gastroenterology. 2008 Jul;135(1):82-90 [18482589.001]
  • [Cites] Am J Clin Nutr. 2008 Jul;88(1):176-84 [18614739.001]
  • (PMID = 19942166.001).
  • [ISSN] 1532-1916
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] ENG
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000043; United States / NCRR NIH HHS / RR / UL1RR024143; United States / NCRR NIH HHS / RR / UL1 RR024143; United States / NCI NIH HHS / CA / U54CA100926; United States / NCI NIH HHS / CA / U54 CA100926
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 163
  • [Other-IDs] NLM/ NIHMS160270; NLM/ PMC3742312
  •  go-up   go-down


59. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, Mendiboure J, Pignon JP, Jooste V, van Endert P, Ducreux M, Zitvogel L, Piard F, Kroemer G: Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene; 2010 Jan 28;29(4):482-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunogenic death of colon cancer cells treated with oxaliplatin.
  • However, OXP, but not CDDP, stimulates pre-apoptotic CRT exposure in a series of murine and human colon cancer cell lines.
  • Subcutaneous injection of OXP-treated colorectal cancer (CRC), CT26, cells induced an anticancer immune response that was reduced by short interfering RNA-mediated depletion of CRT or HMGB1.
  • CT26 tumors implanted in immunocompetent mice responded to OXP treatment in vivo, and this therapeutic response was lost when CRT exposure by CT26 cells was inhibited or when CT26 cells were implanted in immunodeficient mice.
  • In patients with advanced (stage IV, Duke D) CRC, who received an OXP-based chemotherapeutic regimen, the loss-of-function allele of TLR4 (Asp299Gly in linkage disequilibrium with Thr399Ile, reducing its affinity for HMGB1) was as prevalent as in the general population.
  • In conclusion, OXP induces immunogenic death of CRC cells, and this effect determines its therapeutic efficacy in CRC patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Apoptosis / drug effects. Colonic Neoplasms / drug therapy. Colonic Neoplasms / immunology. Organoplatinum Compounds / therapeutic use
  • [MeSH-minor] Aged. Animals. Calreticulin / genetics. Calreticulin / metabolism. Cell Line, Tumor. Cisplatin / pharmacology. Female. HMGB1 Protein / immunology. HMGB1 Protein / metabolism. Humans. Male. Mice. Mice, Inbred BALB C. Middle Aged. Neoplasm Staging. Neoplasm Transplantation. Polymorphism, Genetic. Prognosis. Toll-Like Receptor 4 / deficiency. Toll-Like Receptor 4 / immunology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19881547.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Calreticulin; 0 / HMGB1 Protein; 0 / Organoplatinum Compounds; 0 / Tlr4 protein, mouse; 0 / Toll-Like Receptor 4; 04ZR38536J / oxaliplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


60. Berger TG, Dieckmann D, Efferth T, Schultz ES, Funk JO, Baur A, Schuler G: Artesunate in the treatment of metastatic uveal melanoma--first experiences. Oncol Rep; 2005 Dec;14(6):1599-603
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Artesunate in the treatment of metastatic uveal melanoma--first experiences.
  • Artesunate is approved for the treatment of multidrug-resistant malaria and has an excellent safety profile.
  • It has been shown that Artesunate, apart from its anti-malarial activity, has cytotoxic effects on a number of human cancer cell lines, including leukemia, colon cancer and melanoma.
  • We report on the first long-term treatment of two cancer patients with ART in combination with standard chemotherapy.
  • These patients with metastatic uveal melanoma were treated on a compassionate-use basis, after standard chemotherapy alone was ineffective in stopping tumor growth.
  • The therapy-regimen was well tolerated with no additional side effects other than those caused by standard chemotherapy alone.
  • One patient experienced a temporary response after the addition of ART to Fotemustine while the disease was progressing under therapy with Fotemustine alone.
  • This patient is still alive 47 months after first diagnosis of stage IV uveal melanoma, a situation with a median survival of 2-5 months.
  • Despite the small number of treated patients, ART might be a promising adjuvant drug for the treatment of melanoma and possibly other tumors in combination with standard chemotherapy.
  • [MeSH-major] Artemisinins / therapeutic use. Melanoma / drug therapy. Sesquiterpenes / therapeutic use. Uveal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Artemisia / chemistry. Dacarbazine / administration & dosage. Fatal Outcome. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273263.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Artemisinins; 0 / Sesquiterpenes; 60W3249T9M / artesunate; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


61. Mitchell MS: Cancer vaccines, a critical review--Part I. Curr Opin Investig Drugs; 2002 Jan;3(1):140-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer vaccines, a critical review--Part I.
  • Cancer vaccines are more properly referred to as 'active specific immunotherapy', and are used to treat cancers rather than to prevent them, at least at present.
  • Vaccines augment already established tumor immunity, are far more specific against the tumor than cytokines, have little or no toxicity, and thus may easily be combined with other types of immunotherapy.
  • They also elicit immunological memory, which may check recurrence of the tumor.
  • Controlled trials of Melacine indicate prolongation of survival in patients with resected stage IIB disease, particularly those with one or more of the following HLA class I alleles: HLA-A2 or -A28 (-A6802), HLA-B12, -44 or -45, and HLA-C3.
  • A combination of interferon-alpha2b and Melacine appears to enhance the anti-tumor response in advanced (stage IV) disease, and is being tested in a large randomized controlled trial in resected stage III disease.
  • An irradiated autologous colon carcinoma vaccine has improved relapse-free survival in resected stage II disease (Dukes B) in a controlled trial.
  • Second-generation whole cell vaccines include those incorporating genes such as GM-CSF or CD80 (B7-1) to improve immunogenicity, and the use of immunogenic cell membranes such as large multivalent immunogen (LMI).
  • Upregulation of HLA class II molecules and concomitant inhibition of the Ii molecule are also being explored as a strategyfor improved presentation of tumor-associated antigens in vaccines.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Animals. Humans. Melanoma / drug therapy. Melanoma / immunology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12054065.001).
  • [ISSN] 1472-4472
  • [Journal-full-title] Current opinion in investigational drugs (London, England : 2000)
  • [ISO-abbreviation] Curr Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines
  • [Number-of-references] 32
  •  go-up   go-down


62. Berry J, Caplan L, Davis S, Minor P, Counts-Spriggs M, Glover R, Ogunlade V, Bumpers K, Kauh J, Brawley OW, Flowers C: A black-white comparison of the quality of stage-specific colon cancer treatment. Cancer; 2010 Feb 1;116(3):713-22
MedlinePlus Health Information. consumer health - Health Disparities.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A black-white comparison of the quality of stage-specific colon cancer treatment.
  • BACKGROUND: Several studies have attributed racial disparities in cancer incidence and mortality to variances in socioeconomic status and health insurance coverage.
  • METHODS: To examine the effects of race on colorectal cancer outcomes within a single setting, the authors performed a retrospective cohort study that analyzed the cancer registry, billing, and medical records of 365 university hospital patients (175 blacks and 190 whites) diagnosed with stage II-IV colon cancer between 2000 and 2005.
  • Racial differences in the quality (effectiveness and timeliness) of stage-specific colon cancer treatment (colectomy and chemotherapy) were examined after adjusting for socioeconomic status, health insurance coverage, sex, age, and marital status.
  • RESULTS: Blacks and whites had similar sociodemographic characteristics, tumor stage and site, quality of care, and health outcomes.
  • Age and diagnostic stage were predictors of quality of care and mortality.
  • Although few patients (5.8%) were uninsured, they were more likely to present at advanced stages (61.9% at stage IV) and die (76.2%) than privately insured and publicly insured patients (p = .002).
  • Age, diagnostic stage, and health insurance coverage remained independently associated with mortality.
  • Future studies of disparities in colon cancer treatment should examine sociocultural barriers to accessing appropriate care in various healthcare settings.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 American Cancer Society.
  • [Cites] Cancer. 2004 May 15;100(10):2093-103 [15139050.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1293-300 [12663717.001]
  • [Cites] JAMA. 1988 Sep 23-30;260(12):1743-8 [3045356.001]
  • [Cites] Arch Intern Med. 1993 Jul 26;153(14):1681-8 [8333805.001]
  • [Cites] Med Care. 1996 Sep;34(9):970-84 [8792784.001]
  • [Cites] Am J Public Health. 1996 Dec;86(12):1794-7 [9003140.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2312-20 [9635522.001]
  • [Cites] Med Care. 1999 Jul;37(7):712-7 [10424642.001]
  • [Cites] Ethn Dis. 2005 Winter;15(1):76-83 [15720052.001]
  • [Cites] Med Care. 2005 Mar;43(3 Suppl):I3-8 [15746588.001]
  • [Cites] Med Care. 2005 Mar;43(3 Suppl):I72-81 [15746594.001]
  • [Cites] J Community Health. 2005 Feb;30(1):55-74 [15751599.001]
  • [Cites] BMC Gastroenterol. 2005;5:10 [15755323.001]
  • [Cites] Am J Prev Med. 2005 Jun;28(5):479-82 [15894152.001]
  • [Cites] Cancer. 2005 Aug 1;104(3):629-39 [15983985.001]
  • [Cites] Int J Cancer. 2005 Oct 10;116(6):914-9 [15856472.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 17;97(16):1211-20 [16106026.001]
  • [Cites] Arch Intern Med. 2005 Oct 10;165(18):2129-35 [16217003.001]
  • [Cites] Am J Gastroenterol. 2006 Oct;101(10):2308-18 [17032196.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):612-20 [17186529.001]
  • [Cites] J Natl Med Assoc. 2007 Jul;99(7):723-8 [17668638.001]
  • [Cites] CA Cancer J Clin. 2008 Jan-Feb;58(1):9-31 [18096863.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):222-31 [18282806.001]
  • [Cites] J Natl Cancer Inst. 1999 Nov 17;91(22):1933-40 [10564677.001]
  • [Cites] J Assoc Acad Minor Phys. 1999;10(3):59-67 [10826011.001]
  • [Cites] Med Care Res Rev. 2000;57 Suppl 1:108-45 [11092160.001]
  • [Cites] Cancer. 2001 Jan 1;91(1):178-88 [11148575.001]
  • [Cites] Med Care. 2001 Apr;39(4):361-72 [11329523.001]
  • [Cites] Cancer Causes Control. 2003 Oct;14(8):761-6 [14674740.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):418-24 [14716780.001]
  • [Cites] Cancer Causes Control. 2004 Mar;15(2):193-9 [15017132.001]
  • [Cites] Ann Epidemiol. 2004 Mar;14(3):215-21 [15036226.001]
  • [Cites] Am Surg. 2004 Mar;70(3):259-64 [15055851.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2547-54 [11745188.001]
  • [Cites] Arch Surg. 2002 May;137(5):550-4; discussion 554-6 [11982467.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 7;94(15):1160-7 [12165641.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3999-4005 [12351597.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):493-8 [12518374.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1112-7 [12631615.001]
  • [Cites] Med Care. 2004 Aug;42(8):789-800 [15258481.001]
  • (PMID = 19950126.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCCDPHP CDC HHS / DP / U48 DP000049; United States / NIMHD NIH HHS / MD / 5P60MD000525-04; United States / NIMHD NIH HHS / MD / P60 MD000525-04; United States / NIMHD NIH HHS / MD / P60 MD000525; United States / NCCDPHP CDC HHS / DP / 5U48DP000049-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS153275; NLM/ PMC2815235
  •  go-up   go-down


63. Okuno K: Surgical treatment for digestive cancer. Current issues - colon cancer. Dig Surg; 2007;24(2):108-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment for digestive cancer. Current issues - colon cancer.
  • BACKGROUND: Due to the westernization of the diet in Japan, the incidence of colorectal cancer has increased 4.5 times in the last 25 years.
  • In this review, the recent results of surgical treatment for colonic cancer and the future perspectives in Japan are described.
  • MATERIALS AND METHODS: A multi-institutional registry of large bowel cancer in Japan of 10,809 patients with colonic cancer treated from 1991 to 1994 was investigated.
  • The data have been published in the Guidelines of the Japanese Society for Cancer of the Colon and Rectum (2005).
  • Regarding laparoscopic surgery, 1,495 patients with colon cancer were examined in a multicenter study between April 1993 and August 2002.
  • RESULTS: Radical resection with a curative intent is appropriate for 83-99% of the patients with stage I-III localized colon carcinoma.
  • Adequate lymphadenectomy, including paracolic, intermediate and principal node dissection (D3 lymphadenectomy), is of critical importance for both the accurate staging and local control of the disease.
  • This treatment protocol has now been accepted as a 'standard' operation by Japanese colorectal surgeons.
  • For patients undergoing a curative resection for colon cancer, the 5-year survival rates vary between 62 (stage III) and 91% (stage I).
  • Adjuvant chemotherapy using 5-FU/leucovorin or oral compounds is commonly administered to patients with stage III disease.
  • Laparoscopic surgery for colonic cancer yielded a comparable oncological outcome to that reported for conventional open surgery in the Japanese registry for all disease stages.
  • CONCLUSION: Radical resection with a D3 lymphadenectomy provided satisfactory 5-year survival for patients with stage I-III colon cancer in Japan.
  • However, the survival of patients with stage IV disease is still unsatisfactory (only a 14% 5-year survival).
  • Any further improvements depend on both identifying such patients at an earlier stage as well as developing new and effective treatment modalities.
  • [MeSH-major] Colonic Neoplasms / surgery
  • [MeSH-minor] Humans. Lymph Node Excision. Neoplasm Metastasis. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 17446704.001).
  • [ISSN] 0253-4886
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 21
  •  go-up   go-down


64. Takata O, Kawamura YJ, Konishi F, Sasaki J, Kai T, Miyakura Y, Nagai H, Tsukamoto T: cDNA array analysis for prediction of hepatic metastasis of colorectal carcinoma. Surg Today; 2006;36(7):608-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] cDNA array analysis for prediction of hepatic metastasis of colorectal carcinoma.
  • PURPOSE: Distant metastasis is a significant prognostic factor of colon carcinoma.
  • Adjuvant chemotherapy has been shown to decrease its recurrence.
  • However, there are no definitive methods for the diagnosis of hepatic recurrence after potentially curative surgery.
  • METHODS: Patients with stage III colorectal carcinoma without any recurrence for at least 5 years (group A: n = 9) and patients with stage IV carcinoma with hepatic metastasis (group B: n = 10) were included in this study.
  • Tissue samples were collected from the primary tumor and adjacent normal colonic mucosa at the time of surgery in each patient.
  • Therefore, the positive and negative predictive value of hierarchical clustering analysis for hepatic metastasis was 80.0% and 78.8%, respectively.
  • This method is expected to contribute to the identification of patients at high risk for hepatic recurrence, while also helping in the administration of intensive adjuvant chemotherapy for such high risk patients.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Colorectal Dis. 2002 May;17(3):131-6 [12049305.001]
  • [Cites] Cancer Invest. 2003;21(4):505-11 [14533439.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2003 Aug;15(5):221-6 [12924449.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Am J Pathol. 1996 Nov;149(5):1541-51 [8909244.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3544-9 [11325815.001]
  • [Cites] Science. 1995 Oct 20;270(5235):467-70 [7569999.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Clin Colorectal Cancer. 2003 Aug;3(2):108-12 [12952567.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2936-43 [8523058.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):321-6 [7847642.001]
  • [Cites] Dis Colon Rectum. 2001 Feb;44(2):295-9 [11227951.001]
  • [Cites] Semin Oncol. 2003 Aug;30(4 Suppl 15):40-6 [14523794.001]
  • [Cites] Hua Xi Yi Ke Da Xue Xue Bao. 1999 Jun;30(2):185-7, 191 [12212055.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1155-8 [14520437.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10614-9 [8855227.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1415-21 [11583969.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] Semin Oncol. 2001 Feb;28(1 Suppl 1):9-13 [11273592.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):246-50 [8996149.001]
  • [Cites] Br J Cancer. 2003 Oct 20;89(8):1439-44 [14562014.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):143-52 [11544480.001]
  • [Cites] Lancet. 1995 Apr 15;345(8955):939-44 [7715291.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Aug 3;285(5):1244-9 [11478790.001]
  • [Cites] Ann Surg. 2000 Oct;232(4):576-85 [10998656.001]
  • [Cites] J Gastroenterol. 2002 Nov;37 Suppl 14:83-6 [12572872.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3124-30 [11306497.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):614-6 [7880746.001]
  • (PMID = 16794795.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


65. Lamberti C, Lundin S, Bogdanow M, Gorschlüter M, Schmidt-Wolf IG, Sauerbruch T: [Adjuvant and palliative chemotherapy of colorectal cancer in Germany outside controlled trials]. Dtsch Med Wochenschr; 2006 Mar 10;131(10):485-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant and palliative chemotherapy of colorectal cancer in Germany outside controlled trials].
  • [Transliterated title] Adjuvante und palliative Chemotherapie des kolorektalen Karzinoms in Deutschland ausserhalb kontrollierter Studien.
  • BACKGROUND AND OBJECTIVE: Colorectal cancer is the second most common malignant tumour in Germany with an unfavorable prognosis especially in a locally advanced or metastasizing stage.
  • Although adjuvant and palliative chemotherapy significantly improve 5-year survival, consensus recommendations have in the past been inadequately transformed into clinical practice.
  • PATIENTS AND METHODS: In a multicentre study done between January 2000 and January 2002, tumour stage, primary care, adjuvant or palliative chemotherapy and follow-up of 444 patients (216 males, 228 females) with newly diagnosed colorectal cancer were recorded.
  • RESULTS: 301 patients had colonic and 143 patients rectal cancer.
  • 36 of 96 (38%) patients with stage II colon cancer and 66 of 87 (76%) with stage III disease received adjuvant chemotherapy.
  • 8 of 51 (16%) patients with rectal cancer stage II and 22 of 38 (58%) patients with stage III underwent adjuvant radio- and chemotherapy.
  • The 68 of 84 (81%) patients with stage IV CRC who received palliative chemotherapy were given almost exclusively 5-FU monotherapy.
  • Initial or sequential combination chemotherapy with oxaliplatin or irinotecan were performed in only 24 of 84 (29%) patients.
  • CONCLUSIONS: Stage III colon cancer was predominantly treated according to the existing standard guidelines.
  • In contrast combined radio- and chemotherapy for rectal cancer stage II and III was only performed in one third of the patients, another third receiving neither adjuvant radiation nor chemotherapy.
  • Initial combined or sequential combined chemotherapy for metastasizing colorectal cancer was rarely performed.
  • [MeSH-major] Colorectal Neoplasms / drug therapy. Palliative Care
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Germany. Guideline Adherence. Humans. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Radiotherapy, Adjuvant. Survival Rate

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16511737.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


66. Fietkau R, Zettl H, Klöcking S, Kundt G: Incidence, therapy and prognosis of colorectal cancer in different age groups. A population-based cohort study of the Rostock Cancer Registry. Strahlenther Onkol; 2004 Aug;180(8):478-87
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence, therapy and prognosis of colorectal cancer in different age groups. A population-based cohort study of the Rostock Cancer Registry.
  • PURPOSE: Determination of frequency, treatment modalities used and prognoses of colorectal cancer in a population-specific analysis in relation to age.
  • MATERIAL AND METHODS: In 1999 and 2000, 644/6,016 patients were documented as having colorectal carcinomas in the Cancer Registry of Rostock.
  • RESULTS: The relative percentage of colorectal cancer increases with advanced age (< 60 years 7%; 60-74 years 12%, > or = 75 years 15%; p < 0.001).
  • In older patients with stage III carcinomas, adjuvant treatment was done less frequently in accordance with the treatment recommendations (< 60 years 83-89%; 60-74 years 67-77%; > or = 75 years 29-36% according to stage and tumor localization); in stage IV, the use of chemotherapy was reduced (< 60 years 87.5-100%; 60-74 years 38-47%; > or = 75 years 33-37%).
  • In the univariate analysis, age > or = 75 years (4-year survival rates: < 60 years 68 +/- 4.1%; 60-74 years 58 +/- 2.8%; > or = 75 years 38 +/- 3.7%), UICC stage and surgical treatment had a significant effect on prognosis.
  • Adjuvant treatment had no significant effect on the whole population but on patients with UICC stage III and IV.
  • In the multivariate analysis, however, the only independent prognostic parameters were age > or = 75 years (p = 0.001), performance of chemotherapy (colon cancer) or radiochemotherapy (rectal cancer; p = 0.004-0.001), and tumor stage (p = 0.045-0.001).
  • CONCLUSION: With increasing age, there is a departure in daily practice from the treatment recommendations.
  • The patient's prognosis is dependent upon age (especially > or = 75 years), tumor stage, and therapy.
  • [MeSH-major] Colonic Neoplasms / epidemiology. Colorectal Neoplasms / epidemiology. Colorectal Neoplasms / therapy. Rectal Neoplasms / epidemiology
  • [MeSH-minor] Age Distribution. Aged. Analysis of Variance. Female. Germany / epidemiology. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Registries. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15292968.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


67. López-Cano M, Mañas MJ, Hermosilla E, Espín E: Multivisceral resection for colon cancer: analysis of prognostic factors. Dig Surg; 2010 Aug;27(3):238-45

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multivisceral resection for colon cancer: analysis of prognostic factors.
  • BACKGROUND/AIMS: To assess outcome of multivisceral resection in colon cancer patients and to identify predictors of survival.
  • METHODS: One hundred and thirteen consecutive patients with primary locally advanced colon cancer infiltrating adjacent organs undergoing multivisceral resection between 1998 and 2007 were reviewed.
  • Fifty-two patients had sigmoid tumors and 48 involvement of the small intestine.
  • Eighty-three patients received postoperative adjuvant therapy.
  • Hematochezia and adjuvant chemotherapy were independent factors of favorable outcome and grade G3 and tumor stage III-IV of poor survival.
  • CONCLUSION: Hematochezia and adjuvant chemotherapy were associated with a better survival, and poorly differentiated tumors and stage IV disease with a poor survival.
  • [MeSH-major] Colonic Neoplasms / mortality. Colonic Neoplasms / surgery
  • [MeSH-minor] Abdomen, Acute. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Gastrointestinal Hemorrhage / complications. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20571272.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


68. Javle M, Hsueh CT: Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology. J Hematol Oncol; 2010;3:11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have reviewed the pivotal presentations related to gastrointestinal malignancies from 2009 annual meeting of the American Society of Clinical Oncology with the theme of "personalizing cancer care".
  • Adding trastuzumab to chemotherapy improved the survival of patients with advanced gastric cancer overexpressing human epidermal growth factor receptor 2.
  • Gemcitabine plus cisplatin has become a new standard for first-line treatment of advanced biliary cancer.
  • Octreotide LAR significantly lengthened median time to tumor progression compared with placebo in patients with metastatic neuroendocrine tumors of the midgut.
  • Addition of oxaliplatin to fluoropyrimidines for preoperative chemoradiotherapy in patients with stage II or III rectal cancer did not improve local tumor response but increased toxicities.
  • Bevacizumab did not provide additional benefit to chemotherapy in adjuvant chemotherapy for stage II or III colon cancer.
  • In patients with resected stage II colon cancer, recurrence score estimated by multigene RT-PCR assay has been shown to provide additional risk stratification.
  • In stage IV colorectal cancer, data have supported the routine use of prophylactic skin treatment in patients receiving antibody against epidermal growth factor receptor, and the use of upfront chemotherapy as initial management in patients with synchronous metastasis without obstruction or bleeding from the primary site.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / therapy

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] N Engl J Med. 2001 Apr 19;344(16):1196-206 [11309634.001]
  • [Cites] J Clin Oncol. 2011 Jul 10;29(20):2773-80 [21606427.001]
  • [Cites] Lancet Oncol. 2010 Jan;11(1):48-54 [19932054.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1195-202 [12599225.001]
  • [Cites] Gut. 2003 Apr;52(4):568-73 [12631671.001]
  • [Cites] Ann Surg Oncol. 2003 Jun;10(5):539-45 [12794020.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):35-42 [14695316.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] Science. 1985 Dec 6;230(4730):1132-9 [2999974.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Radiother Oncol. 1998 Mar;46(3):249-56 [9572617.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):273-8 [15668283.001]
  • [Cites] Ann Oncol. 2005 Jul;16(7):1140-6 [15894548.001]
  • [Cites] Ann Oncol. 2005 Dec;16(12):1898-905 [16219623.001]
  • [Cites] Gene. 2006 Jan 17;366(1):2-16 [16377102.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Dig Dis Sci. 2006 Aug;51(8):1371-9 [16868827.001]
  • [Cites] N Engl J Med. 2006 Sep 14;355(11):1114-23 [16971718.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4620-5 [17008704.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 May;59(6):795-805 [17031648.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 2):6913s-20s [18006800.001]
  • [Cites] Lancet. 2007 Dec 15;370(9604):2020-9 [18083404.001]
  • [Cites] Int J Oncol. 2008 Jan;32(1):89-95 [18097546.001]
  • [Cites] Int J Colorectal Dis. 2008 Jun;23(6):559-68 [18330581.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] J Vasc Interv Radiol. 2008 Jun;19(6):855-61 [18503899.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1523-9 [18441328.001]
  • [Cites] J Hematol Oncol. 2009;2:9 [19236713.001]
  • [Cites] J Clin Oncol. 2009 Apr 10;27(11):1814-21 [19273709.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3117-25 [19451425.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3379-84 [19487380.001]
  • [Cites] Br J Cancer. 2009 Aug 18;101(4):621-7 [19672264.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4656-63 [19704057.001]
  • [Cites] World J Surg Oncol. 2009;7:80 [19886993.001]
  • [Cites] J Clin Oncol. 2010 Jan 20;28(3):466-74 [20008640.001]
  • (PMID = 20331897.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 79
  • [Other-IDs] NLM/ PMC2856525
  •  go-up   go-down


69. Abd El-Atti S, Wasicek K, Mark S, Hegazi R: Use of probiotics in the management of chemotherapy-induced diarrhea: a case study. JPEN J Parenter Enteral Nutr; 2009 Sep-Oct;33(5):569-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of probiotics in the management of chemotherapy-induced diarrhea: a case study.
  • Gastrointestinal disturbances (particularly diarrhea) are often induced in response to cancer treatments such as chemotherapy or radiation.
  • Two common oral drugs used in cancer treatment that are known to have gastrointestinal side effects are capecitabine and lapatinib.
  • In this brief communication, the authors discuss a case study of a stage IV breast cancer patient whose chemotherapy-induced diarrhea was treated successfully with a multispecies combination of probiotics.
  • This is a unique study in which grade 3 chemotherapy-induced diarrhea (characterized by 7-9 stools per day and associated with incontinence and abdominal cramping) was treated with only a multispecies combination of probiotics.
  • Probiotics have been used to treat diarrhea in patients with irritable bowel syndrome, ulcerative colitis, pouchitis, and Crohn's disease.
  • More recently, probiotics have been used to treat chemotherapy-induced diarrhea in colon cancer patients.
  • This case study demonstrates that the probiotics can also be used to treat severe cases of chemotherapy-induced diarrhea in breast cancer patients.
  • This study demonstrates that probiotics should be considered for advanced breast cancer patients with chemotherapy-induced diarrhea.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Diarrhea / chemically induced. Diarrhea / therapy. Probiotics / therapeutic use
  • [MeSH-minor] Breast Neoplasms / pathology. Breast Neoplasms / therapy. Capecitabine. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Female. Fluorouracil / adverse effects. Fluorouracil / analogs & derivatives. Fluorouracil / therapeutic use. Humans. Middle Aged. Neoplasm Metastasis / drug therapy. Neoplasm Staging. Quinazolines / adverse effects. Quinazolines / therapeutic use

  • Genetic Alliance. consumer health - Diarrhea.
  • MedlinePlus Health Information. consumer health - Diarrhea.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JPEN J Parenter Enteral Nutr. 2009 Sep-Oct;33(5):573-4 [19556610.001]
  • (PMID = 19423769.001).
  • [ISSN] 0148-6071
  • [Journal-full-title] JPEN. Journal of parenteral and enteral nutrition
  • [ISO-abbreviation] JPEN J Parenter Enteral Nutr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; 0VUA21238F / lapatinib; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


70. Oka T, Tokumo M, Yamakawa T, Onoda Y, Suzuka I, Shiota K: [Long survival of a colon cancer case with synchronous multiple liver metastases responding to S-1]. Gan To Kagaku Ryoho; 2010 May;37(5):931-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long survival of a colon cancer case with synchronous multiple liver metastases responding to S-1].
  • After examination, she was diagnosed with ascending colon cancer and synchronous multiple liver metastases.
  • Postoperative diagnosis after right hemicolectomy and D3 lymph node dissection was T2, N1, H2, P0, M0, and Stage IV.
  • One month after the operation, we started a combination chemotherapy using 5-FU plus UFT as pharmacokinetic modulating chemotherapy with hepatic arterial infusion (HAI-PMC).
  • But abdominal CT scan revealed the increase of multiple liver metastases, PD, after 4 courses of treatment.
  • She continues to undergo outpatient treatment with good QOL without a lesion for 4 years and 6 months.
  • S-1 is expected to be an effective agent for the treatment of advanced colon cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Liver Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Combinations. Female. Humans. Quality of Life. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495332.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


71. Mazaki T, Mado K, Manmoto J, Okame H, Ishii Y, Suzuki K, Masuda H, Takayama T: [Three cases with liver metastasis from gastric or colon cancer successfully treated with S-1 combined with CPT- 11]. Gan To Kagaku Ryoho; 2008 Sep;35(9):1583-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three cases with liver metastasis from gastric or colon cancer successfully treated with S-1 combined with CPT- 11].
  • We report three cases with liver metastasis from gastric or colon cancer successfully treated with S-1 with CPT-11.
  • Case 1: A total gastrectomy was performed for a gastric cancer located in the lower to upper body of the stomach (T3 (SE), N2, H0, P0, por 2, stage III B).
  • Abdominal computed-tomography (CT) revealed a solitary liver metastasis in the S8 subsegment of the liver.
  • We treated the patient with S-1 combined with CPT-11.
  • Case 2: Sigmoidectomy and partial resection of small intestine and abdominal wall were performed for sigmoid colon cancer.
  • The intraoperative findings revealed liver metastases in left lobe of the liver (Si, N1, H1, P0, M0, tub 1, stage IV).
  • After surgery, the patient was treated with S-1 combined with CPT-11.
  • Case 3: Laparoscopic right hemicolectomy was performed for ascending colon cancer (SE, N1, H0, P0, M0, tub 1, stage III a).
  • We treated the patient with S-1 combined with CPT-11.
  • [MeSH-major] Camptothecin / analogs & derivatives. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Combinations. Female. Humans. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18799916.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


72. Weihrauch MR, Stippel D, Fries JW, Arnold D, Bovenschulte H, Coutelle O, Hacker U: Complete remission in a colon cancer patient with a large, irresectable liver metastasis after XELOX/cetuximab/bevacizumab treatment. Onkologie; 2008 Sep;31(8-9):464-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission in a colon cancer patient with a large, irresectable liver metastasis after XELOX/cetuximab/bevacizumab treatment.
  • BACKGROUND: Stage IV colorectal cancer is usually an incurable disease.
  • Even with primarily irresectable disease, cure can be achieved in patients who become operable after neoadjuvant treatment.
  • To improve the prognosis of these patients, highly effective neoadjuvant regimens need to be developed.
  • CASE REPORT: Here, we report the case of a 62-year-old male patient who had been diagnosed with International Union against Cancer (UICC) stage III colon cancer 7 years previously and now presented with a large, irresectable liver metastasis and enlarged perihepatic lymph nodes.
  • After neoadjuvant treatment with cetuximab, bevacizumab and XELOX, the patient showed a complete remission and underwent surgery.
  • Histopathologically, the resected tissue and lymph nodes were free of residual tumor.
  • CONCLUSION: To our knowledge, this is the first report of a complete pathological response in a patient with irresectable colorectal cancer after intensive chemotherapy/anti-EGFR/ VEGF antibody therapy.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Bevacizumab. Cetuximab. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Hepatectomy. Humans. Male. Middle Aged. Treatment Failure. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18787354.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; PQX0D8J21J / Cetuximab; U3P01618RT / Fluorouracil; XELOX
  •  go-up   go-down


73. Niv Y: Biologic behavior of microsatellite-unstable colorectal cancer and treatment with 5-fluorouracil. Isr Med Assoc J; 2005 Aug;7(8):520-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biologic behavior of microsatellite-unstable colorectal cancer and treatment with 5-fluorouracil.
  • High frequency MSI has been associated with a favorable prognosis, however it is not clear whether this is because MSI-H tumors are inherently less aggressive or because they are more sensitive to chemotherapy.
  • Chemotherapy with a combination of 5-fluorouracil and leukovorin or levamizole has been the standard of care for high risk stage II and stage III CRC; it is also used in stage IV CRC.
  • Several in vitro studies have shown that colon cancer cell lines displaying MSI-H are less responsive to fluorouracil than microsatellite-stable cell lines.
  • The selection of patients with CRC for 5-FU treatment has been based so far on the stage of the tumor rather than the biology of the tumor.
  • Although surgical staging is highly predictive of survival, there are indications that the form of genomic instability within a patient's colorectal tumor has clinical implications, with and without 5-FU treatment.
  • This review suggests that patients with MSI-H colorectal tumors may not benefit from 5-FU-based chemotherapy and can avoid its potential side effects (nausea, diarrhea, stomatitis, dermatitis, alopecia, and neurologic symptoms) that occur in half the treated patients.
  • If confirmed by future prospective randomized controlled studies, these findings would indicate that microsatellite-instability testing should be conducted routinely and the results used to direct rational adjuvant chemotherapy in colon cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Colorectal Neoplasms / drug therapy. Fluorouracil / therapeutic use. Microsatellite Repeats / drug effects

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16106779.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Israel
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  • [Number-of-references] 39
  •  go-up   go-down


74. Okamura M, Kamiizumi Y, Kawamura N, Yokoyama R, Itoh K, Abe K, Nakajima Y: [A patient in whom oral UFT/Leucovorin therapy proved markedly effective for lung metastasis after surgery for colon cancer]. Gan To Kagaku Ryoho; 2008 Jul;35(7):1205-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A patient in whom oral UFT/Leucovorin therapy proved markedly effective for lung metastasis after surgery for colon cancer].
  • A 78-year-old male with sigmoid colon cancer underwent sigmoidectomy.
  • The lesion was se, p1(+), n1, and Stage IV.
  • Oral UFT therapy was performed, but was replaced with oral S-1 therapy 1 year and 6 months after surgery.
  • Since the patient did not wish surgery, the treatment was changed to oral UFT/Leucovorin(LV)therapy(UFT 300 mg/ LV 75 mg, 4-week administration and 1-week no-administration periods).
  • Oral UFT/LV therapy is convenient because of the oral route.
  • Adverse reactions are few, and the therapeutic effect has been reported to be comparable to that of intravenous 5-FU/LV therapy.
  • Also, in this patient, no adverse reaction was noted, and complete remission was maintained until the patient died of another disease 31 months after the beginning of oral UFT/LV therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Leucovorin / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary
  • [MeSH-minor] Administration, Oral. Aged. Humans. Male. Tegafur / administration & dosage. Tegafur / therapeutic use. Uracil / administration & dosage. Uracil / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633264.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; Q573I9DVLP / Leucovorin; 1-UFT protocol
  •  go-up   go-down


75. Lo DS, Pollett A, Siu LL, Gallinger S, Burkes RL: Prognostic significance of mesenteric tumor nodules in patients with stage III colorectal cancer. Cancer; 2008 Jan 1;112(1):50-4
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of mesenteric tumor nodules in patients with stage III colorectal cancer.
  • BACKGROUND: Tumor nodules are occasionally found in adjacent mesentery of colorectal cancer specimens and are felt to reflect a worse prognosis.
  • The clinical significance of mesenteric tumor nodules was investigated.
  • METHODS: A review of 786 patients with stage III colorectal cancer referred between 1995 and 1999 was undertaken.
  • TNM staging was standardized by considering mesenteric nodules separately and not assigning them to T or N categories.
  • RESULTS: Mesenteric tumor nodules were found in 116 (14.8%) patients: 48 (41.4%) with colon cancer and 68 (58.6%) rectal cancer.
  • Adjuvant chemotherapy was given to 84.8% of colon cancer patients.
  • Two (2.9%) rectal cancer patients received neoadjuvant chemoradiation, and 63 (92.6%) received adjuvant therapy (chemotherapy and/or radiation).
  • In the cohort with mesenteric nodules, the median time to progression was 23.1 months, the median 5-year disease-free survival was 35%, and the median overall survival (OS) was 47.9 months, with 44% OS at 5 years.
  • In the 19 (16.4%) patients with mesenteric nodules and no lymph nodes the 5-year OS was 60% (SEER stage II 5-year survival 82.5%), whereas in 97 patients who were lymph node-positive the 5-year OS was 40% (SEER 5-year survival stage IIIc 44.3%; stage IV 8.1%).
  • CONCLUSIONS: In comparison to SEER survival data, the presence of mesenteric nodules appears to worsen the prognosis of any T/N0 disease to that of overall stage III disease.
  • Mesenteric nodules with any T/N+ disease had prognosis similar to that of stage IIIC disease, but the prognosis was better than M1 disease. .

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 American Cancer Society
  • (PMID = 18008365.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Allen JA, Adlakha A, Bergethon PR: Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol; 2006 Oct;63(10):1475-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.
  • PATIENT: A 52-year-old man receiving chemotherapy for stage IV rectal carcinoma.
  • RESULTS: Clinical and radiographic evidence consistent with reversible posterior leukoencephalopathy syndrome was found following the administration of irinotecan hydrochloride, leucovorin calcium, and fluorouracil (FOLFIRI) regimen chemotherapy and bevacizumab.
  • CONCLUSIONS: Reversible posterior leukoencephalopathy syndrome following treatment with angiogenesis modulators can occur.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma / drug therapy. Colonic Neoplasms / drug therapy. Dementia, Vascular / chemically induced. Liver Neoplasms / drug therapy. Occipital Lobe / drug effects
  • [MeSH-minor] Angiogenesis Inhibitors / adverse effects. Antibodies, Monoclonal, Humanized. Aphasia / chemically induced. Aphasia / physiopathology. Bevacizumab. Blindness, Cortical / chemically induced. Blindness, Cortical / physiopathology. Blood Vessels / drug effects. Blood Vessels / physiopathology. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Cognition Disorders / chemically induced. Cognition Disorders / physiopathology. Fluorouracil / adverse effects. Humans. Leucovorin / adverse effects. Magnetic Resonance Imaging. Male. Middle Aged. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / physiopathology. Parietal Lobe / drug effects. Parietal Lobe / pathology. Parietal Lobe / physiopathology. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17030665.001).
  • [ISSN] 0003-9942
  • [Journal-full-title] Archives of neurology
  • [ISO-abbreviation] Arch. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


77. Takemoto H, Fukunaga M, Ooshiro R, Fujishima M, Yamamoto K, Tanaka J, Kondo M, Kishimoto T, Nakayama T, Imamura H, Masutani S, Tatsuta M, Kawasaki T, Furukawa H: [A case of peritoneal dissemination disappeared by CPT-11 + TS-1 combination chemotherapy]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1768-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of peritoneal dissemination disappeared by CPT-11 + TS-1 combination chemotherapy].
  • By a diagnosis of descending colon cancer, descending colon ablative operation and D1 lymph node dissection were performed on April 22, 2004.
  • It was P3H0N1SE, Stage IV in perioperative findings.
  • CPT-11 + TS-1 combination chemotherapy was started on June 22nd.
  • In the five weeks of the combination chemotherapy, continuous infusion of CPT-11 (150 mg/body day 1 and 15) was twice administered, and oral administration of TS-1 (120 mg/body/day) was given for 3 weeks (day 1-21).
  • Abdominal CT showed no recurrence on March 3, 2005 since the combination chemotherapy ended 6 months ago.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Administration, Oral. Adult. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Colonic Neoplasms / pathology. Drug Combinations. Humans. Infusions, Intravenous. Male. Neoplasm Seeding. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315935.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


78. Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Lee WY, Chun HK, Park YS: Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol; 2010 Sep;66(4):659-67
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
  • PURPOSE: Colon cancer with DNA mismatch repair (MMR) defects reveals indistinguishable clinical and pathologic aspects, including better prognosis and reduced response to 5-fluorouracil (5-FU)-based chemotherapy.
  • There has been no consensus for p53 as a prognostic marker in colorectal cancer.
  • This study investigated the clinical implication of MSI-H/MMR-D and p53 expression in R0-resected colon cancer patients who received adjuvant oxaliplatin/5-FU/leucovorin (FOLFOX) therapy.
  • EXPERIMENTAL DESIGN: We analyzed 135 patients, who had been treated by adjuvant chemotherapy containing 5-FU and oxaliplatin (FOLFOX) after curative resection (R0) for colon adenocarcinoma between May 2004 and November 2007.
  • Tumor expression of the MMR proteins, MLH1 and MSH2, was detected by immunohistochemistry (IHC) in surgically resected tumor specimens.
  • RESULTS: There were 13 (9.6%) patients with stage II, 108 (80%) with stage III, and 14 (10.4%) with stage IV.
  • Fourteen patients with stage IV (10.3%) had metastases to liver only, all of whom underwent complete metastasectomy for liver metastases.
  • In total, 134 tumor specimens were genotyped, 115 specimens were tested by IHC and 113 cases had both genotyping and IHC results available for analysis.
  • MMR status was not significantly associated with DFS (P = 0.56) or OS (P = 0.61) in patients with colon cancer (n = 135) receiving adjuvant FOLFOX.
  • CONCLUSION: The MMR status or p53 positivity was not significantly associated with outcomes to FOLFOX as adjuvant chemotherapy in colon cancer patients with R0 resection.
  • Adding oxaliplatin in adjuvant chemotherapy may overcome negative impact of 5-FU on colon cancers with MSI-H/MMR-D.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Colonic Neoplasms / genetics. Microsatellite Instability / drug effects
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. DNA Mismatch Repair. Female. Fluorouracil / therapeutic use. Genetic Markers. Genotype. Humans. Immunohistochemistry. Leucovorin / therapeutic use. Male. Middle Aged. Organoplatinum Compounds / therapeutic use. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis. Tumor Suppressor Protein p53 / genetics

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20033812.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / Organoplatinum Compounds; 0 / Tumor Suppressor Protein p53; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


79. Okamura S, Nakata K, Suzuki R, Uji K, Yoshida A, Yoshimura M, Okada K, Nakahira S, Miki H, Sugimoto K, Tamura S: [A case of advanced sigmoid colon cancer performed resection of liver metastases after long-term control by S-1 and CPT-11 combination chemotherapy]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2168-70
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced sigmoid colon cancer performed resection of liver metastases after long-term control by S-1 and CPT-11 combination chemotherapy].
  • A 60-year-old man diagnosed as advanced sigmoid colon cancer was performed sigmoidectomy and D3 lymph node dissection.
  • Intra-operative findings were SE, P0H1N4M (-), and Stage IV.
  • One month after the operation, we started a combination chemotherapy using S-1 plus CPT-11 as one course for five weeks.
  • The combination chemotherapy was once finished after eight courses due to the patient's request.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Oxonic Acid / therapeutic use. Sigmoid Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Carcinoembryonic Antigen / blood. Drug Combinations. Humans. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106559.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


80. Silvéra L, Galula G, Tiret E, Louvet C, Leroux JL, Trutt B: Assessment of management practices for colonic cancer in the Paris metropolitan area in 2002. Gastroenterol Clin Biol; 2006 Jun-Jul;30(6-7):852-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of management practices for colonic cancer in the Paris metropolitan area in 2002.
  • OBJECTIVE: To assess the management of patients aged 18 years or older with colonic adenocarcinoma (including the rectosigmoid junction), compared with French guidelines (ANAES and SOR).
  • METHODS: This retrospective study carried out in 2003 by the Ile-de-France regional union of health insurance funds from hospital discharge and operative and pathology reports of patients exempted from copayment between April 2001 and March 2002.
  • RESULTS: In all, 1 842 patients were included; mean age was 68.7 +/- 12.7 years and the M/F ratio was 1.09.
  • 37.7% of stage II patients had chemotherapy while 10.8% of stage III and 9.8% of stage IV patients did not.
  • Age was a determining factor in the decision of chemotherapy (P<0.0001).
  • CONCLUSION: Implementation of guidelines for the management of colon cancer can be improved, notably regarding pathologic analysis and indications of chemotherapy.
  • [MeSH-major] Adenocarcinoma / therapy. Colonic Neoplasms / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Colon / pathology. Data Collection. Data Interpretation, Statistical. Female. Guideline Adherence. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary / therapy. Paris. Practice Guidelines as Topic. Retrospective Studies. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885869.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] France
  •  go-up   go-down


81. Fukuda Y, Fujio N, Ihara T, Takatori H, Tsukazaki T, Koyama I, Tsukazaki Y, Osugi H: [A case of cecal cancer with multiple liver metastases responding to irinotecan (CPT-11)/cisplatin (CDDP) combination therapy for elevation of CA19-9 after complete response (CR) by l-leucovorin(LV)/5-fluorouracil(5-FU) therapy]. Gan To Kagaku Ryoho; 2005 Nov;32(12):1949-52
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of cecal cancer with multiple liver metastases responding to irinotecan (CPT-11)/cisplatin (CDDP) combination therapy for elevation of CA19-9 after complete response (CR) by l-leucovorin(LV)/5-fluorouracil(5-FU) therapy].
  • She was diagnosed with advanced cecal cancer with simultaneous multiple liver metastases.
  • The serum level of CA 19-9 was 420 U/ ml.
  • Pathological examination demonstrated II, 5.0 x 2.5 cm, mod, se, INFgamma, ly(1), v(1), n(2), stage IV.
  • Systemic l-leucovorin/5-fluorouracil (l-LV/5-FU) + HAI of weekly high-dose 5-FU combination therapy was initiated at postoperative 14 days.
  • The serum CA 19-9 level decreased immediately but was not within the normal range.
  • On abdominal computed tomography (CT), liver metastatic lesions decreased 9 9% on May 27, 2002 and disappeared on August 26, 2002.
  • Though there were no signs of recurrence, the serum CA 19-9 level elevated as of October, 2002.
  • The serum CA 19-9 level elevated inspite of the continuation of the l-LV/5-FU therapy which we increased an amount of 5- FU.
  • Thus, we changed low-dose irinotecan (CPT-11)/cisplatin (CDDP) therapy.
  • The serum level of CA 19-9 decreased gradually and got with in normal range on March, 2004.
  • Low-dose CPT-11/CDDP therapy may be useful for patients with advanced colon cancer thought to be resistant to 5-FU as second-line chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CA-19-9 Antigen / blood. Cecal Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Hepatic Artery. Humans. Infusion Pumps, Implantable. Leucovorin / administration & dosage. Middle Aged

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16282733.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


82. Martí-Ragué J, Parés D, Biondo S, Navarro M, Figueras J, de Oca J, Pareja L, Cambray M, del Río C, Osorio A, Novell V, Jaurrieta E: [Survival and recurrence in the multidisciplinary approach of colorectal cancer]. Med Clin (Barc); 2004 Sep 11;123(8):291-6
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival and recurrence in the multidisciplinary approach of colorectal cancer].
  • [Transliterated title] Supervivencia y recidiva en el tratamiento multidisciplinario del carcinoma colorrectal.
  • BACKGROUND AND OBJECTIVE: Colorectal cancer is one of the most frequent causes of death in the general population.
  • Our aim was to analyze our experience in the multidisciplinary approach of colorectal carcinoma during a three year period.
  • PATIENTS AND METHOD: Between January 1996 and December 1998, we studied prospectively 807 patients with colorectal cancer.
  • The epidemiology, treatment and outcome(recurrence and survival) were analyzed.
  • RESULTS: There were 598 colon (65.5%) and 279 rectal (34.5%) tumors in all the series.
  • Surgical treatment was elective in 84% and urgent in 16%, and was considered radical in 598 cases (74.1%).
  • Chemotherapy or radiotherapy was administered in 49.6% and 18.3% patients, respectively.
  • The overall 3-year survival was as follows: stage I 97.5%, stage II 90.6%, stage III 75.2%, and stage IV 12.6%.
  • The 3-year free-disease survival was as follows: in colon cancer 97.8% for stage I, 87.3% for stage II, and 71.4% for stage III; and in rectal cancer 96.8% for stage I, 85.1% for stage II, and 75.4% for stage III.
  • During the follow-up 124 patients (20.7%) developed recurrence: local (2.8%), systemic (15.9%) or both (2%).
  • [MeSH-major] Colorectal Neoplasms / mortality. Colorectal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Prospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15373975.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


83. Habal N, Gupta RK, Bilchik AJ, Yee R, Leopoldo Z, Ye W, Elashoff RM, Morton DL: CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. Ann Surg Oncol; 2001 Jun;8(5):389-401
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer.
  • BACKGROUND: The immunogenicity of the polyvalent tumor cell vaccine CancerVax has been correlated with the survival of patients receiving active immunotherapy for melanoma.
  • Because the various antigens expressed on the vaccine are common to colon adenocarcinoma cells, we examined the survival impact of immune responses elicited by CancerVax in patients with advanced colon cancer refractory to standard therapy.
  • METHODS: Twenty-seven patients with American Joint Committee on Cancer (AJCC) stage IV colorectal adenocarcinoma were entered prospectively into the study.
  • CancerVax was coadministered with bacille Calmette-Guerin (BCG) for the first 2 weeks of vaccine treatment.
  • Blood was drawn at the start of therapy and every 2 weeks thereafter to measure serum titers of immunoglobulin (Ig)G and IgM against TA90 (a 90-kD immunogen common to colon cancer and CancerVax cells) and against purified protein derivative (PPD), a nontumor control antigen.
  • Cellular immune responses were evaluated by delayed-type hypersensitivity (DTH) reaction to vaccine cells and to PPD.
  • Mean follow-up time was 17.5 months.
  • CONCLUSIONS: CancerVax can induce measurable humoral and cellular immune responses to tumor-associated antigens in patients with advanced-stage colon cancer.
  • This novel therapeutic regimen for patients with advanced colon cancer merits further investigation.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / immunology. Cancer Vaccines / immunology. Cancer Vaccines / therapeutic use. Colonic Neoplasms / drug therapy. Colonic Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / immunology. BCG Vaccine / administration & dosage. Enzyme-Linked Immunosorbent Assay. Female. Humans. Hypersensitivity, Delayed / immunology. Male. Middle Aged. Survival Rate. Time Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11407512.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA 12.582; United States / NCI NIH HHS / CA / T32 CA 09.689
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / BCG Vaccine; 0 / Cancer Vaccines; 0 / TA90 immune complex; 0 / polyvalent melanoma cell vaccine
  •  go-up   go-down


84. Sato Y, Takayama T, Nikaido T, Wada Y, Sagawa T, Abe S, Sato T, Iyama S, Murase K, Araki H, Sato Y, Kato J, Niitsu Y, Chiba H: Report of an autopsy case of colon cancer with amyotrophic lateral sclerosis. Nihon Shokakibyo Gakkai Zasshi; 2007 Sep;104(9):1365-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Report of an autopsy case of colon cancer with amyotrophic lateral sclerosis.
  • Amyotrophic lateral sclerosis (ALS) is a degenerative disease involving both upper and lower motor neurons and the pathogenesis of this disorder is still unknown.
  • However, it is still under discussion whether ALS occurring in cancer patients is paraneoplastic.
  • A 60-year-old man with rectal cancer (Stage IV) having multiple lung, liver and para-aortic lymph node metastases underwent anterior resection of the rectum as palliative surgery.
  • He was referred to our hospital for adjuvant chemotherapy.
  • Lung and lymph node metastases decreased after 2 courses of chemotherapy using CPT-11 and 5-FU/LV but liver metastases were enlarged, following up increase in CEA.
  • For second line chemotherapy, he was treated with low-dose CDDP/5-FU over 6 courses.
  • As a result, the size the of metastatic lesions markedly reduced and CEA was decreased to the normal level.
  • Although significant tumor reduction was observed, his neurological symptoms rapidly progressed.
  • Autopsy revealed that his neuropathological findings were compatible with ALS, and it was thought to be the primary cause of death in the because of absence of cancer progression.
  • In this case the neurological syndrome was not affected by cancer therapy.
  • Thus our case does not support the hypothesis that ALS in associated with cancer and the relationship between both disorders remains uncertain.
  • [MeSH-major] Adenocarcinoma / secondary. Amyotrophic Lateral Sclerosis / etiology. Colonic Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged

  • Genetic Alliance. consumer health - Amyotrophic Lateral Sclerosis.
  • MedlinePlus Health Information. consumer health - Amyotrophic Lateral Sclerosis.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17827908.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


85. Mamiya N, Kono T, Mamiya K, Satomi M, Chisato N, Ebisawa Y: [A case of neurotoxicity reduced with goshajinkigan in modified FOLFOX6 chemotherapy for advanced colon cancer]. Gan To Kagaku Ryoho; 2007 Aug;34(8):1295-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of neurotoxicity reduced with goshajinkigan in modified FOLFOX6 chemotherapy for advanced colon cancer].
  • In performing FOLFOX (infusional 5-FU/LV with oxaliplatin) for advanced colorectal cancer, neurotoxicity of oxaliplatin (L-OHP) is the serious dose limiting factor.
  • We have applied goshajinkigan (TJ 107) for a case of advanced colon cancer with mFOLFOX 6, and experienced a reduction in numbness, the adverse effect of LOHP.
  • A 57-year-old woman with descending colon cancer (H 1, P 3, Stage IV) underwent hemicolectomy D 2, rt.colectomy, bilateral oophorectomy, cholecystectomy and transverse colonostomy.
  • In order to reduce the neurotoxicity of L-OHP, TJ 107 was used together from the third course.
  • TJ 107 could reduce or prevent the neurotoxicity of L-OHP.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Drugs, Chinese Herbal / administration & dosage. Neurotoxicity Syndromes / prevention & control
  • [MeSH-minor] Drug Administration Schedule. Drug Therapy, Combination. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Middle Aged. Organoplatinum Compounds / administration & dosage

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17687217.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Organoplatinum Compounds; 0 / gosha-jinki-gan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


86. Kolh P, Honore P, Degauque C, Gielen J, Gerard P, Jacquet N: Early stage results after oesophageal resection for malignancy - colon interposition vs. gastric pull-up. Eur J Cardiothorac Surg; 2000 Sep;18(3):293-300
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early stage results after oesophageal resection for malignancy - colon interposition vs. gastric pull-up.
  • OBJECTIVE: The aims of our study were to determine if using the colon as a digestive transplant after oesophagectomy for cancer was associated with increased postoperative complications, and to assess the impact of preoperative radiochemotherapy on postoperative hospital outcome.
  • Indications were squamous cell carcinoma in 69 patients and adenocarcinoma in 61.
  • Preoperatively 30 patients (eight in stage IIB, 18 in stage III, and four in stage IV) received radiochemotherapy.
  • There were 84 subtotal oesophagectomies, with anastomosis in the neck in 44 patients and at the thoracic inlet in 40, and 46 distal oesophageal resections.
  • Digestive continuity was restored with the stomach in 92 patients (age: 63.4+/-10.2 years) and the colon in 38 (age: 52.3+/-12.8 years).
  • With the exception of age (P<0.0001), there was no significant preoperative difference between gastric and colonic groups.
  • One patient (2.5%) died in the colonic graft group and ten (11%) in the gastric pull-up group (P=0.17).
  • Postoperative complications occurred in 40 patients (31%), respectively, in ten (26%) and 30 (33%) patients after colonic and gastric transplants (P=0.48), and were pulmonary insufficiency or infection in 29 patients, anastomotic fistula in six, myocardial infarction in five, recurrent nerve palsy in four, renal insufficiency in three, and cerebrovascular accident in one.
  • The incidence of postoperative pulmonary complications was 70% (21/30 patients) in the subgroup who received preoperative radiochemotherapy, as compared to 11% (5/44 patients) in the subgroup of comparable staging, but without preoperative treatment (P<0.001).
  • CONCLUSIONS: Colonic grafts are not associated with increased postoperative mortality or complications.
  • Our results suggest that preoperative neoadjuvant treatment significantly increases postoperative pulmonary complications.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Colon / transplantation. Esophageal Neoplasms / surgery. Esophagus / surgery. Stomach / surgery
  • [MeSH-minor] Anastomosis, Surgical / methods. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophagectomy. Female. Hospital Mortality. Humans. Male. Middle Aged. Palliative Care. Reoperation. Retrospective Studies. Stomach Neoplasms / drug therapy. Stomach Neoplasms / mortality. Stomach Neoplasms / radiotherapy. Stomach Neoplasms / surgery. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10973538.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


87. Nakao K, Tsunoda A, Amagasa H, Suzuki N, Yamazaki K, Kusano M: [A case report of poorly-differentiated adenocarcinoma in sigmoid colon cancer with liver and pulmonary metastasis responding to TS-1 and CPT-11]. Gan To Kagaku Ryoho; 2006 Jan;33(1):109-12
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of poorly-differentiated adenocarcinoma in sigmoid colon cancer with liver and pulmonary metastasis responding to TS-1 and CPT-11].
  • A 66-year-old woman (156 cm, 58 kg) underwent sigmoid colectomy for cancer.
  • After operation, CT showed multiple liver metastasis and a high level of CEA and CA19-9 .
  • Pathological findings were type 3, 30 x 20 mm, poorly-differentiated adenocarcinoma, se, ly 2, v 2, n 2 (+), ow (-), aw(-), H 3, P 0 (stage IV).
  • Treatment of the patient consisted of daily oral administration of 80 mg TS-1 for 21 days and 60 mg CPT-11 on 1 day and 15 day as one course.
  • After 2 courses, tumor sizes of liver metastases and the level of tumor markers became reduced.
  • The current case suggested that the administration of TS-1 and CPT-11 may have a potent therapeutic efficacy in advanced colorectal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Drug Administration Schedule. Drug Combinations. Female. Humans. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410709.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


88. Fleming DR, Glisson SD, Bhupalam L, Michelson GD, Goldsmith GH, LaRocca RV: Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies. Am J Clin Oncol; 2000 Aug;23(4):349-52
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A phase I study was designed to evaluate the toxicity of escalating doses of gemcitabine along with fixed-dose paclitaxel in patients heavily pretreated with chemotherapy or radiotherapy.
  • All patients had no prior therapy with the study drugs and possessed both adequate performance and end organ function.
  • Characteristics included a median age of 66 years (range, 41 to 77) and stage IV disease in all patients; there were six patients with colon cancer, two with bladder cancer, three with non-small-cell lung cancer, two with esophageal cancer, three with pancreatic cancer, and two with cancer of unknown primary.
  • The treatment cycled every 21 days.
  • The combination of gemcitabine and paclitaxel seems to be well tolerated, and the recommended starting dose for a phase II study, in pretreated patients using a day 1/day 8 treatment schedule, should be 900 mg/m2 for gemcitabine (days 1 and 8) along with 150 mg/m2 for paclitaxel (day 1).
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Paclitaxel / administration & dosage
  • [MeSH-minor] Adult. Aged. Carcinoma, Non-Small-Cell Lung / drug therapy. Colonic Neoplasms / drug therapy. Diarrhea / chemically induced. Esophageal Neoplasms / drug therapy. Exanthema / chemically induced. Female. Humans. Lung Neoplasms / drug therapy. Male. Middle Aged. Nausea / chemically induced. Neoplasm Staging. Neoplasms, Unknown Primary / drug therapy. Neutropenia / chemically induced. Pancreatic Neoplasms / drug therapy. Paresthesia / chemically induced. Urinary Bladder Neoplasms / drug therapy. Vomiting / chemically induced

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10955861.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


89. mukai M, Moriya H, Himeno S, Oida Y, mukohyama S, Nishi T, Nakasaki H, Satoh S, Makuuchi H: Efficacy of oral UFT plus leucovorin therapy for colon cancer with ovarian and multiple liver metastases: report of two cases. Oncol Rep; 2001 Sep-Oct;8(5):1079-83
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of oral UFT plus leucovorin therapy for colon cancer with ovarian and multiple liver metastases: report of two cases.
  • Case 1: a patient was diagnosed as having ascending colon cancer with right ovarian metastasis, and underwent palliative right hemicolectomy plus oophorectomy.
  • The tumor was a well-differentiated adenocarcinoma with right ovarian metastasis, and the disease was classified as stage IV.
  • Oral chemotherapy with UFT plus LV was performed for about 3 years, and the patient is still being followed up with no recurrence at 5 years postoperatively.
  • Case 2: a patient was diagnosed as having incomplete large bowel obstruction caused by ascending colon cancer, and underwent curative right hemicolectomy.
  • The tumor was a moderately differentiated adenocarcinoma, and the disease was classified as stage II.
  • Since multiple liver metastases developed at 3 months postoperatively, oral chemotherapy with UFT plus LV was started.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Leucovorin / therapeutic use. Liver Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Tegafur / therapeutic use. Uracil / therapeutic use
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Colectomy. Female. Humans. Neoplasm Staging. Ovariectomy. Postoperative Period. Remission Induction. Tomography, X-Ray Computed


90. Higashi D, Ishibashi Y, Tamura T, Nii K, Egawa Y, Koga M, Tomiyasu T, Harimura T, Tanaka R, Futatsuki R, Noda S, Futami K, Maekawa T, Takaki Y, Hirai F, Matsui T: Clinical features of and chemotherapy for cancer of the small intestine. Anticancer Res; 2010 Aug;30(8):3193-7
Genetic Alliance. consumer health - Small intestine cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of and chemotherapy for cancer of the small intestine.
  • BACKGROUND: Cancer of the small intestine is a rare disease, and its clinical features have not been clearly elucidated.
  • Techniques such as double balloon endoscopy and capsule endoscopy allow the preoperative diagnosis of cancer of the small intestine, but this cancer is often detected at an advanced state and in many cases postoperative chemotherapy is required.
  • This study evaluated the pre- and postoperative clinical course of cancer of the small intestine and the effectiveness of chemotherapy.
  • PATIENTS AND METHODS: Patients who underwent surgery for cancer of the small intestine in this Department from July 1985 to December 2008 were included in this study.
  • Duodenal cancer has vastly different origins, methods of diagnosis, and surgical procedures, so this form of cancer was excluded.
  • There were 8 cases of jejunal or ileal cancer treated during the study period.
  • The pre- and postoperative course of these cases was reviewed, as well as the effectiveness of chemotherapy in cases of recurrence.
  • Six patients underwent a partial resection of the small intestine, and a right hemicolectomy, and a bypass were performed in one case each.
  • The tumor type according to Borrmann's classification indicated that 5 tumors were type 2, 2 were type 3, and 1 was type 5; the mean tumor size was 6.3±5.3 (2.5-18.0) cm.
  • TNM staging indicated that 3 tumors were stage II, 1 was stage III, and 4 were stage IV.
  • Six patients underwent postoperative chemotherapy.
  • One patient underwent adjuvant chemotherapy of, and 5 patients with recurring or advanced cancer underwent therapeutic chemotherapy of.
  • The course of chemotherapy for the 5 patients with recurrent or advanced cancer resulted in 4 patients with progressive disease (PD) and 1 with stable disease (SD).
  • CONCLUSION: The basic treatment for cancer of the small intestine is surgical resection.
  • Palliative surgery and chemotherapy are considered in cases where resection is not possible or the cancer recurs.
  • Nevertheless, there is no established regimen for such chemotherapy.
  • Cancer of the small intestine is currently being treated with chemotherapy based on the treatment strategies for colon cancer, but there are few reports of its success.
  • Chemotherapy was unsuccessful in treating any of the patients with recurring or advanced cancer reviewed in this report.
  • The diagnosis must therefore be improved and postoperative chemotherapy will be needed to treat cancer of the small intestine given its increasing incidence, and therefore physicians are working as quickly as possible to establish an optimal treatment regimen.
  • [MeSH-major] Intestinal Neoplasms / drug therapy. Intestine, Small / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871040.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


91. Keswani SG, Boyle MJ, Maxwell JP 4th, Mains L, Wilks SM, Hunt JP, O'Leary JP: Colorectal cancer in patients younger than 40 years of age. Am Surg; 2002 Oct;68(10):871-6
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal cancer in patients younger than 40 years of age.
  • Previous studies have suggested a poor outcome for patients presenting with colorectal cancer under the age of 40 years.
  • A retrospective study was designed to review all patients under the age of 40 with a diagnosis of colorectal cancer from January 1990 to December 2000.
  • There were 664 patients presenting with colorectal cancer during the 10-year period; of these 24 presented for surgery under the age of 40.
  • Eleven (44%) patients had a positive family history of colorectal cancer.
  • Twelve were stage IV, six stage III, five stage II, and one stage I.
  • The eight rectal cancer patients received preoperative chemoradiation therapy (33%).
  • Twelve (50%) patients with colon cancer received postoperative 5-fluorouracil-based chemotherapy.
  • We conclude that colorectal cancer patients less than 40 years of age present at an advanced stage and tend to have a positive family history.
  • Long-term survival is as predicted for their advanced stage of presentation.
  • [MeSH-minor] Adenocarcinoma. Adenocarcinoma, Mucinous. Adult. Age of Onset. Female. Humans. Louisiana / epidemiology. Male. Prognosis. Survival Analysis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12412713.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Yu X, McBean AM: Screening mammography use and chemotherapy among female stage II colon cancer patients: a retrospective cohort study. BMC Health Serv Res; 2010 Apr 19;10:98
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening mammography use and chemotherapy among female stage II colon cancer patients: a retrospective cohort study.
  • BACKGROUND: Although chemotherapy is not a routine recommendation for stage II colon cancer by the U.S. national guidelines, 20-30% of patients have received chemotherapy.
  • This study investigated whether screening mammography use before the cancer diagnosis was associated with chemotherapy use among female elderly patients with stage II colon cancer.
  • METHODS: Retrospective cohort study on 2910 female stage II colon cancer patients aged 67-79 using the Surveillance, Epidemiology and End Results (SEER)-Medicare data (1996-2002).
  • Screening mammography use and chemotherapy use were identified using Medicare claims data.
  • RESULTS: About 25% of female elderly patients received chemotherapy.
  • The chemotherapy rates increased from 22% in 1996-1998 to 26% in 2001-2002.
  • After adjusting for socio-demographic variables, tumor characteristics and Charlson index for comorbidities, the odds of receiving chemotherapy were 28% higher among those who had a screening mammogram before the cancer diagnosis than those who did not (OR: 1.28, 95% CI: 1.07-1.54).
  • Those with a prior mammogram also received chemotherapy earlier than those without.
  • In addition, patients with unfavorable tumor characteristics were more likely to receive chemotherapy.
  • Mammography use before the cancer diagnosis was associated with favorable tumor characteristics.
  • CONCLUSIONS: Despite the controversy about the chemotherapy use among stage II colon cancer, female elderly patients still received chemotherapy at a high rate.
  • Our findings suggest that patient's health beliefs and health care seeking behavior, together with physician's recommendation, play important roles in the cancer treatment decision.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acad Radiol. 2005 Apr;12(4):451-8 [15831418.001]
  • [Cites] J Behav Med. 1994 Aug;17(4):391-406 [7966260.001]
  • [Cites] Womens Health Issues. 2005 Nov-Dec;15(6):249-57 [16325138.001]
  • [Cites] J Natl Cancer Inst. 2006 May 3;98(9):610-9 [16670386.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2368-75 [16618946.001]
  • [Cites] Med Care. 2006 Oct;44(10):921-8 [17001263.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2581-8 [17078055.001]
  • [Cites] Int J Colorectal Dis. 2007 Aug;22(8):887-95 [17235506.001]
  • [Cites] JAMA. 2007 Nov 14;298(18):2149-54 [18000198.001]
  • [Cites] Lancet. 2007 Dec 15;370(9604):2020-9 [18083404.001]
  • [Cites] Am J Obstet Gynecol. 2008 Jan;198(1):86.e1-8 [18166316.001]
  • [Cites] J Cancer Surviv. 2007 Dec;1(4):275-82 [18648962.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):850-7 [11390534.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-55-61 [12187169.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3999-4005 [12351597.001]
  • [Cites] Am J Gastroenterol. 2003 Aug;98(8):1875-80 [12907347.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] J Clin Epidemiol. 1992 Jun;45(6):613-9 [1607900.001]
  • [Cites] Am J Med. 2005 Oct;118(10):1078-86 [16194635.001]
  • (PMID = 20403187.001).
  • [ISSN] 1472-6963
  • [Journal-full-title] BMC health services research
  • [ISO-abbreviation] BMC Health Serv Res
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 098974
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2868844
  •  go-up   go-down


93. Baldwin LM, Dobie SA, Billingsley K, Cai Y, Wright GE, Dominitz JA, Barlow W, Warren JL, Taplin SH: Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst; 2005 Aug 17;97(16):1211-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Explaining black-white differences in receipt of recommended colon cancer treatment.
  • BACKGROUND: Black-white disparities exist in receipt of recommended medical care, including colorectal cancer treatment.
  • This retrospective cohort study examines the degree to which health systems (e.g., physician, hospital) factors explain black-white disparities in colon cancer care.
  • METHODS: Data from the Surveillance, Epidemiology, and End Results program; Medicare claims; the American Medical Association Masterfile; and hospital surveys were linked to examine chemotherapy receipt after stage III colon cancer resection among 5294 elderly (> or = 66 years of age) black and white Medicare-insured patients.
  • Logistic regression analysis was used to identify factors associated with black-white differences in chemotherapy use.
  • RESULTS: Black and white patients were equally likely to consult with a medical oncologist, but among patients who had such a consultation, black patients were less likely than white patients (59.3% versus 70.4%, difference = 10.9%, 95% confidence interval [CI] = 5.1% to 16.4%, P < .001) to receive chemotherapy.
  • Overall, patient, physician, hospital, and environmental factors accounted for approximately 50% of the disparity in chemotherapy receipt among patients aged 66-70 years; surgical length of stay and neighborhood socioeconomic status accounted for approximately 27% of the disparity in this age group, and health systems factors accounted for 12%.
  • CONCLUSIONS: Black and white Medicare-insured colon cancer patients have an equal opportunity to learn about adjuvant chemotherapy from a medical oncologist but do not receive chemotherapy equally.
  • Further qualitative research is needed to understand the factors that influence the lower receipt of chemotherapy by black patients.

  • MedlinePlus Health Information. consumer health - African American Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Epidemiol. 1997 Aug;50(8):899-901 [9291874.001]
  • [Cites] J Natl Med Assoc. 1998 Jan;90(1):25-33 [9473926.001]
  • [Cites] Ann Intern Med. 1998 May 1;128(9):729-36 [9556466.001]
  • [Cites] Ethn Dis. 1998 Winter;8(1):43-51 [9595247.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2312-20 [9635522.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):320-30 [9669815.001]
  • [Cites] Cancer Nurs. 1998 Oct;21(5):349-57 [9775485.001]
  • [Cites] Am J Public Health. 1998 Nov;88(11):1681-4 [9807536.001]
  • [Cites] Prev Med. 2002 Sep;35(3):199-206 [12202061.001]
  • [Cites] Cancer. 2002 Oct 1;95(7):1401-14 [12237908.001]
  • [Cites] NHPF Issue Brief. 2002 Sep 9;(782):1-23 [12240698.001]
  • [Cites] Arch Intern Med. 2002 Nov 25;162(21):2458-63 [12437405.001]
  • [Cites] Gerontologist. 2003 Feb;43(1):62-72 [12604747.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1499-506 [12627515.001]
  • [Cites] J Natl Med Assoc. 1999 Aug;91(8):439-46 [12656432.001]
  • [Cites] Am J Public Health. 2003 Apr;93(4):618-23 [12660207.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1293-300 [12663717.001]
  • [Cites] JAMA. 2003 May 21;289(19):2517-24 [12759323.001]
  • [Cites] Ann Intern Med. 2003 Oct 7;139(7):558-63 [14530226.001]
  • [Cites] Am J Prev Med. 2003 Nov;25(4):301-7 [14580631.001]
  • [Cites] Med Care. 2003 Nov;41(11):1240-55 [14583687.001]
  • [Cites] Urology. 2003 Dec;62(6):1035-9 [14665350.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):575-84 [15295050.001]
  • [Cites] Am J Public Health. 1986 Dec;76(12):1446-8 [3490796.001]
  • [Cites] JAMA. 1998 Nov 18;280(19):1690-1 [9832001.001]
  • [Cites] J Public Health Manag Pract. 1999 May;5(3):35-46 [10537605.001]
  • [Cites] Med Care. 1999 Jul;37(7):712-7 [10424642.001]
  • [Cites] JAMA. 1999 Aug 11;282(6):583-9 [10450723.001]
  • [Cites] J Gen Intern Med. 1999 Sep;14(9):537-46 [10491242.001]
  • [Cites] N Engl J Med. 1999 Oct 14;341(16):1198-205 [10519898.001]
  • [Cites] N Engl J Med. 1999 Nov 25;341(22):1661-9 [10572155.001]
  • [Cites] Am Heart J. 2000 May;139(5):848-57 [10783219.001]
  • [Cites] J Am Geriatr Soc. 2000 Jul;48(7):735-40 [10894310.001]
  • [Cites] J Natl Med Assoc. 2000 Jun;92(6):281-4 [10918763.001]
  • [Cites] Circulation. 2000 Aug 8;102(6):642-8 [10931804.001]
  • [Cites] N Engl J Med. 2000 Nov 23;343(21):1537-44, 2 p preceding 1537 [11087884.001]
  • [Cites] Med Care Res Rev. 2000;57 Suppl 1:146-61 [11092161.001]
  • [Cites] Med Care Res Rev. 2000;57 Suppl 1:218-35 [11092164.001]
  • [Cites] J Womens Health Gend Based Med. 2000 Nov;9(9):1025-31 [11103103.001]
  • [Cites] Cancer. 2001 Jan 1;91(1):164-72 [11148573.001]
  • [Cites] J Epidemiol Community Health. 2001 Feb;55(2):111-22 [11154250.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):850-7 [11390534.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]
  • [Cites] Prev Med. 2001 Nov;33(5):495-502 [11676592.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1192-202 [11870160.001]
  • [Cites] Ethn Dis. 2002 Winter;12(1):77-86 [11913611.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1786-92 [11919235.001]
  • [Cites] Ethn Dis. 2002 Spring;12(2):276-83 [12019938.001]
  • [Cites] Cancer Detect Prev. 2002;26(1):28-32 [12088200.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-55-61 [12187169.001]
  • [Cites] Am J Public Health. 1989 Jun;79(6):772-5 [2729474.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] Am J Public Health. 1991 Apr;81(4):501-4 [2003635.001]
  • [Cites] Am J Public Health. 1992 May;82(5):703-10 [1566949.001]
  • [Cites] J Clin Epidemiol. 1993 Oct;46(10):1075-9; discussion 1081-90 [8410092.001]
  • [Cites] Am Heart J. 1994 Feb;127(2):287-95 [8296695.001]
  • [Cites] JAMA. 1994 Aug 17;272(7):530-4 [8046807.001]
  • [Cites] Soc Sci Med. 1994 Aug;39(4):519-26 [7973851.001]
  • [Cites] Health Care Financ Rev. 1994 Summer;15(4):77-90 [10172157.001]
  • [Cites] Cancer Nurs. 1995 Oct;18(5):385-92 [7585493.001]
  • [Cites] Am J Public Health. 1996 Apr;86(4):582-6 [8604797.001]
  • [Cites] Health Care Financ Rev. 1995 Winter;17(2):61-70 [10157380.001]
  • [Cites] Nurs Outlook. 1996 Jan-Feb;44(1):18-21 [8650004.001]
  • [Cites] Ann Intern Med. 1996 Aug 1;125(3):173-82 [8686974.001]
  • [Cites] N Engl J Med. 1996 Sep 12;335(11):791-9 [8703185.001]
  • [Cites] Med Care. 1996 Sep;34(9):970-84 [8792784.001]
  • [Cites] Am J Prev Med. 1996 Sep-Oct;12(5):327-37 [8909641.001]
  • (PMID = 16106026.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA089544-01; United States / NCI NIH HHS / CA / R01 CA089544; United States / NCI NIH HHS / CA / R01 CA089544-01; United States / NCI NIH HHS / CA / R01CA089544
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS270165; NLM/ PMC3138542
  •  go-up   go-down


94. Luo R, Giordano SH, Zhang DD, Freeman J, Goodwin JS: The role of the surgeon in whether patients with lymph node-positive colon cancer see a medical oncologist. Cancer; 2007 Mar 1;109(5):975-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of the surgeon in whether patients with lymph node-positive colon cancer see a medical oncologist.
  • BACKGROUND: Chemotherapy improves survival for patients with stage III colon cancer, but some older patients with lymph node-positive colon cancer do not see a medical oncologist and, thus, do not receive adjuvant chemotherapy.
  • METHODS: To evaluate the role of the surgeon in determining referrals to medical oncology among patients with stage III colon cancer, the authors conducted a retrospective cohort study of 6158 patients aged >or=66 years who were diagnosed with stage III colon cancer from 1992 through 1999 by using the Surveillance, Epidemiology, and End Results-Medicare linked database.
  • RESULTS: Twenty-one percent of the total variance in seeing a medical oncologist was attributable to the surgeon after adjusting for available patient, tumor, and surgeon characteristics.
  • The individual surgeon characteristics that significantly predicted whether the patient saw a medical oncologist were year since graduation (<or=10 years vs >20 years; hazard ratio [HR], 1.60; 95% confidence interval [95% CI], 1.19-2.16), practicing in a teaching hospital (yes vs. no: HR; 1.30; 95% CI, 1.07-1.58), and volume of patients with colon cancer (<30 patients vs >or=121 patients; HR, 0.66; 95% CI, 0.46-0.94).
  • Surgeon sex, race, board certification, and type of practice were not independent predictors of medical oncology referral.
  • Interventions at the level of the surgeon may be appropriate to improve the care of patients with colon cancer.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Epidemiol. 2000 Dec;53(12):1258-67 [11146273.001]
  • [Cites] Oncologist. 2006 Oct;11(9):1025-33 [17030645.001]
  • [Cites] Cancer J. 2001 May-Jun;7(3):213-8 [11419029.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]
  • [Cites] Ann Intern Med. 2002 Mar 5;136(5):349-57 [11874307.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1716-8 [11919225.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1786-92 [11919235.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-82-95 [12187173.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-96-103 [12187174.001]
  • [Cites] Ann Surg Oncol. 2003 Jul;10(6):606-15 [12839844.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4627-35 [14673052.001]
  • [Cites] Med Care. 2004 Sep;42(9):901-6 [15319616.001]
  • [Cites] Med Care. 1985 Aug;23(8):939-45 [4021579.001]
  • [Cites] Med Care. 1991 Jan;29(1):50-63 [1986177.001]
  • [Cites] BMJ. 1991 May 25;302(6787):1250-2 [2043851.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):594-601 [8319193.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):899-906 [8143995.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):363-70 [8054286.001]
  • [Cites] N Engl J Med. 1994 Dec 15;331(24):1625-9 [7969344.001]
  • [Cites] Lancet. 1995 Apr 15;345(8955):939-44 [7715291.001]
  • [Cites] Med Care. 1996 May;34(5):479-89 [8614169.001]
  • [Cites] Health Serv Res. 1996 Apr;31(1):5-19 [8617610.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):918-26 [8756390.001]
  • [Cites] J Fam Pract. 1997 Jul;45(1):47-53 [9228914.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):295-300 [9440756.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] Lancet. 2005 Jan 8-14;365(9454):153-65 [15639298.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 17;97(16):1211-20 [16106026.001]
  • [Cites] JAMA. 2005 Dec 7;294(21):2703-11 [16333005.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):850-7 [11390534.001]
  • (PMID = 17265530.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA105631; United States / NCI NIH HHS / CA / R01 CA104949; United States / AHRQ HHS / HS / R24 HS011618
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS19823; NLM/ PMC1851914
  •  go-up   go-down


95. Baars A, Claessen AM, Wagstaff J, Giaccone G, Scheper RJ, Meijer S, Schakel MJ, Gall HE, Meijer CJ, Vermorken JB, Pinedo HM, van den Eertwegh AJ: A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma. Br J Cancer; 2002 Apr 22;86(8):1230-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma.
  • Active specific immunotherapy, using vaccines with autologous tumour cells and BCG, significantly reduces the rate of tumour recurrence in stage II colon cancer patients, while no clinical benefit has yet been observed in stage III patients.
  • Adjuvant treatment with 5-Fluorouracil/Leucovorin is now considered standard therapy for stage III colon carcinoma and results in an absolute survival benefit of approximately 10%.
  • Yet, the 5-year overall survival rate of stage III colon cancer patients is only 40-50%.
  • Combining chemotherapy and immunotherapy might improve prognosis for stage III patients, especially when considering that active specific immunotherapy and chemotherapy have shown synergistic effects in pre-clinical tumour models.
  • We performed a phase II study with 56 patients, using the combination of active specific immunotherapy and chemotherapy as an adjuvant therapy in stage III colon cancer patients to assess the influence of 5-Fluorouracil/Leucovorin on anti-tumour immunity induced by autologous tumour cell vaccinations.
  • Anti-tumour immunity was measured before and after chemotherapy by means of delayed type hypersensitivity reactions, taken 48 h after the third and the fourth vaccination.
  • We also investigated the toxicity of this combined immuno-chemotherapy treatment.
  • Delayed type hypersensitivity reactions before chemotherapy had a median size of 20.3 mm, while after chemotherapy delayed type hypersensitivity size was 18.4 mm (P=0.01), indicating that chemotherapy hardly affected anti-tumour immunity.
  • In 30% of the patients grade III or grade IV chemotherapy related toxicity was seen; this is comparable to what is normally observed after adjuvant chemotherapy alone.
  • This study shows that the active specific immunotherapy-induced anti-tumour immune response is only minimally impaired by consecutive chemotherapy and that the combined treatment of stage III colon cancer patients with active specific immunotherapy and 5-Fluorouracil/Leucovorin does not cause unexpected toxicity.
  • [MeSH-major] Chemotherapy, Adjuvant. Colonic Neoplasms / drug therapy. Colonic Neoplasms / therapy. Fluorouracil / therapeutic use. Immunotherapy, Active. Leucovorin / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Humans. Hypersensitivity, Delayed. Male. Middle Aged. Neoplasm Staging

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Cancer Research UK
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):321-6 [7847642.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):899-906 [8143995.001]
  • [Cites] Science. 1996 Oct 4;274(5284):94-6 [8810254.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):246-50 [8996149.001]
  • [Cites] Science. 1997 Oct 3;278(5335):117-20 [9311915.001]
  • [Cites] Lancet. 1999 Jan 30;353(9150):345-50 [9950438.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1129-34 [10506695.001]
  • [Cites] J Immunol. 1999 Dec 1;163(11):6292-300 [10570323.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):148-57 [10623705.001]
  • [Cites] Ann Oncol. 2000 Aug;11(8):965-70 [11038032.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1127-35 [11350875.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8809-14 [11427731.001]
  • [Cites] N Engl J Med. 1975 Sep 4;293(10):501-2 [1152865.001]
  • [Cites] Cancer Res. 1979 Apr;39(4):1353-60 [217533.001]
  • [Cites] Science. 1982 Jul 23;217(4557):367-9 [6283635.001]
  • [Cites] Cancer Immunol Immunother. 1990;32(1):62-6 [2289200.001]
  • [Cites] Cancer. 1993 Jan 15;71(2):493-509 [8422644.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • [Cites] Lancet. 1995 Apr 15;345(8955):939-44 [7715291.001]
  • (PMID = 11953877.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2375342
  •  go-up   go-down


96. Dobie SA, Baldwin LM, Dominitz JA, Matthews B, Billingsley K, Barlow W: Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst; 2006 May 3;98(9):610-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Completion of therapy by Medicare patients with stage III colon cancer.
  • BACKGROUND: Certain factors, such as race or age, are known to be associated with variation in initiation of adjuvant chemotherapy for stage III colon cancer, but little is known about what factors are associated with completion of adjuvant therapy.
  • METHODS: We studied 3193 stage III colon cancer patients whose diagnosis was recorded in 1992-1996 SEER program data linked to 1991-1998 Medicare claims and who initiated adjuvant chemotherapy after colon cancer resection.
  • We defined a measure of adjuvant chemotherapy completion as one chemotherapy administration claim in a month.
  • We tested the validity of the created measure and its relation to 3-year cancer mortality adjusted for demographic, clinical, and environmental variables.
  • We explored the association of patient characteristics and treating physician characteristics with chemotherapy completion by use of multivariable logistic regression modeling.
  • Risk of cancer-related mortality was statistically significantly lower among those completing chemotherapy (relative risk = 0.79, 95% confidence interval = 0.69 to 0.89) than those with no adjuvant therapy.
  • Patients who were female, widowed, increasingly elderly, rehospitalized, and living in certain regions were less likely to complete adjuvant chemotherapy than other patients.
  • Race and other clinical, environmental, and physician characteristics were not associated with completion of therapy.
  • CONCLUSIONS: Factors associated with incomplete adjuvant chemotherapy may represent physical frailty, treatment complications, and lack of social and psychological support.
  • Interventions to mitigate these influences are a logical next step toward increasing chemotherapy completion rates.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2002 Aug 7;94(15):1160-7 [12165641.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-55-61 [12187169.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-82-95 [12187173.001]
  • [Cites] Ann Surg. 2002 Nov;236(5):583-92 [12409664.001]
  • [Cites] Bone Marrow Transplant. 2002 Dec;30(11):741-8 [12439696.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1293-300 [12663717.001]
  • [Cites] J Surg Oncol. 2003 Jun;83(2):68-78; discussion 78-9 [12772198.001]
  • [Cites] Soc Sci Med. 2003 Dec;57(11):2137-47 [14512244.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1479-85 [15083172.001]
  • [Cites] Int J Aging Hum Dev. 2004;58(4):241-65 [15357328.001]
  • [Cites] Cancer. 1983 Dec 1;52(11):1986-92 [6354419.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] J Clin Oncol. 1989 Oct;7(10):1447-56 [2778478.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] Am J Epidemiol. 1991 Apr 1;133(7):672-82 [2018022.001]
  • [Cites] Eur J Cancer. 1992;28A(11):1817-20 [1389517.001]
  • [Cites] Health Rep. 1993;5(1):87-90 [8334243.001]
  • [Cites] Med Care. 1993 Aug;31(8):732-48 [8336512.001]
  • [Cites] J Clin Epidemiol. 1993 Oct;46(10):1075-9; discussion 1081-90 [8410092.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • [Cites] Cancer. 1995 Jan 1;75(1):11-7 [7804963.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):321-6 [7847642.001]
  • [Cites] J Am Geriatr Soc. 1995 Mar;43(3):267-70 [7884116.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):918-26 [8756390.001]
  • [Cites] J Clin Epidemiol. 1997 Aug;50(8):939-45 [9291879.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):295-300 [9440756.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2312-20 [9635522.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(4):336-40 [9744780.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3537-41 [9817272.001]
  • [Cites] JAMA. 1998 Nov 18;280(19):1690-1 [9832001.001]
  • [Cites] Eur J Cancer. 1998 Nov;34(12):1871-5 [10023308.001]
  • [Cites] Cancer Detect Prev. 1999;23(5):428-34 [10468896.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1165-71 [15693031.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2412-8 [10561304.001]
  • [Cites] Lancet. 2000 Oct 14;356(9238):1326-7 [11073026.001]
  • [Cites] Am J Public Health. 2000 Nov;90(11):1746-54 [11076244.001]
  • [Cites] JAMA. 2000 Dec 20;284(23):3028-35 [11122590.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 4;93(7):501-15 [11287444.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):850-7 [11390534.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]
  • [Cites] Br J Cancer. 2001 Nov 16;85(10):1437-43 [11720425.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1192-202 [11870160.001]
  • [Cites] Ann Intern Med. 2002 Mar 5;136(5):349-57 [11874307.001]
  • [Cites] Med Care. 2002 Mar;40(3):201-11 [11880793.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1491-8 [11896096.001]
  • [CommentIn] J Natl Cancer Inst. 2006 May 3;98(9):570-1 [16670377.001]
  • [CommentIn] J Natl Cancer Inst. 2006 Nov 1;98(21):1582 [17077360.001]
  • (PMID = 16670386.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA089544-01; United States / NCI NIH HHS / CA / R01 CA089544; United States / NCI NIH HHS / CA / R01 CA089544-01; United States / NCI NIH HHS / CA / R01CA089544
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS270166; NLM/ PMC3124351
  •  go-up   go-down


97. Link KH, Sagban TA, Mörschel M, Tischbirek K, Holtappels M, Apell V, Zayed K, Kornmann M, Staib L: Colon cancer: survival after curative surgery. Langenbecks Arch Surg; 2005 Apr;390(2):83-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon cancer: survival after curative surgery.
  • Several new aspects have evolved during the past years concerning factors that influence survival in surgically and medically treated colon cancer patients that are relevant to the treating team for the treatment strategy and patient's choice.
  • The 5-year-survival rates dependent on UICC stages/substages (I: 68%-100%, II: 58%-90%, III: 33%-76%, IV: <5%-9%) show remarkable variations between published reports, surgical hospital units, individual surgeons, and continents (USA vs Europe).
  • Survival times and cure rates are significantly improved by adjuvant chemotherapy in UICC III and in substages of UICC II (e.g.
  • In three recently published trials standard adjuvant chemotherapy was further improved by increased survival rates, e.g. from 59% to 71% in stage III and IIB patients.
  • Molecular and genetic factors, such as thymidylate synthase (TS), microsatellite instability (MSI) or loss of chromosome 18q/"DCC" might have an independent impact on prognosis in the spontaneous course, and TS could help to better select patients for adjuvant chemotherapy.
  • [MeSH-major] Colonic Neoplasms / mortality. Colonic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chirurg. 2002 Feb;73(2):138-45; discussion 145-6 [11974477.001]
  • [Cites] Z Gastroenterol. 1997 Nov;35(11):1019-27 [9490552.001]
  • [Cites] Cancer Lett. 1997 Sep 16;118(1):29-35 [9310257.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):613-4 [10749623.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1128-37 [11948273.001]
  • [Cites] Chirurg. 1999 Apr;70(4):407-14 [10354837.001]
  • [Cites] Cancer. 1992 Sep 15;70(6 Suppl):1732-9 [1516028.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1260-5 [14520457.001]
  • [Cites] J Clin Epidemiol. 2003 Dec;56(12):1185-91 [14680669.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):899-906 [8143995.001]
  • [Cites] Lancet. 2000 Jul 8;356(9224):93-6 [10963244.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2936-43 [8523058.001]
  • [Cites] J Natl Cancer Inst. 1998 Dec 2;90(23 ):1810-6 [9839521.001]
  • [Cites] Br J Cancer. 2003 Jun 16;88(12):1859-65 [12799627.001]
  • [Cites] Arch Surg. 1987 Nov;122(11):1253-6 [3675188.001]
  • [Cites] World J Surg. 2001 Dec;25(12 ):1495-8; discussion 1499 [11775180.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1343-9 [11350904.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1721-8 [11919227.001]
  • [Cites] BMJ. 1991 Jun 22;302(6791):1501-5 [1713087.001]
  • [Cites] Cancer. 2000 Aug 15;89(4):893-900 [10951355.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):178-87 [16041207.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):6012-9 [14676127.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1787-94 [11251010.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1735-43 [14630678.001]
  • [Cites] Natl Cancer Inst Monogr. 1961 Sep;6:101-21 [13889176.001]
  • [Cites] Br J Surg. 1990 Dec;77(12):1345-8 [2276014.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2912-9 [12885809.001]
  • [Cites] Eur J Cancer. 2003 Dec;39(18):2600-10 [14642922.001]
  • [Cites] Recent Results Cancer Res. 1996;142:311-52 [8893349.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):246-50 [8996149.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):213-8 [12679304.001]
  • [Cites] Br J Cancer. 1998 Apr;77(8):1349-54 [9579845.001]
  • [Cites] Lancet. 2002 Aug 31;360(9334):671-7 [12241873.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Dis Colon Rectum. 1993 Jul;36(7):636-43; discussion 643-4 [8348848.001]
  • [Cites] Br J Surg. 2002 Aug;89(8):1008-13 [12153626.001]
  • [Cites] Z Gastroenterol. 2002 Nov;40(11):921-4 [12436369.001]
  • [Cites] World J Surg. 2002 Jan;26(1):59-66 [11898035.001]
  • [Cites] Comput Programs Biomed. 1985;19(2-3):197-207 [3839736.001]
  • [Cites] Lancet. 1995 Jun 17;345(8964):1582-3 [7791476.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4116-24 [14519634.001]
  • [Cites] J Gastrointest Surg. 2001 May-Jun;5(3):275-81 [11419451.001]
  • [Cites] J Clin Epidemiol. 1999 May;52(5):447-52 [10360340.001]
  • [Cites] JAMA. 2000 Dec 20;284(23):3028-35 [11122590.001]
  • [Cites] Chirurg. 1996 Jun;67(6):604-9; discussion 609-10 [8767088.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):295-300 [9440756.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3553-9 [10550154.001]
  • [Cites] Chirurg. 1996 Aug;67(8):769-70 [8964148.001]
  • [Cites] Cancer. 2000 Jul 15;89(2):288-96 [10918158.001]
  • [Cites] Ann Intern Med. 2003 Oct 21;139(8):649-57 [14568853.001]
  • [Cites] Br J Cancer. 2001 Nov 16;85(10):1437-43 [11720425.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):972-6 [11592768.001]
  • [Cites] N Engl J Med. 2001 Apr 19;344(16):1196-206 [11309634.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • [Cites] Chirurg. 1994 Apr;65(4):287-97 [8020349.001]
  • (PMID = 15455234.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 73
  •  go-up   go-down


98. Mosolits S, Nilsson B, Mellstedt H: Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. Expert Rev Vaccines; 2005 Jun;4(3):329-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials.
  • Colorectal carcinoma is a leading cause of cancer-related mortality.
  • Despite the introduction of new cytotoxic drugs, improved surgical and radiotherapeutic techniques, a large proportion of colorectal carcinomas remain incurable.
  • New targeted therapeutic strategies, including immunotherapy, are being explored as complementary treatments.
  • Recent advances in immunology and molecular biology have opened new avenues for the clinical testing of rationally designed vaccination strategies against cancer.
  • The present report reviews the results of therapeutic vaccine trials in colorectal carcinoma, published mainly in the past 6 years.
  • Tumor-associated antigens (self-antigens) have been targeted by therapeutic vaccination in more than 2000 colorectal carcinoma patients.
  • The results demonstrate that tumor antigen-specific immune responses are reproducibly induced; that is, tolerance can be reversed, without the induction of serious adverse events or autoimmune disorders.
  • No long-term autoimmune side effects have been observed after a minimum follow-up of 4 years in over 700 patients.
  • Over 1300 colorectal carcinoma patients with minimal residual disease have been enrolled in randomized controlled Phase II/III trials using autologous tumor cell vaccines.
  • A significantly improved overall survival was noted for Stages I-IV colorectal carcinoma patients utilizing Newcastle-disease virus as an adjuvant.
  • Autologous tumor cells mixed with bacillus Calmette-Guerin (BCG) were of significant clinical benefit for patients with Stage II colon cancer.
  • Although it is unlikely that active specific immunotherapy will provide a standard complementary therapeutic approach for colorectal carcinoma in the near future, the results so far are encouraging.
  • Randomized controlled vaccine trials targeting molecularly defined tumor antigens are warranted, particularly in colon carcinoma with minimal residual disease.
  • [MeSH-major] Cancer Vaccines / administration & dosage. Clinical Trials as Topic / methods. Clinical Trials as Topic / trends. Colorectal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16026248.001).
  • [ISSN] 1744-8395
  • [Journal-full-title] Expert review of vaccines
  • [ISO-abbreviation] Expert Rev Vaccines
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines
  • [Number-of-references] 141
  •  go-up   go-down


99. Mori T, Munakata M, Kasai M, Nozaki T, Kawamura S, Sawamura N, Hiraga H, Sakata Y: [Successful treatment of 5-FU intraarterial infusion on the third postoperative day for a patient with multiple liver metastases from colon cancer and high risk of liver failure]. Gan To Kagaku Ryoho; 2004 Jul;31(7):1101-3
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment of 5-FU intraarterial infusion on the third postoperative day for a patient with multiple liver metastases from colon cancer and high risk of liver failure].
  • A 68-year-old man with multiple liver metastases from stage 4 advanced descending colon cancer who underwent partial resection of the colon and simultaneous catheter insertion into the gastroduodenal artery for arterial infusion chemotherapy.
  • Intraarterial infusion of 5-FU 600 mg/m2 (1,000 mg/body) for 6 hours weekly and intravenous administration of methylpredonisolone 125 mg were started for emergency chemotherapy on the third postoperative day.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Colonic Neoplasms / pathology. Fluorouracil / administration & dosage. Liver Failure. Liver Neoplasms / drug therapy
  • [MeSH-minor] Aged. Benzimidazoles / administration & dosage. Colectomy. Drug Administration Schedule. Hepatic Artery. Humans. Infusions, Intra-Arterial. Male. Postoperative Period. Risk

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15272594.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Benzimidazoles; 0 / methylproamine; U3P01618RT / Fluorouracil
  •  go-up   go-down


100. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M, West Japan Oncology Group: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol; 2010 Feb;11(2):121-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
  • BACKGROUND: Patients with non-small-cell lung cancer harbouring mutations in the epidermal growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase inhibitor gefitinib.
  • However, whether gefitinib is better than standard platinum doublet chemotherapy in patients selected by EGFR mutation is uncertain.
  • 177 chemotherapy-naive patients aged 75 years or younger and diagnosed with stage IIIB/IV non-small-cell lung cancer or postoperative recurrence harbouring EGFR mutations (either the exon 19 deletion or L858R point mutation) were randomly assigned, using a minimisation technique, to receive either gefitinib (250 mg/day orally; n=88) or cisplatin (80 mg/m(2), intravenously) plus docetaxel (60 mg/m(2), intravenously; n=89), administered every 21 days for three to six cycles.
  • FINDINGS: Five patients were excluded (two patients were found to have thyroid and colon cancer after randomisation, one patient had an exon 18 mutation, one patient had insufficient consent, and one patient showed acute allergic reaction to docetaxel).
  • The gefitinib group had significantly longer progression-free survival compared with the cisplatin plus docetaxel goup, with a median progression-free survival time of 9.2 months (95% CI 8.0-13.9) versus 6.3 months (5.8-7.8; HR 0.489, 95% CI 0.336-0.710, log-rank p<0.0001).
  • Two patients in the gefitinib group developed interstitial lung disease (incidence 2.3%), one of whom died.
  • INTERPRETATION: Patients with lung cancer who are selected by EGFR mutations have longer progression-free survival if they are treated with gefitinib than if they are treated with cisplatin plus docetaxel.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Cisplatin / administration & dosage. Lung Neoplasms / drug therapy. Quinazolines / administration & dosage. Taxoids / administration & dosage






Advertisement